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lation and its relationship with cardiovascular risk factors and morbidity. In addi-
tion, we investigate whether these associations are present at levels of urinary al-
bumin excretion currently considered to be "normal". In chapter 6 the associa-
tion between the level of urinary albumin excretion and ischemic electrocardio-
graphic abnormalities is evaluated, taking into account conventional cardiovascu-
lar risk factors. In chapter 7 we determine predictive properties of urinary al-
bumin excretion and the form of relationship with respect to cardiovascular and
non-cardiovascular death in the general population. In chapter 8 several aspects
of the relation between the kidney and the heart (and vasculature) are reviewed.
Classical and novel concepts of causal interrelations are presented and the poten-
tial options of interfering medically in the cardiorenal axis to prevent cardiovas-
cular morbidity and mortality are discussed.
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During the last 20 years we have witnessed a marked decline in morbidity and
mortality from cardiovascular disease, due to advances in coronary risk factor
modification and a better understanding of the atherosclerotic process. Notwith-
standing, cardiovascular disease remains a frequent cause of mortality in indus-
trialised countries, in partcular in high risk patients, such as smokers or obese
subjects or subjects with hypertension, glucose intolerance, and dyslipidemia.
Multifactorial risk factor modification has been proven to positively influence
morbidity and mortality from both cardiovascular disease and stroke. However,
some typical 'major' risk factors, like high blood pressure, elevated cholesterol or
left ventricular hypertrophy, do not always have a clear predictive role for car-
diovascular mortality in certain subgroups such as the elderly at extremely high
ages, while in these individuals risk indicators usually labeled as 'minor' like se-
rum uric acid or proteinuria, may have a strong predictive value. Identification of
new morphological and or/functional alterations of the cardiovascular system
will help to target individuals most likely to benefit from specific treatments.
To date, the role of the kidney in cardiovascular disease has mainly been con-
sidered within the context of excessive salt and water retention due to reduced
renal blood flow. Recent data however, indicate that the kidney plays a more de-
cisive role in the progression and prognosis of cardiovascular disease. Nephro-
sclerosis may develop in parallel with systemic atherosclerosis and the kidneys
may play an important role in the development of cardiovascular risk factors
such as e.g. proteinuria, hyperlipidemia and uric acid. It is well known that se-
vere proteinuria can induce hyperlipidemia, that uric acid is elevated in renal im-
pairment and that hypertension develops in most end stage renal diseases.
The current thesis studies several aspects of the relation between the kidney
and the heart (and vasculature). The diagnosis of a deranged renal function is
based in this thesis on changes in serum creatinine or its clearance, and the detec-
tion of an elevated urinary excretion of albumin. We discuss classical and novel
concepts of causal interrelations between the kidney and the heart in various
stages of cardiovascular disease and the potential options of renoprotective medi-
cation to prevent cardiovascular morbidity and mortality.
In chapter 2 we study whether renal function is a predictor for mortality in
advanced chronic heart failure, and we assess its relative contribution compared
with other established risk factors. In addition, attention is paid to the relation be-
tween renal function and neurohormonal activation. In chapter 3 the course of
renal function changes after first myocardial infarction is examined, and the po-
tential protective effect of angiotensin converting enzyme inhibition. In addition,
we study the prognostic value of baseline renal function. In chapter 4 it is hy-
pothesized that an elevated urinary albumin excretion might be an important and
early sign for progressive renal function loss also in a nondiabetic population. In




activation, and survival in patients
with chronic heart failure
Hans L. Hillege, Armand R.J. Girbes, Pieter J. de Kam,
Frans Boomsma, Dick de Zeeuw, Andrew Charlesworth,




Background—Because renal function is affected by chronic heart failure
(CHF) and it relates to both cardiovascular and hemodynamic properties, it
should have additional prognostic value. We studied whether renal function is a
predictor for mortality in advanced CHF, and we assessed its relative contribu-
tion compared with other established risk factors. In addition, we studied the re-
lation between renal function and neurohormonal activation.
Methods and Results—The study population consisted of 1,906 patients with
CHF who were enrolled in a recent survival trial (Second Prospective Random-
ized study of Ibopamine on Mortality and Efficacy). In a subgroup of 372 pa-
tients, plasma neurohormones were determined. The baseline glomerular filtra-
tion rate (GFRc ) was calculated using the Cockroft Gault equation. GFRc was
the most powerful predictor of mortality; it was followed by New York Heart
Association functional class and the use of angiotensin-converting enzyme in-
hibitors. Patients in the lowest quartile of GFRc values (44 mL/min) had almost 3
times the risk of mortality (relative risk, 2.85; P < 0.001) of patients in the high-
est quartile (76 mL/min). Impaired left ventricular ejection fraction (LVEF) was
only modestly predictive (P = 0.053). GFRc was inversely related with N-
terminal atrial natriuretic peptide (ANP; r = −0.53) and, to a lesser extent, with
ANP itself (r = −0.35; both P < 0.001).
Conclusions—Impaired renal function (GFRc) is a stronger predictor of
mortality than impaired cardiac function (LVEF and New York Heart
Association class) in advanced CHF, and it is associated with increased levels of
N-terminal ANP. Moreover, impaired renal function was not related to LVEF,
which suggests that factors other than reduced cardiac output are causally
involved in mortality risk.
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Introduction
Chronic heart failure (CHF) is caused by a loss of ventricular function and by
various adaptational responses, including neurohormonal activation, peripheral
vasoconstriction, and salt and water retention1. A large number of clinical,
haemodynamic, biochemical, and electrophysiological factors have now been
identified that are related to prognosis in patients with CHF2. In routine clinical
practice, left ventricular function (including left ventricular ejection fraction
[LVEF]), the clinical severity of the disease (e.g., New York Heart Association
functional class ([NYHA]), and cause of the disease all carry independent prog-
nostic value. Biochemical markers, including serum sodium, urea, and creatinine,
and neurohormones may have additive value3,4. It has been suggested that the ac-
tivation of the renin-angiotensin-aldosterone system (RAAS), which occurs when
renal perfusion pressure is reduced in CHF, is not primarily a response to pre-
serve circulatory homeostasis, but a renal compensatory reaction to preserve re-
nal function5. It could thus be postulated that renal function can indirectly be
used as an indicator of cardiovascular status in CHF and may, therefore, poten-
tially be a powerful prognostic indicator.
Two previous studies reported the prognostic value of renal function (serum
creatinine) in patients with CHF, but whether renal function contributed inde-
pendently to mortality was not discussed6,7. Therefore, we examined renal func-
tion as a predictor of mortality in advanced CHF. Our secondary aim was to iden-
tify the relative contribution of renal function compared with established risk fac-
tors to the prognosis of the disease. Finally, we determined whether the relation
between renal function and mortality was linked through neurohormonal activa-
tion. The study population consisted of patients who were enrolled in a recent
survival trial (Second Prospective Randomised study of Ibopamine on Mortality
and Efficacy [PRIME-II])8. In a subgroup of 372 patients, a predefined neuro-
hormonal substudy was conducted9.
Methods
Design and study population
The details of PRIME-II have been described previously8. Briefly, the study was
designed to investigate the effect of the oral dopamine agonist ibopamine on
mortality in advanced CHF. The study was conducted in 13 European countries,
and 1,906 patients were included. PRIME-II was prematurely discontinued in
August 1995 when a significantly higher fatality rate was observed in the ibopa-
mine group. Patients, aged 18 to 80 years, were eligible for PRIME-II if they had
moderate to severe CHF (NYHA class III to IV) and evidence of left ventricular
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dysfunction (including LVEF < 0.35). In the predefined substudy, which was
performed only in the Netherlands, blood for plasma neurohormone detection
was collected from 372 patients9.
Renal function
The glomerular filtration rate (GFR) is the standard indicator of renal function.
Under steady-state conditions, GFR is estimated from serum creatinine using a
formula that accounts for the influence of age and body weight on creatinine
production (the Cockroft Gault equation)10: GFRc = [(140−age in years) × (body
weight in kg)] / (72 × serum creatinine in mg/dL). In women, the value is multi-
plied by 0.85. This formula has been validated in several studies of CHF and re-
nal dysfunction, and it showed a correlation > 0.90, with accurately measured
GFR11-15.
Neurohormonal measurements
The method of handling, storing, and determining neurohormonal levels has been
previously described in detail9. Plasma norepinephrine, epinephrine, and dopa-
mine levels were determined by high-performance liquid chromatography with
fluorometric detection. Active plasma renin concentration was measured by a ra-
dio-immunoassay of generated angiotensin I. To measure aldosterone, endo-
thelin, atrial natriuretic peptide (ANP), and plasma N-terminal ANP, commer-
cially available kits were used.
Statistical methods
The influence of baseline renal function on survival in the total study population
was studied with Kaplan Meier methods and Cox regression. To isolate the inde-
pendent effect of GFRc on overall mortality, the statistical analysis included ad-
justments for several possible risk factors, including age, sex, blood pressure,
heart rate, rhythm, cause and duration of CHF, and concomitant medication (in
particular, angiotensin-converting enzyme [ACE] inhibitors, diuretics, digoxin,
and antiarrhythmic drugs). The effects of ibopamine on survival and other base-
line characteristics that were prognostically relevant were also used in this analy-
sis. A further description of risk factors can be found elsewhere8,9.
Continuous variables were modelled with indicator variables into quartiles,
and relative risks with the lowest risk quartile were calculated for those in the
second, third, and fourth quartiles. Test for trends are presented. Only variables
with P < 0.10 in the univariate Cox regression analysis were used in the multiple
Cox regression analysis. Cumulative relative risks were calculated within the
sub-groups defined by GFRc strata with degree of LVEF and NYHA class. Inter-
action terms were used to examine effect modification. To reduce the risk of bias
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by the empirical use of arbitrary values for missing items of data, we excluded
observations with missing values for contributing variables in the multivariate
model. Stepwise linear regression analysis was used to determine the relationship
between each of the plasma neurohormones with GFRc and LVEF and other
relevant, significant baseline variables. Plasma neurohormone values were not
normally distributed, and their natural logarithms were incorporated. Pearson or
Spearman correlation coefficients were calculated to determine which independ-
ent variables had a significant univariate association with serum creatinine. To
examine all possible interactions of the effects of various variables, secondary
analysis that included interaction terms was performed. In addition, we per-
formed a separate analysis of the subgroups with and without ibopamine. All re-




Table 1 shows the baseline characteristics of the total population (n=1,906) and
the neurohormonal subgroup (n = 372). In 204 of the 1,906 patients, values were
missing for ≥ 1 contributing variable in the multivariate model; these patients
were excluded from the analysis. Therefore, full analyses of GFRc were per-
formed on 1,702 patients. No significant demographic or clinical differences
were found between the total and actual study populations.
Renal function and overall mortality
After a median follow-up of 277 days (range, 0 to 1091 days), 343 patients had
died. In unadjusted analyses, GFRc at baseline was strongly associated with all-
cause mortality, with a clear separation of curves and a marked stepwise increase
in the cumulative incidence of mortality for successively lower quartiles of GFRc
(Figure 1). Table 2 summarises the univariate and multivariate results of inde-
pendent predictors that remained significantly associated (with the exception of
LVEF) with mortality. GFRc was the most powerful predictor of mortality, as
expressed by the Wald statistics; this was followed by NYHA class and use of
ACE inhibitors. Patients in the lowest quartile of GFRc values ( < 44 mL/min)
had almost 3 times the risk of mortality (relative risk, 2.85; P = 0.001) of the pa-
tients in the highest quartile ( > 76 mL/min). LVEF contributed only modestly to
mortality quartiles (P = 0.053 for trend). The risk of mortality was almost equal
for the first 2 GFRc quartiles. A similar observation was present for the first 3
quartiles of LVEF (Figure 2).
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Age, yrs 64.7 ± 9.5 67.7 ± 8.0
Male gender 1532 (80.4%) 288 (77.4%)
Diabetes 394 (20.7%) 82 (22.0%)
History of myocardial infarction 1025 (53.9%) 280 (75.3%)
Duration of heart failure, mo 30 (12–60) 24 (11- 48)
Heart rate, bpm 81.0 ± 14.8 81.1 ± 14.8
Blood pressure, mmHg
Systolic 121.6 ± 19.8 124.4 ± 18.1
Diastolic 75.1 ± 11.1 76.1 ± 9.4
Atrial fibrillation 453 (23.8%) 78 (21.0%)
Calculated GFR, mL/min 62.9 ± 26.2 59.6 ± 22.5
NYHA class
III 1138 (59.7%) 253 (68.0%)
III/IV 607 (31.8%) 107 (28.8%)
IV 161 (8.4%) 12 (3.2%)
Cause of CHF
Ischemic heart disease 1120 (58.8%) 284 (76.3%)
Cardiomyopathy 600 (31.5%) 61 (16.4%)
Hypertension 106 (5.6%) 18 (4.8%)
Other 106 (5.6%) 14 (3.8%)
Current treatment of heart failure
Digitalis 1222 (64.1%) 221 (59.4%)
Diuretics (furosemide) 1882 (98.7%) 369 (99.2%)
≤ 80 mg 1154 (61.3%) 232 (62.9%)
> 80 mg 728 (38.7%) 137 (37.1%)
ACE inhibitors 1745 (91.6%) 352 (94.6%)
High dose 479 (27.4%) 84 (23.9%)
Moderate dose 953 (54.6%) 169 (48.0%)
Low dose 313 (17.9%) 99 (28.1%)
β-Blockers 118 (6.2%) 33 (8.9%)
Antiarrhythmics 463 (24.3%) 69 (18.5%)
Anticoagulants 819 (43.0%) 265 (71.2%)
Evidence of severity of heart failure
LVEF, % 26.2 ± 9.1 23.4 ± 7.5
Left ventricular end internal diastolic diameter, cm 6.9 ± 1.0 6.8 ± 0.8
Serum
Creatinine, mmol/L 120.5 ± 45.5 118.2 ± 37.6
Potassium, mmol/L 4.3 ± 0.5 4.2 ± 0.5
Sodium, mmol/L 138.5 ± 4.9 139.0 ± 3.4
Urea, mmol/L 27.7 ± 34.9 9.6 ± 4.5
Plasma neurohormones
Norepinephrine, pg/mL - - - 501 (363 – 696)
Epinephrine, pg/mL - - - 39 (27 – 66)
Aldosterone, pg/mL - - - 113 (67 – 220)
Dopamine, pg/mL - - - 20 (13 – 32.3)
Epinine, pg/mL - - - 6 (2 – 22)
Renin, mU/mL - - - 86 (34.8 - 226.1)
ANP, pmol/L - - - 103 (63 – 174)
N-terminal ANP, pmol/L - - - 1088 (628 – 1798)
Endothelin, pg/mL - - - 4 (3.4 - 11.4)
Continuous variables are expressed as mean ± SD, duration of heart failure and plasma neurohormones are expressed
as median (25 th –75 th percentiles), and other variables are n (%).
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Table 2. Stepwise Cox proportional hazard analysis of risk factors at baseline for














> 76 466 64 1.00 1.00 0.0000 55.20
76–59 467 82 1.32 (0.95–1.82) 1.27 (0.90–1.80) 0.1749
58–44 467 116 1.95 (1.44–2.65) 1.91 (1.38–2.64) 0.0001
< 44 466 170 3.23 (2.42–4.31) 2.85 (2.08–3.90) 0.0000
NYHA class
III 197 1138 1.00 1.00 0.0000 26.25
III/IV 607 186 1.96 (1.60–2.40) 1.51 (1.21–1.89) 0.0003
IV 161 56 2.55 (1.89–3.43) 2.13 (1.55–2.93) 0.0000
ACE inhibitors
No 161 66 1.00 1.00 0.0000 19.53
Yes 1745 373 0.43 (0.33–0.56) 0.51 (0.38–0.69)
Systolic blood pressure, mmHg
> 133 479 77 1.00 1.00 0.0025 14.21
133–120 611 131 1.34 (1.01–1.18) 1.24 (0.92–1.68) 0.1585
119–110 367 92 1.73 (1.28–2.34) 1.48 (1.06–2.06) 0.0217
< 110 448 139 2.14 (1.62–2.83) 1.78 (1.29–2.43) 0.0004
Sodium, mmol/L
> 141 419 76 1.00 1.00 0.0108 11.12
141–139 597 113 1.05 (0.79–1.40) 1.05 (0.78–1.43) 0.7457
139–137 380 98 1.56 (1.16–2.11) 1.39 (1.01–1.90) 0.0422
< 137 487 149 1.97 (1.50–2.60) 1.51 (1.12–2.03) 0.0075
Digitalis
No 607 132 1.00 1.00 0.0049 7.93
Yes 1098 307 1.48 (1.21–1.82) 1.37 (1.10–1.71)
LVEF, %
>30 449 98 1.00 1.00 0.0528 7.71
30–26 403 73 0.85 (0.63–1.15) 0.94 (0.69–1.29) 0.7151
25–21 404 93 1.05 (0.79–1.40) 1.16 (0.87–1.56) 0.3184
< 21 492 135 1.33 (1.02–1.72) 1.35 (1.03–1.77) 0.0281
β-Blockers
No 1788 429 1.00 1.00 0.0090 6.83
Yes 118 10 0.40 (0.22–0.75) 0.39 (0.19–0.79)
Ibopamine
No 953 199 1.00 1.00 0.0206 5.17
Yes 953 240 1.26 (1.05–1.52) 1.27 (1.03–1.55)
History of myocardial infarction
No 878 171 1.00 1.00 0.0367 4.36
Yes 1025 268 1.30 (1.07–1.58) 1.25 (1.01–1.54)
RR indicates relative risk; CI, confidence interval.
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Figure 2. Relation, in quartiles, of LVEF and GFRc to the risk of mortality
using the multivariate proportional hazards regression model.

















































Figure 1. Kaplan-Meier mortality curves for quartiles of GFRc.
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Weak prognostic values for mortality (relative risks < 2.0) were found for NYHA
class, systolic blood pressure, digitalis use, history of myocardial infarction, so-
dium level, β-blocker use, use of anticoagulants, LVEF, and ibopamine use. The
proportional relationship of GFRc with mortality was also evident in the Cox-
adjusted survival plot (Figure 3). When performing secondary analyses, no inter-
action term was statistically significant in the multivariate analysis, including
ibopamine treatment and renal function (P = 0.194). In the separate subgroup
analyses according to treatment with and without ibopamine, similar highly sig-
nificant trends in relative risks for successively lower quartiles were observed
when compared with the highest quartile of GFRc (relative risks of 1.31, 2.36,
and 2.48, respectively, for the ibopamine group [P = 0.001] and of 1.35, 1.66,
and 3.41, respectively, for the placebo group [P = 0.001]). Additional adjust-
ments for univariate prognostic variables for mortality, such as age, heart rate,
body weight, diastolic blood pressure, serum potassium level, urea and creatinine
levels, cause of CHF, diabetes mellitus, intraventricular conduction disorders,
absence of sinus rhythm, orthopnea, dyspnea, peripheral oedema, fatigue, nitrate
Figure 3. The proportional relationship of GFRc with mortality in Cox-adjusted
survival analysis.
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use, use of direct vasodilators, the administered dose of ACE inhibitors, and fu-
rosemide use were nonsignificant in the multivariate model and were not in-
cluded.
Mortality and the relationship between GFRc, LVEF, and NYHA class
Cumulative relative risk estimates for the GFRc categories in combination with
NYHA classes and LVEF are shown in Figures 4 and 5. A stepwise increase in
mortality risks with decreasing GFRc and LVEF was present. When divided into
quartiles, LVEF showed lower risk estimates than GFRc. No interaction between
GFRc and LVEF was observed, so GFRc and LVEF had an effect that was addi-
tive in terms of predicting mortality. An identical analysis of GFRc with NYHA
class revealed a similar pattern. In addition, only weak inverse correlations were
observed between baseline GFRc and NYHA class and between LVEF and
NYHA class (r = −0.062, P = 0.002 and r = −0.030, P = 0.142, respectively).
There was no correlation between GFRc and LVEF (r = −0.013, P = 0.422).
GFRc, LVEF, and plasma neurohormones
The neurohormonal subpopulation was largely similar to the general PRIME-II
population (Table 1). Most neurohormones were elevated compared with normal
values, but epinephrine, dopamine, and aldosterone levels were within the nor-
mal range. Univariate correlation coefficients for neurohormones with GFRc and
LVEF and the results of the stepwise multivariate regression analyses are pre-
sented in Table 3. The majority of plasma neurohormones showed a statistically
significant, but only moderate, relation with GFRc and LVEF. In general, a more
pronounced association was found with GFRc, and the strongest associations
were found for ANP (r = −0.35) and N-terminal ANP (r = −0.53).
Table 3. Relationship between neurohormones and LVEF and GFRc
GFRc LVEF
r Univariate Multivariate R Univariate Multivariate
Norepinephrine -0.28 < 0.001 0.001 -0.15 0.004 NS
Epinephrine -0.05 0.365 NS -0.15 0.004 0.007
Dopamine -0.23 <0.001 0.001 -0.08 0.143 NS
Renin -0.13 0.013 0.005 -0.22 0.001 NS
Aldosterone -0.15 0.005 0.006 -0.04 0.501 NS
ANP -0.35 0.001 0.001 -0.27 0.001 0.002
N-terminal ANP -0.53 0.001 0.001 -0.33 0.001 0.001
Endothelin -0.10 0.069 NS -0.18 0.001 0.046
Epinine -0.07 NS 0.201 -0.01 0.899 NS
NS indicates not significant.


























































Figure 5. Three-dimensional bar graph showing risk of mortality (vertical
axis) in relation to decreasing NYHA class (horizontal axis) and decreasing
quartiles of GFRc (diagonal axis).
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Figure 4. Three-dimensional bar graph showing risk of mortality (vertical
axis) in relation to decreasing quartiles of LVEF (horizontal axis) and de-
creasing quartiles of GFRc (diagonal axis).
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Discussion
The important new finding in this study is that renal function, as measured by
GFRc, is strongly associated with mortality in patients with advanced CHF; it
seems to be independent of the impaired LVEF found in these patients. Renal
function was more closely associated with mortality in patients with advanced
CHF than any other established risk factor, including NYHA class and LVEF. In
addition, renal function correlated significantly, and more strongly than LVEF,
with plasma neurohormones (in particular, N-terminal ANP).
Renal function as a marker of prognosis and clinical status?
Patients with renal dysfunction had a significantly poorer prognosis compared
with patients with relatively preserved renal function, despite a similar NYHA
functional class and LVEF. A number of studies focusing on specific groups
such as hypertensive individuals, the elderly, patients with recent stroke, survi-
vors of myocardial infarction, and patients after open heart surgery indicated that
elevated serum creatinine may be an independent predictor of all-cause and of
cardiovascular disease mortality16-19. Two previous studies have reported the
prognostic value of renal function in patients with CHF; both used serum
creatinine as a measure for renal function6,7. However, the patient characteristics
of those populations were limited and, remarkably, the impact of this observation
was not discussed in either article. In another study, it was speculated that renal
function might carry prognostic information, but this study mainly dealt with
changes in serum creatinine20.
In several studies, LVEF has been shown to correlate directly with survival in
patients with CHF. Although LVEF is an indicator of left ventricular dysfunc-
tion, it does not have a strong relationship with clinical symptoms3,21. Renal
function includes both cardiovascular and hemodynamic properties and, thus, its
prognostic value in CHF could be expected. It may be postulated that because
renal function is measured on a continuous scale, it is more likely to be a more
powerful predictor of the clinical status of the patient than, for example, NYHA
class. However, the present study shows that LVEF, GFRc, and NYHA class are
prognostically important and that they act in part independently and show only
weak correlations with each other. This is demonstrated by the relatively large
number of patients with severely impaired renal function who do not have se-
verely impaired cardiac function and vice versa. Further, it supports the hypothe-
sis that cardiac function, clinical status, and renal function represent, in part, dif-
ferent prognostic entities of CHF.
Treatment with ibopamine was a unique aspect of this study. Ibopamine is an
oral dopamine analogue with vasodilatory, positive inotropic, and diuretic ef-
fects22. In the PRIME-II study, ibopamine increased the risk of death among pa-
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tients with advanced CHF, but the reasons for this increase are not clear. In a post
hoc subgroup analysis, antiarrhythmic treatment was a significant predictor of
increased mortality in ibopamine-treated patients8. The possibility that ibopamine
may have contributed to the relationship between GFRc and mortality was inves-
tigated by interaction analysis in the total population and in a separate analysis of
the subgroups. Although in this exploratory analysis ibopamine did not seem to
modify this effect, a confounding influence still may have been present. The pre-
sent findings must, therefore, be viewed cautiously.
Relation between renal and cardiac dysfunction and neurohormonal activation
In the early stages of CHF, GFR is well maintained by compensatory increases in
filtration fraction; in patients with more severe CHF, GFR becomes more de-
pendent on afferent arteriolar flow and the stimulation of hemodynamic and
hormonal pathways20,23. Furthermore, the fall in effective renal blood flow is
relatively more pronounced and therefore disproportional to the reduction in car-
diac output23,24. Nevertheless, it was recently demonstrated that renal hemody-
namic reserve is already impaired in patients with asymptomatic left ventricular
dysfunction25. Traditionally, the contribution of the kidneys to CHF has been
considered an adaptive response mechanism evoking a series of compensatory
neurohormonal changes, in particular, increased adrenergic drive and activation
of the RAAS to maintain perfusion to vital organs and to expand the inadequate
arterial blood volume20,23-31. With respect to the kidneys, however, activation of
the RAAS is not only a response to preserve systemic circulatory volume; in-
deed, it is primarily a response to preserve GFR as renal blood flow decreases
and renal perfusion pressure declines5. Therefore, it could be postulated that the
association between renal function and prognosis is linked by neurohormonal ac-
tivation. In our study, renal function correlated significantly, and more strongly
than LVEF, with neurohormonal activation (in particular, with N-terminal ANP).
N-terminal ANP is a powerful predictor of cardiovascular mortality32. The major-
ity of the other vasoactive neurohormones, including those related to the RAAS,
however, were only weakly associated with renal function. A direct relationship
between the kidney and natriuretic peptides has never been demonstrated, but the
main counteracting mechanism available to the circulation to break through the
vicious circle of salt and water retention induced by the failing kidneys is the
production of ANP. In the present study, a relation between renal function and
ANP and N-ANP was indeed observed. Renal responsiveness to natriuretic pep-
tides, however, seems to decrease as CHF worsens, even in the presence of rising
plasma concentrations of these peptides33.
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Limitations of the study
This study is limited by its observational nature. GFR was calculated using the
Cockroft-Gault equation. Thus, GFR in patients with severe CHF could poten-
tially be overestimated because serum creatinine is dependent on muscle mass,
which may be lowered in patients with CHF, particularly in those with cachexia.
However, if one takes that into account, the results would be even more convinc-
ing. Also, this study constitutes cross-sectional observational data and, thus, can
only be used to generate new hypotheses. In this respect, it must be noted that
half of the patients were treated with ibopamine, which showed an increased risk
for mortality in the original study. Further, although medication was in general
similar, not all patients were using the same drugs or doses of drugs. Although
we corrected for these differences, their true influence may not have been ade-
quately represented by the multivariate analysis.
Clinical implications
Our findings have several clinical implications; the most important is that renal
function may serve as one of the most important determinants of prognosis in ad-
vanced CHF and that it seems to be more powerful than cardiac parameters
(such as LVEF) in discriminating patients at risk. Moreover, in a substantial
number of patients, the compromised renal function is probably not caused by
cardiac disease. We speculate that nephrosclerosis, which seems to run in parallel
with systemic atherosclerosis, accounts for the impaired renal function34. A
strong, direct relationship between renal function and activation of the RAAS
could not be established, but a significant correlation between plasma levels of
N-terminal ANP and GFRc was found. Therefore, determination of renal function
may serve to identify CHF patients at risk, which may have therapeutic implica-
tions. This hypothesis will require further prospective studies. It must be empha-
sised, however, that a population with severe CHF was studied, and the results
cannot be automatically extrapolated to patients with less severe CHF.
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Abstract
Background— Information regarding the cardiorenal axis in patients after a
myocardial infarction (MI) is limited. We examined the change in renal function
after a first MI, the protective effect of angiotensin converting enzyme (ACE)
inhibition and the prognostic value of baseline renal function.
Methods and Results— The study population consisted of 298 patients with a
first anterior wall MI who were randomised to the ACE inhibitor captopril or pla-
cebo after completion of streptokinase infusion. Renal function, by means of
glomerular filtration rate (GFR), was calculated using the Cockroft-Gault equa-
tion (GFRc). In the placebo group, renal function (GFRc) declined by 5.5 ml/min
within one year, versus only 0.5 ml/min in the ACE inhibitor group (P < 0.05).
This beneficial effect of captopril was most pronounced in patients with the most
compromised renal function at baseline. The incidence of chronic heart failure
(CHF) within one year increased significantly with decreasing GFRc (divided
into tertiles: 24.0%, 28.9%, and 41.2%; P < 0.01. The risk-ratio for GFRc < 81
ml/min vs. >103 ml/min was 1.86 (95%CI, 1.11-3.13; P = 0.019).
Conclusions— Renal function markedly deteriorates after a first MI, but is
significantly preserved by ACE inhibition. Furthermore, an impaired baseline re-
nal function adds prognostic risk to develop CHF in patients after a first anterior
MI.
Renal function and acute myocardial infarction 33
Introduction
The degree of renal dysfunction is one of the most powerful prognostic markers
in patients with chronic heart failure (CHF)1,2. Recently, it has been demonstrated
that moderate renal insufficiency, while tolerated in patients with a normal heart,
could independently precipitate the development of overt CHF in patients with
asymptomatic CHF1. “Subclinical” impaired renal function is not uncommon in
the general population. In a large community sample elevated serum creatinine
values were found in 8.7% of men and 8.0% of women3. The Framingham data
shows that the presence of mild renal insufficiency is associated with other car-
diovascular risk factors4. Some of these risk factors could contribute simultane-
ously to an increase in the cardiovascular risk and to an early decline in renal
function. Although there is increasing evidence that renal dysfunction is strongly
associated with cardiovascular disease it is not clear whether they are independ-
ent or are more likely to interact with each other.
To answer this question the cardiorenal axis in patients with acute myocardial
infarction is of interest. An accelerated decline of renal function, even in subjects
without renal disease, has been observed in diabetics, severe hypertension,
dyslipidemia and CHF5-8. A history of myocardial infarction (MI) is the strongest
predictor of CHF but the time course and prognostic value of renal function in
patients with a MI have never been evaluated. Angiotensin converting enzyme
(ACE) inhibition has demonstrated to reduce cardiac morbidity and improve sur-
vival post-MI9. Furthermore, ACE inhibition showed to be protective against
progressive renal function loss in both diabetic and non-diabetic renal disease pa-
tients10-12.
The objectives of the present study were therefore three-fold. We studied the
changes in renal function following first MI, and the potential renal protective
effect of ACE inhibition. In addition, we studied the prognostic value of baseline
renal function for the development of CHF.
Methods
Design and study population
The study population consisted of patients who were enrolled in a post-MI trial
(CATS: Captopril and Thrombolysis Study)13. Details of the CATS study have
been described previously. Briefly, the study investigated the effect of captopril
relative to placebo on the preservation of left ventricular volume as measured by
serial echocardiography. The study was conducted in 12 centres in the Nether-
lands and 298 patients with a first anterior wall MI were randomised to captopril
or placebo, initiated immediately upon completion of the streptokinase infusion.
Chapter 334
Patients were excluded in case of severe CHF (Killip class III or IV), severe renal
insufficiency (serum creatinine > 180 micromol/L), systolic blood pressure
(SBP) > 200 mm Hg or < 100 mg Hg, diastolic blood pressure > 120 mmHg or <
55 mmHg. Double blind medication was initiated provided SBP was stable and
above or equal to 100 mmHg and continued provided that the SBP was above or
equal to 95 mmHg. If the SBP was below 95 mm Hg, study medication was
withheld until the next dosing scheme. The target maintenance dose of captopril
was 25 mg TID. During the 12 months of double blind therapy, concomitant
therapy with calcium antagonists, beta-blockers or nitrates was instituted only for
specific reasons, e.g angina pectoris and hypertension. The recommended dose of
aspirin was 80 mg.
Renal endpoint parameter
The glomerular filtration rate (GFR) is the standard indicator of renal function.
Under steady-state conditions, GFR can be estimated from serum creatinine us-
ing the Cockgroft-Gault formula that accounts for the influence of age and body
weight on creatinine production: GFRc = [(140-age in yr) x (body weight in kg) /
[72 x serum creatinine in mg/dl]. In women, the value is multiplied by 0.8514.
This formula has been validated in several studies in different patient populations
and is frequently used in patients with increased cardiovascular risk and
CHF1,2,15,16. Patients were studied on 6 separate occasions over a 12-month pe-
riod, with the day of myocardial infarction taken as baseline assessment (day 0),
day 3, 10, 90, 180 and 360 after infarction.
Cardiac endpoint parameters
CHF was defined as classified by the CATS investigators13. All patients were
considered to have CHF in whom open treatment with diuretics, digoxin, and/or
an ACE inhibitor was started for typical signs and/or symptoms related to CHF,
or in whom hospitalisation was prolonged or were hospitalised due to the pres-
ence of symptoms of CHF. Details of the echocardiography in CATS and the
definition of left ventricular dilatation have been described previously13. Left
ventricular end-systolic and end diastolic volumes were calculated from a two-
and four-chamber view using the modified biplane Simpson’s rule17. Further-
more, regional wall abnormalities were evaluated using the wall motion score
recommended by the American Society of Echocardiography17. The left ventri-
cle, assessed by two-dimensional echocardiography on apical four- and two-
chamber views, was considered dilated if one of the following conditions was
fulfilled: [1] Left ventricular volume index (either end-systolic or end-diastolic)
had to be one standard deviation above the reference value which was obtained
from all patients with small enzymatic infarct sizes, [2] the sum of end-systolic
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and end-diastolic volume index had to be 1.5 standard deviation above the sum
of the respective reference values.
Statistical analysis
To estimate and compare the time course of renal function, adjusting for patient
covariates, a mixed model of repeated analyses (ANOVA) was performed
(Analysis I). This is a type of repeated-measures analysis that allows for incom-
plete data. We assumed a model with a random intercept and a compound sym-
metry covariance structure among serial GFRc calculations and introduced GFRc
at baseline as a covariate. The computations proceeded in two stages. First, an
intention to treat approach, in which an appropriate regression model was se-
lected for all measurements available to characterise the typical renal function
response curve for patients after a MI. Second, a more unbiased analysis, in
which individual time course curves were calculated at the patient level of analy-
sis, excluding GFRc calculations following the moment the clinical diagnosis
CHF was made (Analysis II). Individual slopes (Analysis II) could be calculated
in 225 patients: 104 were treated with placebo and 121 were treated with capto-
pril. A slope calculation was not possible because of development of CHF within
a time period of 10 days after inclusion (n = 49), and because of missing baseline
and/or follow-up data or patient withdrawal (n = 24). Patients without slope es-
timation were slightly older, had a higher prevalence of diabetes, used more often
diuretics, showed an increased infarct size, and their wall-motion score was sig-
nificantly more impaired. CHF was diagnosed in the group without slope estima-
tion in 54 (74.0%) out of 73 patients compared to 37 (16.4%) out of 225 patients
for the group with slope estimation. Between-group differences in stratified base-
line renal function groups are expressed as medians and analysed by the Mann
Whitney U test or Wilcoxon rank sum test. Because patients with diabetic neph-
ropathy have a progressive decline in glomerular function, a secondary analysis
was performed in patients with diabetes mellitus. We used stepwise Cox propor-
tional-hazards regression analyses to evaluate the association between baseline
renal function and the risk of CHF adjusting for important risk modifiers as pre-
sented in Table 1. For those who had died before the development of CHF, fol-
low-up was censored at the time of death. Continuous variables were modelled
into tertiles and relative risks were calculated for the second and third versus the
first tertile. Test for trends are presented. P values for entry and removal of 0.10
were used. To examine effect-modification, interaction terms were used for vari-
ables that showed significant main effects. Observations with missing values for
contributing variables in the multivariate model were excluded. The statistical
computer packages SPSS and SAS were used for the statistical analysis. Results
are expressed as means ± SEM, except when stated otherwise. P values are two-




During the enrolment period of CATS, 298 patients were included with 149 pa-
tients in each treatment group. A complete clinical follow-up over the 12-month
period was obtained in 245 patients. Twenty-three patients died (all were classi-
fied as cardiovascular), 92 patients developed CHF within one year of follow-up
(53 in the placebo and 39 patients in the captopril group), and 30 patients with-
drew from the study during the one year of follow-up; 13 in the placebo group,
from which 6 due to intolerance and 7 for other reasons, and 17 patients in the
captopril group, from which 11 due to intolerance and 6 for other reasons. The
clinical baseline characteristics of the entire study population, classified by GFRc
tertiles, are presented in Table 1. Patients randomised to captopril were almost
similarly distributed (47%, 52% and 53%) across the three groups.









Age, yrs 67.1 ± 5.2 59.6 ± 7.8 51.3 ± 8.2 <0.001
Male gender, % 59.8 78.4 87.5 <0.001









Ischemic heart disease, % 12.4 8.2 5.3 NS
Hypertension, % 26.8 22.7 15.8 NS
Diabetes Mellites, % 14.4 8.2 6.3 NS
Current smoker, % 51.5 61.1 76.8 <0.001
Beta-blockers, % 24.7 18.6 15.6 NS
Calcium antagonists, % 10.3 18.6 14.6 NS
Diuretics, % 14.4 12.4 8.3 NS
Nitrates, % 12.4 11.3 7.3 NS
Systolic blood pressure, mmHg 125.9 ± 22.9 128.2 ± 19.4 125.2 ± 17.7 NS
Diastolic blood pressure, mmHg 76.9 ± 13.8 76.6 ± 10.8 77.4 ± 13.5 NS
Pulse Pressure, mmHg 47.8 ± 11.8 51.4 ± 11.4 47.8 ± 11.8 NS
Heart rate, bpm 82.0 ± 16.6 80.5 ± 12.8 83.3 ± 15.2 NS
QHbdh(25th-75thpercentile) 1158 (543-1767) 1015 (601-1846) 1052 (532-1609) NS
LVEF, % 53.0 ± 10.0 54.9 ± 10.6 57.6 ± 9.3 0.006
LVESVI, ml/m2 27.6 ± 11.7 25.6 ± 9.5 23.6 ± 8.4 0.014
LVEDVI, ml/m 57.6 ± 16.3 56.1 ± 12.5 54.7 ± 11.8 NS
WMSI 1.91 ± 0.40 1.87 ± 0.40 1.77 ± 0.41 0.020
Creatinine, micromol/L 100.3 ± 20.5 90.3 ± 13.9 79.2 ± 13.6 <0.001
Sodium, mmol/L 139.1 ± 3.0 140.1 ± 3.4 139.0 ± 2.9 NS
GFRc , ml/min 67.0 ± 10.1 92.8 ± 6.0 125.3 ± 19.0 -
LEVF indicates left ventricular ejection fraction; LVESVI left ventricular end-systolic volume index; LVEDI left
ventricular end-diastolic volume index; WMSI wall motion score index. Values shown are %, mean ± SD or for
QHbdh median (25th-75thpercentile).
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Renal function correlated negatively with age, male gender, Killip class and
smoking, and positively with left ventricular injection fraction (LVEF), and left
ventricular end-systolic volume index (LVESVI).
Renal function after MI and the effects of ACE inhibition
The time course of renal function for the entire study population after MI, ad-
justed for baseline GFRc, using all measurements available, is shown in Figure 1.
A prompt decrease in GFRc in the first 3 to 10 days of 2.8 ml/min/yr and a slower
decline in the next 12 months of 2.6 ml/min/yr accounted for an overall loss of
5.4 ml/min in the first year after MI. The best fit was achieved by modelling time
exponentially. Significant effects were found for age ( P = 0.01), baseline GFRc (
P = 0.01), study medication ( P = 0.029) and the interaction term medication x
time ( P = 0.034).
The time course of renal function after MI for placebo and captopril treated pa-
tients, in which all calculations of GFRc following the moment of the diagnosis
CHF were excluded is shown in Figure 2. In placebo treated patients the loss
over the first year amounted to 5.5 ml/min/yr from day 3 post MI. For the group
treated with captopril the GFRc decreased particularly in the first three days but
remained stable during the one-year follow-up (0.5 ml/min/yr).
Figure 1. Loss of GFRc for the total group versus baseline GFRc (day 0) over the
first year after the myocardial infarction. Values are expressed in mean ± SEM.
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n = 4138 3346 3037
Figure 2. Loss of GFRc over the first year after the myocardial infarction for the
groups treated with placebo or captopril versus baseline GFRc (day 0), in which all
calculations of GFRc up until the diagnosis of CHF are included. Values are expressed
in mean ± SEM.
Figure 3. Median slope values of renal function loss stratified for baseline GFRc
divided into tertiles. All calculations of GFRc up until the diagnosis of CHF are
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> 103 ml/min versus < 81 ml/min p=0.019
Figure 4. The proportional relationship of GFRc with CHF in Cox proportional-
hazards regression analyses
The impact of initial GFRc, grouped into tertiles, on GFRc slope calculations
starting from day 3, is shown in Figure 3. For the placebo group, a relatively con-
stant rate of decline in GFR over different baseline tertiles was found with a sig-
nificant difference between the highest and lowest tertile (P < 0.003). Losses, in
contrast were, for the captopril treated group not related with baseline renal func-
tion. Within each tertile the loss in GFRc was significantly less for captopril
when compared with placebo (highest P = 0.03, intermediate P = 0.002 and low-
est tertile P < 0.001). Finally, a secondary analysis was carried out in which dia-
betic patients were excluded. Almost similar results were found (data not
shown).
Prognostic value of baseline renal function
In the total group 7.6% of the patients had a baseline GFRc below 60 ml/min.
Incidence of CHF, but not of left ventricular dilatation, increased significantly
with decreasing baseline tertiles of GFRc: 24.0%, 28.9%, 41.2%; P < 0.01 versus
53.8%, 53.3%, 54.4%; P = 0.93, respectively.
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Table 2 summarises the results by hazard (risk) ratios of the Cox regression
analysis for CHF. The risk ratio (RR) for CHF increased with decreasing GFRc.
The multivariate RR for CHF of the lowest tertile of GFRc compared with the
highest tertile was 1.86 (95%CI 1.11-3.13; P = 0.019). A clear separation of the
curve with a marked increase in the cumulative incidence of CHF for the lowest
tertile of GFRc was found (Figure 4). Of interest is the relationship of GFRc with
age. Age is a strong univariate predictor of CHF, which is expected because age
is used to calculate GFRc. When age and GFRc are examined stepwise, GFRc re-
mains in the model while age does not, indicating that GFRc provides predictive
information additive to age alone.
Table 2: Univariate and multivariate Cox proportional hazards regression









> 103 23/96 1.00 1.00
81-103 28/97 1.22 (0.70-2.11) 0.485 1.23 (0.70-2.13) 0.466
< 81 40/97 2.08 (1.24-3.47) 0.005 1.86 (1.11-3.13) 0.019
WMSI
< 1.7 26/92 1.00 1.00
1.7-2.0 24/96 0.86 (0.49-1.49) 0.585 0.87 (0.50-1.52) 0.626
> 2.0 40/96 1.65 (1.01-2.70) 0.049 1.55 (0.94-2.54) 0.083
Age, yrs
< 56 22/94 1.00
56-63 24/83 1.34 (0.75-2.38) 0.328
> 63 45/68 2.06 (1.23-3.43) 0.007
Male
No 27/72 1.00
Yes 64/218 0.73 (0.46-1.14) 0.167
Killip Class
I 64/221 1.00
II 27/68 1.54 (0.98-2.41) 0.062
Current smoker
No 35/106 1.00
Yes 56/181 0.86 (0.56-1.32) 0.491
LVEF, %
< 52 21/72 1.00
52-56 23/74 1.02 (0.57-1.85) 0.940
> 56 17/74 0.67 (0.35-1.28) 0.230
LVESVI, ml/m2
< 20 16/73 1.00
20-30 24/74 1.51 (0.80-2.85) 0.199
> 30 21/73 1.49 (0.78-2.86) 0.227
CHF indicates chronic heart failure; LVEF left ventricular ejection fraction; LVESVI left ventricular
end- systolic volume index; WMSI wall motion score index. Hazard (risk) ratios (RR) and 95% CI were
derived from stepwise Cox proportional hazard regression analysis using those variables related to GFRc
as listed in table 1.
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Finally, the incidence of CHF, when stratified for GFRc at baseline, increased
with decreasing baseline tertiles for the placebo group (10%, 15% and 30%) but
not for the group treated with captopril (16%, 17% and 14%). Because of the
small sample sizes of the different strata, these differences were not statistically
significant. The incidence of left ventricular dilatation did not change with de-
creasing tertiles of renal function in both groups: 61%, 64% and 50% for the pla-
cebo and 46%, 44% and 44% for the group treated with captopril.
Discussion
The data presented show that a first anterior MI is associated with progressive
loss in renal function during the first year of follow-up. This loss seems to be
particularly increased in patients with an already impaired renal function. Impor-
tantly, in this type of patients treatment with the ACE inhibitor captopril appears
to protect the kidney against a progressive long-term function loss. Furthermore,
an impaired baseline renal function is an additive prognostic risk factor to de-
velop CHF in patients after a first anterior MI. It should taken into consideration,
that these observations were made in subjects with mostly sub-clinical renal
function impairment, that would normally not require medical attention in itself,
and not in patients with overt disease.
Time course of renal function
We found a distinct loss of renal function of 2-3 ml/min/yr in the first days after
an acute MI with a subsequent steady decline of approximately 3 ml/min/yr that
is in excess of the normal age-related rate of renal function loss. In a longitudinal
population study a yearly mean loss of 1 ml/min/year of GFR in normal subjects
has been reported18. The loss observed in our study might be clinically relevant
since its magnitude is comparable to the rate of renal function loss observed in
renal disease10,19. Although an early decline in GFR occurred at initiation of ther-
apy, our data shows that ACE inhibition preserves renal function, with a yearly
loss close to normal (1 ml/min/yr), with the highest benefit compared to placebo
in patients with the most impaired renal function. Long-term information regard-
ing renal function and ACE inhibition post MI is limited. Beneficial renal effects
of captopril after MI have been reported in a six-month follow-up study but ACE
inhibition in this study was started on day 7 post-MI20. The authors explained
these effects by an improved cardiac function that is mediated by ACE inhibition.
However, another phenomenon could also explain the observed reno-protection
of ACE inhibition in this type of patients. It is well known from patients with re-
nal disease due to various aetiologies, that ACE inhibitors or angiotensin II an-
tagonists retard the progression of renal disease10,12,21,22. Angiotensin II in the
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kidney constricts the efferent arteriole much more than the efferent arteriole, con-
tributing to elevated glomerular pressure implicated in the pathogenesis of most
experimental and human renal disease. Moreover, neurohormonal activation, in
particular angiotensin II, plays an important role in the pathophysiology and
prognosis of heart failure and renal disease. There is now ample evidence that
pharmacological inhibition of angiotensin II attenuates the decline of cardiac as
well as renal function.
The initial fall of GFR in the group treated with captopril, initiated immedi-
ately upon completion of the streptokinase infusion, has not been reported be-
fore. It might be speculated that starting ACE inhibition later on might prevent
this early decline in renal function. However, the decline may be important, and
beneficial, since in renal patients an inverse correlation was observed between
the amount of initial renal function loss at onset of ACE inhibition therapy and
the subsequent rate of long-term decline in renal function23,24. Thus, the magni-
tude of the early renal hemodynamic effect of ACE inhibition predicts its effi-
cacy in long-term renal protection.
Prognostic value of renal function.
A number of studies have reported serum creatinine as a marker for increased
risk of cardiac disease16,25-27. Preliminary data, showed that pre-existing chronic
renal insufficiency in patients presenting with an acute MI have higher rates of
adverse events than patients without chronic renal insufficiency28. Another study
reported independent prognostic value of serum creatinine during a five-year fol-
low-up in survivors of MI29. However, in this study baseline serum creatinine
measurements were performed within a 6 months period after MI and results
could be secondary related to the event. In our study renal function was measured
within 6-hours after onset of MI symptoms and distinction was made in patients
with and without impaired renal function by dividing them in tertiles. The kinet-
ics of creatinine generation and excretion are well characterized, and even an
abrupt change in renal function will not result in gross changes in serum
creatinine within 6-hours30. The 6-hour time period is too short to measure a
change in serum creatinine due to changed renal hemodynamics. Thus our esti-
mation of renal function should reflect the renal status before the event.
Why does an impaired renal function add prognostic risk to the development
CHF? Clearly, a sub-clinical decreased renal function is unlikely to be the direct
cause. An impaired renal function is, however, associated with several other risk
factors that may themselves be causal or linked with causal processes. First, renal
function is known to correlate with a variety of cardiovascular risk factors like
insulin resistance, dyslipidemia, hyperuricemia, and hyperparathyroidism31. The
same risk factors that lead to the cardiovascular disease (myocardial infarction)
could contribute to the pathogenesis of renal disease. So, renal function, which
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has been associated with several cardiovascular risk factors and other morbidity
parameters including age, could be an indicator for more generalised atheroscle-
rosis. Second, a large number of metabolic abnormalities is related to impaired
renal function and induce myocardial dysfunction and damage and elevates the
risk of cardiovascular disease. Thirdly, neurohormonal activation is not only ap-
parent in patients with chronic heart failure but also after myocardial infarc-
tion20,29,32-34. Especially angiotensin II, the central product of the renin-
angiotensin system, may play a central role in the pathophysiology and progres-
sion of cardiovascular and renal diseases35-37.
Interactive therapeutic kidney and cardiac effects
Of major interest in this study is the protective effect of ACE inhibition. The in-
cidence of CHF in the CATS study was significantly reduced by captopril13.
Several other large prospective studies have examined the effect of ACE inhibi-
tors on mortality after MI in unselected patients and showed that the incidence of
CHF was reduced by ACE inhibitors9. This study demonstrates that the use of
captopril is associated with a decreased risk of CHF particularly in patients with
an impaired renal function at baseline. This finding suggests that the beneficial
effect of ACE inhibition on the development of CHF might be mediated, at least
in part, by its effect on renal function. It could also imply that therapy capable of
improving or stabilising renal function may improve prognosis in patients after
MI. On the basis of these findings and the results of several clinical trials study-
ing the effect of ACE inhibition in patients with acute MI the need for starting
ACE inhibitors as soon as possible could be anticipated 9.
Limitations of the study
This study is limited by its observational nature and the relative small number of
patients studied, which is expressed by the wide confidence intervals, thus can
only be used to generate new hypotheses. Furthermore, it could be questioned
whether GFRc accurately quantifies the glomerular filtration rate. This estimated
GFR could potentially overestimate the true GFR, especially in the lower ranges,
because creatinine is actively secreted by the proximal tubule and the secretion of
creatinine tends to increase to a maximum with increasing creatinine in the se-
rum. However, if one takes that into account the results would even be more
convincing. Finally, patients were excluded with e.g. low blood pressure or se-




The results of the present study indicate that an acute MI is associated with pro-
gressive loss in renal function. This loss seems to be particularly increased in pa-
tients with an already impaired renal function. Also, sub-clinical impairment in
renal function, that would not require medical attention in itself, predicts the de-
velopment of CHF in patients with a MI. Most importantly, treatment with ACE
inhibitors appears to counteract the progressive loss of both cardiac and renal
function. Better understanding of the factors that contribute to these beneficial
effects may ultimately allow improved management of patients suffering of MI.
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Abstract
Background—Microalbuminuria (MA) is an important early sign of diabetic
nephropathy. Hyperfiltration and impaired filtration in relation to albuminuria
has been well investigated in diabetic subjects. This study tested the hypothesis
that an increased urinary albumin excretion (UAE) is associated with renal func-
tional abnormalities also in nondiabetic subjects.
Methods and Results—The relation between UAE and creatinine clearances
(Ccr) in 7728 nondiabetic subjects was studied. Subjects were divided in four
groups according to UAE (mg/24 h): 0 to 15 (control), 15 to 30 (high-normal al-
buminuria [HNA]), 30 to 300 (MA), > 300 (macroalbuminuria). An elevated fil-
tration and a diminished filtration were defined as a Ccr exceeding or below the
95% confidence interval (CI) of the individual mean (i.e. prediction interval) of
the age and sex related control group. Ccr followed a parabolic trend, with a
higher Ccr in the HNA as compared with control and a lower Ccr in the MA and
macroalbuminuria group as compared with HNA. With each increasing UAE
level, male sex, age, body mass index, minimal waist circumference, systolic and
diastolic BP, plasma glucose, and a positive family history for diabetes all fol-
lowed a significant linear increasing trend (P < 0.001). After adjustment for age,
gender, body mass index, plasma glucose, a positive family history for diabetes,
systolic and diastolic BP, antihypertensive medication, and smoking in a multi-
variate analysis, HNA and MA were independently associated with an elevated
filtration (RR 1.8 [95% confidence interval, 1.30 to 2.51] and 1.7 [1.17 to 2.45]).
Macroalbuminuria was independently associated with a diminished filtration (4.3
[range, 1.97 to 9.36]).
Conclusions—An elevated UAE might be an important and early sign for
progressive renal function loss in a nondiabetic population.
Albuminuria and renal function in nondiabetics 51
Introduction
Microalbuminuria (MA; 30 to 300 mg/24 h) is an important early sign of incipi-
ent diabetic nephropathy in insulin-dependent diabetes mellitus (IDDM) and, al-
beit less specific, in non–insulin-dependent diabetes mellitus (NIDDM)1-4. Hy-
perfiltration has been observed in both IDDM and NIDDM and is thought to oc-
cur before the renal function loss5-11. Therefore, in diabetic patients, the devel-
opment of nephropathy typically follows a biphasic pattern, characterised by MA
and hyperfiltration in the initial phase, followed by progression to overt proteinu-
ria and renal function decline once overt nephropathy ensues.
Whether this biphasic pattern is typical for diabetic nephropathy or can also be
observed in nondiabetic renal disease is still unknown. From animal experimental
data, it has been suggested that a period of hyperfiltration might precede progres-
sive renal function loss in nondiabetic renal disease12,13. Furthermore, from other
animal experiments, there is evidence that hyperfiltration induces proteinuria,
suggesting that the concomitant increased intraglomerular pressure in hyperfiltra-
tion might be responsible for both albuminuria/proteinuria and the later renal
function loss14-16.
It is interesting that MA also occurs frequently in nondiabetic subjects and is
associated with several risk factors, such as hypertension, hyperlipidemia, obe-
sity, and older age17-21. Little is known about the relation between albuminuria
and renal function in nondiabetic subjects, especially whether nondiabetic sub-
jects also exert early renal functional changes such as hyperfiltration, because
they usually come to medical attention only after the development of renal dam-
age. We therefore hypothesized that an increased urinary albumin excretion
(UAE) is associated with early and late renal functional abnormalities, such as an
elevated filtration and a diminished filtration in a nondiabetic population. To test
this hypothesis, we studied renal function in relation to UAE in a large cross-
sectional study of nondiabetic subjects in the city of Groningen, the Netherlands.
Methods
Study population
This study is part of the ongoing PREVEND study (Prevention of REnal and
Vascular ENd stage Disease), running in the city of Groningen, the Netherlands.
All inhabitants of the city of Groningen between the ages of 28 and 75 yr (85,421
subjects) were asked to send in a morning urine sample and to fill out a short
questionnaire on demographics and cardiovascular history. A total of 40,856 sub-
jects (47.8%) responded. From this group, 30,890 subjects had a urinary albumin
concentration of < 10 mg/L and 9,966 subjects had a urinary albumin concentra-
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tion of ≥ 10 mg/L in their morning urine sample. After exclusion of subjects
with IDDM and pregnant women, all subjects with a urinary albumin concentra-
tion of ≥ 10 mg/L (n = 7,768) together with a randomly selected control group
with a urinary albumin concentration of < 10 mg/L (n = 3,395) were invited for
further investigations in an outpatient clinic (total n = 11,163). Finally, 8,592
subjects completed the total screening program, rendering us the actual study co-
hort. The study was approved by the medical ethics committee and conducted in
accordance with the guidelines of the declaration of Helsinki. All participants
who attended the outpatient clinic gave written informed consent.
Study design
The screening program in the outpatient clinic consisted of two visits. At the first
visit, participants completed a self-administered questionnaire regarding demo-
graphics; cardiovascular and renal history; family history on diabetes; and the use
of medication for diabetes, hypertension, or hyperlipidemia. Subjects were classi-
fied as having renal disease when they were being treated for proteinuria as a
consequence of renal disease, and subjects were classified as having a positive
family history for diabetes when at least one first-degree relative had diabetes.
After shoes and heavy clothing were removed, weight was measured to the near-
est 0.5 kg with a Seca balance scale (Vogel and Halke, Hamburg, Germany).
Height was measured to the nearest 0.5 cm. Minimal waist circumference was
measured on bare skin at the natural indentation between the 10th rib and the iliac
crest22. At both visits, BP was measured in supine position, every minute, for 10
and 8 min, respectively, with an automatic Dinamap XL Model 9300 series de-
vice (Johnson and Johnson, Medical Inc., Arlington, TX). Subjects were asked to
collect two consecutive 24-h urine in the last week before the second visit. The
subjects were given oral and written instructions on how to collect 24-h urine,
and they were instructed to postpone urine collection in case of fever, urinary
tract infection, or menstruation and to refrain from heavy exercise during collec-
tion as much as possible. Furthermore, the subjects were asked to store the urine
cold (4°C) for a maximum of 4 d before the second visit. Measurements of uri-
nary volume and albumin and creatinine concentrations were performed for each
collection. At the second visit, blood was drawn, after an overnight fast, for de-
termination of plasma glucose and serum creatinine. Calculations Systolic and
diastolic BP was calculated as the mean of the last two measurements of the two
visits. Body mass index (BMI) was calculated as the ratio between weight (kg)
and the square of height (m) (weight/height2). Body surface area (BSA) was cal-
culated according to DuBois and DuBois23. UAE was calculated as the mean of
the two 24-h UAE. Similar to most large epidemiologic studies, we estimated
GFR according to the Cockcroft and Gault formula, but because we also col-
lected 24-h urine, we were also able to calculate creatinine clearance (Ccr) by
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taking the mean of the two 24-h urinary creatinine excretions divided by plasma
creatinine and corrected for BSA (ml/min per 1.73m2)24. We analysed our data
both with the Cockcroft clearance and the Ccr. Because both analyses gave the
same results, we show the results only of the Ccr. Because 24-h urine collection
might be inaccurate as a result of collection errors, we carried out a second vali-
dation step. First, we analysed our data after excluding subjects who had a differ-
ence between their 24-h Ccr and Cockcroft clearance of 2 x the SD according to
the Bland-Altman method24,25. Second, we analyzed our data after excluding sub-
jects who had a difference between their Ccr of the first urine collection and of
the second urine collection of 2 x the SD according to the Bland-Altman method.
Therefore, we analyzed our data only of subjects for whom both Ccr were the
same. Because both the first and the second analyses gave the same results as
with the crude Ccr (in which we did not exclude subjects on these grounds), we
show only the crude results.
Laboratory methods
Urinary albumin concentration was determined by nephelometry with a threshold
of 2.3 mg/L and intra- and interassay coefficients of variation of ≤ 4.3% and ≤
4.4%, respectively (Dade Behring Diagnostic, Marburg, Germany). Plasma glu-
cose and serum and urinary creatinine were determined by Kodak Ektachem dry
chemistry (Eastman Kodak, Rochester, NY). Urinary leukocyte and erythrocyte
measurements were done by Nephur-test + leuco sticks (Boehringer Mannheim,
Mannheim, Germany).
Data handling and definitions
In the present analysis, we started with the 8,592 subjects from our actual study
cohort. We excluded from this analysis 433 subjects because of erythrocyturia or
leukocyturia, according to dipstick analysis (erythrocytes > 50/µl or leukocytes
> 75/µl, or leukocytes = 75/µl and erythrocytes > 5/µl) and 239 subjects because
of diabetes, which was defined as fasting plasma glucose levels of ≥ 7.8 mmol/L
or nonfasting plasma glucose levels of ≥ 11.1 mmol/L or the use of oral antidia-
betic medication. Another 46 subjects were excluded because they were treated
for proteinuria as a consequence of a renal disease. Finally, 146 subjects were
excluded because of missing data on albuminuria, erythrocyturia, leukocyturia,
plasma glucose levels, or renal disease. Altogether, 7,728 subjects were eligible
for this analysis. Because it has been suggested that excess cardiovascular and
renal risk may already be present at levels of UAE lower than the conventional
definition of MA (30 to 300 mg/24 h), we also investigated borderline elevated
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This rendered us the following groups: the control group (0 to 15 mg/24 h; n =
5,608), the high-normal albuminuria (HNA) group (15 to 30 mg/24 h; n = 1,106),
the MA group (30 to 300 mg/24 h; n = 932), and the macroalbuminuria group (>
300 mg/24 h; n = 82). Obesity was defined as having a BMI of > 30 kg/m2. Early
and late renal functional abnormalities, such as elevated filtration and diminished
filtration, were defined as a Ccr exceeding or below the 95% confidence interval
(CI) of the individual mean (i.e. prediction interval) of the age and sex related
control group11. The prediction intervals were obtained by means of a linear re-
gression analysis.
Statistical analyses
All calculations were performed with SPSS version 9.0 software (SPSS, Chi-
cago, IL). Continuous data are reported as mean ± SD. In case of skewed distri-
bution, the median with 25th and 75th percentiles was used. All P values are two-
tailed. A P value of < 0.05 was considered statistically significant. Differences
among the four UAE groups were assessed by χ2 analysis or ANOVA and tested
for trend.
To investigate the risk of an elevated filtration or a diminished filtration, logis-
tic regression analysis was used. Logistic regression analysis was used to test the
independent relation among the four albuminuria groups and an elevated or a di-
minished filtration. The four albuminuria groups were entered into the regression
analysis, and odds ratios were estimated after adjustment for possible confound-
ing factors. We adjusted in this analysis for age, gender, BMI, systolic and dia-
stolic BP, antihypertensive medication, plasma glucose, a positive family history
for diabetes, and smoking. The calculated odds ratios and 95% CI are expressed
as an approximation of RR.
Results
The characteristics of our study group according to the four different UAE
groups are shown in Table 1. Age, BMI, minimal waist circumference, systolic
and diastolic BP, and glucose showed a significant linear trend with each subse-
quent UAE level. Similarly, the frequencies of male gender, obesity, a positive
family history, and the use of antihypertensive treatment also showed a linear
trend with each subsequent UAE level. These differences remained statistically
significant after adjusting for age and gender. There was no significant difference
in smoking among the four different albuminuria groups. Concerning the renal
characteristics, serum creatinine also followed a linear trend with each subse-
quent UAE level (P < 0.001). In contrast, the mean values for the 24-h Ccr fol-
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Urinary albumin excretion (mg/24 hr)























lowed a parabolic trend with each subsequent UAE level (P < 0.001). In other
words, Ccr in the HNA group was elevated as compared with the control group,
whereas it showed a decreasing trend in the MA and macroalbuminuria groups as
compared with the HNA group. To investigate whether this observed parabolic
pattern could still be found after adjustment for the two most important con-
founders, age and gender, we analysed Ccr in a general linear model. This addi-
tional analysis supported the finding of this parabolic pattern (Figure 1).
Because the mean Ccr of a certain group is only the sum of subjects with a nor-
mal Ccr and subjects with an abnormal Ccr, this does offer optimal information
about the relationship between albuminuria and an elevated or a diminished fil-
tration as compared with normal subjects. Therefore, we also analysed our data
for subjects with an elevated or a diminished filtration. In a linear regression
model, including age and gender, mean Ccr was calculated with the 2 × SD bor-
ders. This is shown in Figure 2. Mean Ccr was 103 ± 19 ml/min per 1.73m2 in
males 30 yr of age and 85 ± 19 ml/min per 1.73m2 in males 70 yr of age. In fe-
males 30 yr of age and 70 yr of age, the Ccr was 101 ± 18 ml/min per 1.73m2,
and 76 ± 18 ml/min per 1.73m2, respectively.
Figure 1. Creatinine clearance (Ccr) according to the four different albuminuria
groups. The error bars represent the 95% confidence intervals. The numbers in
the bars represent the age-and gender-adjusted mean of the Ccr (ml/min per
1.73m2 ).
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Figure 2. Ccr (ml/min per 1.73m2 ) as a function of age, with the two lines rep-
resenting the upper and lower 95% CI of the individual mean (i.e. prediction
interval) according to the regression analysis of the control group. (A) Males.
(B) Females. The subjects above the upper line represent subjects with an ele-
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The prediction interval borders show the subjects with an elevated Ccr (n = 263)
and with a diminished Ccr (n = 181), taking men and women together. To inves-
tigate further the relation between an elevated or diminished Ccr and albuminu-
ria, we analysed our data in a logistic regression analysis (Table 2). We first ana-
lysed our data adjusting only for age and gender. After also adjusting for all other
possible confounders, such as BMI, plasma glucose, a positive family history for
diabetes, BP, antihypertensive medication, and smoking, the results remained the
same. An elevated filtration was associated with albuminuria, BMI, and plasma
glucose, whereas it was inversely associated with the use of antihypertensive
medication. Furthermore, a diminished filtration was associated with albuminu-
ria, BMI, male gender, and antihypertensive medication, whereas it was inversely
associated with plasma glucose. HNA and MA were associated with an increased
RR for an elevated filtration (RR 1.8 [95% CI, 1.30-2.51], P < 0.001; and RR 1.7
[1.17-2.45]), P < 0.01, respectively). Macroalbuminuria was also associated with
an increased RR for an elevated filtration (RR 1.8 [0.64-5.23]), but this was not
significant probably because of the small sample size (n = 82). Conversely,
macroalbuminuria was associated with an increased RR for a diminished filtra-
tion (RR 4.3 [1.97-9.36], P < 0.001), whereas HNA was associated with a de-
creased RR for a diminished filtration (RR 0.3 [0.13-0.59], P < 0.001). In other
words, HNA and MA are characterised by an elevated filtration, whereas macro-
albuminuria is characterised by a diminished filtration. Moreover, a diminished
filtration is not observed in association with HNA.
Discussion
This is the first, albeit cross-sectional, study that might shed some light on renal
functional abnormalities in nondiabetic subjects in an early phase. Because dia-
betic subjects are usually followed for their diabetic disease, the course of their
renal function is usually well known. Nondiabetic subjects come to medical at-
tention only after the development of renal damage, which explains why little is
known about early renal functional abnormalities in these subjects. This study
shows that the GFR in nondiabetic subjects might have a parabolic pattern that is
associated with the different levels of UAE. In other words, the MA group has
more subjects with an elevated filtration, whereas in the macroalbuminuria group
more subjects with a diminished filtration can be found. It is interesting that the
association between an elevated filtration and albuminuria was even more pro-
nounced in subjects with a UAE thus far considered to be normal: 15 to 30
mg/24h.
One could argue that those subjects with an elevated filtration or a diminished
filtration have such a filtration only by coincidence, because of miscollection or
Chapter 460
because of the variability of the measurement. To test the validity of our data, we
also analysed our data after excluding subjects by the Bland-Altman method. The
Bland-Altman method investigates the agreement between two measurements,
which should measure the same. When there was more than a 2 x SD difference
of the mean between the two measurements, either Cockcroft versus Ccr, to cor-
rect for miscollections, or first versus second 24 h Ccr, to correct for variability,
we excluded these subjects from the validity analysis. In other words, we ana-
lysed our data only with subjects in whom the estimated Cockcroft clearancé was
similar to the calculated 24-h Ccr and in whom the first versus the second calcu-
lated 24-h Ccr was similar. Because there was no difference in outcome, we did
the final analysis without excluding any subjects on the basis of these grounds to
avoid selection bias. We conducted a second validation by analysing our data
with Ccr not corrected for BSA. The uncorrected Ccr gave, if any, a somewhat
higher RR. Because it is known that body mass influences renal function and be-
cause subjects with higher rates of albuminuria were also more obese, we thought
it more appropriate to use the data of Ccr corrected for BSA. We observed an
increase in both Ccr and serum creatinine in the HNA group as compared with
the control group (Table 1). This discrepancy could be due to a difference in
body composition between the high-normal albuminuria group and the control
group. Males were more prevalent in the HNA group, consistent with a greater
muscle mass, which might explain the observed discrepancy.
The observed elevated or diminished filtration in the different albuminuria
groups might be explained by other factors, such as age, gender, hypertension or
antihypertensive treatment, hyperglycemia, and obesity. Indeed, hypertension,
hyperglycemia, and obesity have been described to be related to hyperfiltration,
and it has been shown that antihypertensive treatment may also influence GFR27-
31
. Because these factors were more prevalent in the groups with higher UAE,
this may have introduced bias in the presented relation between albuminuria and
Ccr. However, even after adjusting for systolic and diastolic BP, antihypertensive
treatment, plasma glucose, and BMI, the association between albuminuria and an
elevated or a diminished filtration persisted. It is therefore suggested that HNA
and MA are independently associated with an elevated filtration, whereas macro-
albuminuria is independently associated with a diminished filtration. The finding
that HNA is associated with a lower risk for a diminished filtration emphasizes
the finding that this group is mainly characterized by an elevated filtration.
The parabolic pattern in Ccr as shown in Figure 1 seems similar to the widely
known parabolic or biphasic pattern in renal function as observed in diabetes. Al-
though the renal hemodynamic abnormalities in diabetes are likely to be specific
for the diabetic condition, it has been suggested that determinants of progressive
renal function loss are similar for patients with established nondiabetic and dia-
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betic renal disease32,33. One of the underlying mechanisms responsible for the
observed early renal functional abnormalities in our nondiabetic subjects may be
the consequence of insulin resistance. As mentioned before, subjects with an ele-
vated UAE had higher BP, higher BMI, higher minimal waist circumference, and
higher plasma glucose levels. These characteristics have been related to the insu-
lin resistance syndrome34. The insulin resistance syndrome may not only underlie
NIDDM but can also be found in nondiabetic subjects34. Within this context, MA
has been argued to be part of the insulin resistance syndrome in diabetic and
nondiabetic subjects20,35-39. The underlying mechanism for hyperfiltration or an
impaired filtration might be related to hyperinsulinemia, associated with insulin
resistance. In both animal and human experimental research, hyperinsulinemia
has been reported to influence GFR and has even been related to hyperfiltra-
tion40-42. It has also been argued that insulin may also be responsible for an al-
tered permeability of the glomerular membrane for albumin43. Because this study
population after the selection procedure was enriched for albuminuria, one could
argue that the population was also enriched for prediabetes. After correction in a
multivariate model for characteristics of prediabetes, i.e., plasma glucose, BMI,
systolic and diastolic BP, and a diabetic family history, the results remained the
same. Therefore, there seems to be a robust effect of albuminuria on renal func-
tion, independent of prediabetes or insulin resistance. It is, however, difficult to
unravel the responsibility of each unique part on renal function in a cross-
sectional study. Nevertheless, these were nondiabetic subjects with early renal
functional abnormalities in relation to albuminuria, which has not been shown
before. Apart from the observed elevated filtration in the HNA and microalbu-
minuric subjects, we observed an independent association with a diminished fil-
tration in macroalbuminuric subjects. Taking together this parabolic pattern in
Ccr, it is tempting to speculate that the group with "hyperfiltration" will eventu-
ally progress to renal functional impairment. However, we conducted only a
cross-sectional study and cannot draw that conclusion without a longitudinal fol-
low-up. When a longitudinal follow-up can confirm that subjects with an ele-
vated filtration will indeed progress to renal functional impairment with a con-
comitant increase in UAE, an elevated UAE might be an important and early sign
for progressive renal function loss in a nondiabetic population. In conclusion, we
found an association between UAE and renal function, i.e., an elevated Ccr in the
stages of slightly elevated albuminuria and a lower Ccr in groups with higher
UAE. Moreover, in these nondiabetic subjects, increased UAE is associated with
a metabolic profile resembling the insulin resistance syndrome. Screening for al-
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Abstract
Background— Microalbuminuria is associated with an increased risk for renal
and cardiovascular morbidity and mortality in diabetic patients, patients with hy-
pertension and in elderly subjects. However, the significance of microalbuminu-
ria as a common independent risk factor in a non-diabetic, non-hypertensive
population is still a matter under debate. The aim of the present large population
based study was to assess the prevalence of microalbuminuria in the general
population, especially in non-diabetic and non-hypertensive subjects, and its as-
sociation with known cardiovascular risk factors and cardiovascular morbidity.
Methods and results— All inhabitants of the city of Groningen, The Nether-
lands, aged between 28 and 75 years, were send a postal questionnaire and a vial
to collect an early morning urine sample (n = 85,421). Of these 40,856 subjects
(47.8%) responded. Cardiovascular risk factors and morbidity were validated in
a well defined non-hypertensive and non-hypertensive group of 5,241 subjects.
Microalbuminuria, self-reported cardiovascular risk and cardiovascular morbidity
in the total study cohort, and additionally more detailed measurements in a subset
of the total population. Microalbuminuria (20 to 200 mg/L) was present in 7.2% of
the subjects and independently associated with age, gender, hypertension, diabetes,
smoking, previous myocardial infarction and stroke. Some of these associations
were already observed at albuminuria levels of 10-20 mg/L. After exclusion of the
diabetic and hypertensive subjects, microalbuminuria was still prevalent in 6.6% of
the subjects.
Conclusions— Microalbuminuria appears to be common not only in the
general population but also in a non-diabetic, non-hypertensive population and is
independently associated with increased cardiovascular risk factors and
cardiovascular morbidity. Importantly, some of these associations are present at
urinary albumin levels currently considered to be normal. These findings suggest
that urinary albumin measurements may be useful in early risk profiling and
prevention of cardiovascular disease in the population at large.
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Introduction
Microalbuminuria is associated with an increased risk for renal and cardiovascu-
lar morbidity and mortality in diabetic patients, patients with hypertension and in
elderly subjects1-11. In a recent study it is suggested that an increased urinary al-
bumin excretion is associated with an increased risk of ischemic heart disease in
subjects without renal and ischemic heart disease or diabetes mellitus12. How-
ever, the significance of microalbuminuria as a common independent risk factor
in a non-diabetic, non-hypertensive population is still a matter under debate
which needs to be solved in view of the potential significance of microalbuminu-
ria as a risk factor. Reliable data on the prevalence of microalbuminuria in the
general population and its association with cardiovascular risk factors and car-
diovascular morbidity is limited. The relevance of previous research to the gen-
eral population is debated because most published data to date have been derived
from small studies or subjects who were referred because of suspected disease13-
17
. The aim of the present large population based study was to determine the
prevalence of microalbuminuria in the general population and its relationship
with cardiovascular risk factors and morbidity. In addition, we have investigated
whether these associations were present at levels of urinary albumin excretion
currently considered to be "normal". Results were validated in a non-diabetic,




The PREVEND (Prevention of REnal and Vascular ENd stage Disease) study
was designed to prospectively investigate the natural-course of microalbuminuria
and its relation with renal and cardiovascular disease in a large cohort drawn
from the general population. All inhabitants of the city of Groningen (The Neth-
erlands), between the age of 28 to 75 years, in total 85,421 subjects, were sent a
postal questionnaire and a vial to collect an early morning urine sample, and al-
together 40,856 people (47.8%) responded. The one-page questionnaire provided
information on the presence of the established risk factors for cardiovascular dis-
ease and documented cardiovascular morbidity. Subjects were considered being
diabetic when they positively answered the question whether they had a physi-
cian diagnosis of diabetes, regardless of the type of anti-diabetic treatment. Those
who reported taking antihypertensive or lipid lowering medication were regarded
as hypertensive and hyperlipidaemic, respectively. Subjects were classified as
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smokers if they reported smoking or having smoked cigarettes during the previ-
ous 5 years. A history of myocardial infarction or stroke was considered present
if the subject reported having been hospitalized for at least three days due to that
condition. A family history of cardiovascular disease was considered present if at
least one first degree relative had documented angina pectoris, myocardial infarc-
tion or stroke before the age of 65 years.
Sample of population in which more detailed measurements were obtained
We determined robustness of results by performing a similar analysis comprising
a selection of the non-diabetic and non-hypertensive subjects that visited the out-
patient clinic. This study cohort consists of all responding subjects with a morn-
ing urinary albumin concentration of 10 mg/L or above together with a randomly
selected control group of the total study population with morning urinary albu-
min excretion of < 10 mg/L, willing to participate in a long-term natural course
programme. Details of this protocol have been described elsewhere18. In this
natural-course program the subjects were at baseline examined on two occasions
within a week. The examination consisted of blood pressure measurements (with
an automatic Dinamap device), electrocardiography and collection of two con-
secutive 24 hour urine specimens for accurate albumin measurements. Blood
samples were taken to determine plasma levels of glucose and cholesterol. Insu-
lin using diabetic subjects and pregnant women were excluded. All subjects
(n=8,592) completed the baseline measurements of the natural-course pro-
gramme. Systolic and diastolic blood pressure measurements were calculated as
the mean of the last two out of 10 successive measurements of the two visits.
Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic
blood pressure of ≥ 90 mmHg or the use of antihypertensive medication. Diabe-
tes was defined using impaired glucose tolerance criteria; fasting glucose levels
of ≥ 6.1 mmol/L or non-fasting plasma glucose level of 7.8 mmol/L, or the use of
oral antidiabetic drugs. Hyperlipidaemia was defined as a total serum cholesterol
concentration of ≥ 6.5 mmol/L, or in the case of a previous myocardial infarction
≥ 5.0 mmol/L, or the use of lipid lowering medication. A myocardial infarction
was defined as reported hospitalisation or electrocardiographic evidence of myo-
cardial infarction according to the Minnesota criteria19. The non-diabetic and
non-hypertensive subgroup consisted of 5,421 subjects.
Urinary albumin measurements
Morning urinary albumin concentration (MUAC) was determined by a commer-
cial immunoturbidimetry assay with sensitivity of 2.3 mg/L and inter- and intra-
assay coefficients of variation of 4.4% and 4.3%, respectively (Dade Behring Di-
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agnostica). Urine samples could not be analysed for 237 of the 40,856 subjects.
The number of the studied subjects was thus reduced to 40,619. Microalbuminu-
ria is conventionally defined as a urinary albumin excretion between 30 to 300
mg/24h for timed 24 hour urine collections. Microalbuminuria can be defined for
untimed samples as urinary albumin excretion between 20 to 200 mg/L20. Sub-
jects with the morning urinary albumin concentration of 10 to 20 mg/L were con-
sidered to have "high-normal" albuminuria and those with less than 10 mg/L
were regarded to have “low-normal” albuminuria. Of the 8,592 subjects who
completed the natural- course programme 433 subjects were excluded because of
erythrocyturia or leukocyturia (erythrocytes > 50/ul or leukocytes > 75/ul, or
leukocytes = 75/ul and erythrocytes > 5/ul). In this group albuminuria was ex-
pressed as the mean value for two 24 hour urine collections. Microalbuminuria
was defined as 30 to 300 mg/24hr, “high-normal” as 15 to 30 mg/24hr and “low-
normal” as 0 to 15mg/24hr.
Statistical analysis
Age and sex-adjusted prevalence rates were calculated by the direct method. Age
categories were below 39, 40 to 49, 50 to 69 and 70 years and older. The age and
sex distribution in the total study group was used as the standard population.
Logistic regression analysis was performed to predict microalbuminuria from
cardiovascular risk and morbidity factors, sex and age.
Patients with a urinary albumin concentration above 200 mg/L for the total
study population and above 300 mg/24hr for the subgroup of the total population
were excluded from these analyses.
Because the subgroup was not a simple random sample of the total study
population these data were analyzed using a “design-based” logistic regression
analysis that takes the sample design into account.
Odds ratios were taken as approximation of relative risk and expressed with 95%
confidence intervals. All P-values are two tailed. Analyses were performed using
the statistical packages SPSS version 8.0, SAS version 6.12 and for the “design-
based” logistic regression analysis STATA 6.0.
Results
Microalbuminuria (20 to 200 mg/L) was present in 7.2% (95%CI, 6.9-7.4%) of
the subjects. In 282 subjects (0.7%) [0.6-0.8%] a morning urinary albumin con-
centration higher than 200 mg/L was found. The group-specific characteristics






















age, male sex and the presence of diabetes, hypertension, hyperlipidaemia, smok-
ing, myocardial infarction and stroke were seen more frequent in subjects with
increased levels of albuminuria.
Table 1. Characteristics of the total study population









Age, years, mean (SD) 49.4(12.7) 47.9(12.9) 53.1 (13.2) 57.2 (12.7) 49.5 (12.9)
Male,% 43.4 51.5 53.8 59.2 45.6












Diabetes, % 2.1 2.9 6.2 17.6 2.6
Hypertension, % 10.3 10.9 18.9 38.1 11.2
Hyperlipidaemia, % 4.5 4.4 6.7 17.2 4.7
Positive family history of cardiovascular
disease, % 32.0 31.7 33.2 40.9 32.1
Smoking, % 40.0 48.8 49.4 48.2 42.2
Myocardial infarction, % 2.7 2.8 6.0 11.0 3.0
Stroke, % 0.7 0.8 1.6 4.7 0.8
Figure 1 shows age and sex adjusted prevalences of microalbuminuria in dia-
betic, in hypertensive subjects and in non-hypertensive non-diabetic subjects.
Figure 1. Age and sex adjusted prevalences of microalbuminuria in diabetic,
in hypertensive, and in non-diabetic non-hypertensive subjects.
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Although micro- and macroalbuminuria were found more frequently in the dia-
betic and hypertensive subgroup, microalbuminuria was still prevalent in 6.6% of
the non-diabetic, non-hypertensive subjects. 2,186 (74.9%) out of 2,918 subjects
with microalbuminuria and 5,682 (84.2%) out of 6,749 subjects with “high-
normal” albuminuria reported not to have diabetes and/or hypertension.
The associations between microalbuminuria and various cardiovascular
risk factors in the total study population are shown in Table 2 on the next page.
A morning urinary albumin concentration in the microalbuminuric range was as-
sociated with age and sex and the presence of diabetes, hypertension, smoking,
previous myocardial infarction or stroke but not with a family history of cardio-
vascular disease. The independent contribution of the various risk factors and age
and sex was further explored by modelling microalbuminuria as dependent vari-
able in a mutually adjusted model. Only hyperlipidaemia remained not signifi-
cant in the mutually adjusted model.
Table 3. Characteristics of the subset of the population in which more detailed
measurements were performed and in which diabetic and hypertensive subjects
were excluded









Age, years, mean (SD) 43.9(10.7) 46.0(11.6) 48.3 (12.4) 50.0 (14.7) 44.5 (11.0)
Male, % 44.9 55.2 55.5 68.0 46.9












Hyperlipidaemia, % 18.9 19.6 26.3 37.5 19.6
Positive family history of cardiovas-
cular disease, % 28.5 29.2 32.0 40.0 28.9
Smoking, % 39.9 44.9 46.5 32.0 40.8
Myocardial infarction, % 3.7 4.7 7.7 8.7 4.1
Stroke, % 0.5 0.2 2.0 0.0 0.9
We also examined in the total study population the association between a level of
urinary albumin excretion nowadays considered to be normal and the cardiovas-
cular risk factors of interest. Relative risks for age, sex, diabetes, hypertension,
and smoking were already increased in the group with “high-normal” albuminu-
ria (10 to 20 mg/L) compared with the group with a urinary albumin excretion
level between 0 and 10 mg/L, although hypertension was not significant in the
univariate analysis (Table 2). The group-specific characteristics of the 5,421 non-
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were obtained are presented in Table 3. Table 4 describes the associations in this
subset of the total population. The point estimates of the relative risks were rather
similar for the majority of cardiovascular risk factors and morbidity parameters,
when compared with the total population, whereas the 95% confidence intervals
were considerably larger. The association with microalbuminuria remained statis-
tically significant for age, sex and stroke in the multivariate analysis.
Discussion
Microalbuminuria is common in the general population with a prevalence of
7.2% and independently associated with cardiovascular risk factors and cardio-
vascular morbidity. The majority of these microalbuminuric subjects (74.9%) has
no reported diabetes or hypertension. The results show that even after excluding
the diabetic and hypertensive subjects microalbuminuria is still prevalent in 6.6%
of the subjects. Cardiovascular risk factors were already elevated at levels of al-
buminuria currently considered to be normal (10 to 20 mg/L or 15 to 30
mg/24hr).
To appreciate these findings some issues need to be addressed. Current opin-
ions about the prevalence of microalbuminuria in a general population are based
on a number of studies. Reported prevalences vary significantly due to variations
in ethnic groups, specimen collection, the cut-off level of albumin excretion, and
analytical methods. The distribution of demographic and co-existing diseases
may also contribute. In addition, the studies are limited in size and not strictly
population-based, which limits the general applicability of the results. In case we
restrict ourselves to studies performed in the Western European population four
“general population” studies reported prevalences of microalbuminuria in ranges
from 2.2% to 10.2%13,15,21,22. However, the number of included subjects ranges
from 171 to 1,684 subjects and may not reflect the situation in the general popu-
lation. In one relatively large non-European study, which included also 4,330
European subjects, a prevalence of 2.7% was reported, but the definition for mi-
croalbuminuria was based on a cut-off value of 30 mg/L15. In case we use their
criteria the prevalence of microalbuminuria in our study is reduced to 4.5%. Our
study group is significantly larger, unselected and covers a wide age range, thus
providing not only an adequate estimate of the prevalence of microalbuminuria
in the general adult population but also in subgroups as non-diabetic, non-
hypertensive subjects.
The clinical relevance of microalbuminuria as a common independent risk
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A number of studies, addressed as being a sample of the general population,
showed cross-sectionally and longitudinally that microalbuminuria is
independently associated with an adverse cardiovascular risk profile and
increased cardiovascular risk10,12-16,21,23,24. However, most published data are
small sized, excluded not on purpose diabetic and hypertensive subjects and were
mainly derived from subjects that were referred because of suspected disease,
which limits extrapolation of the results to the general population. This study is
the first that shows an independent association between urinary albumin
excretion and cardiovascular risk factors not only in the population at large but
also in a strict non-diabetic non-hypertensive subset of the general population.
The higher prevalence of microalbuminuria in men, and the finding that
microalbuminuria is age dependent is in agreement with previous
reports13,15,16,16,21,24. The association between urinary albumin excretion and
several cardiovascular disease risk factors was apparent already in albuminuria
ranges currently considered to be "normal". Several studies have shown a
gradual relationship between levels of urinary albumin in microalbuminuria-
ranges (30 to 300 mg/24hr) and cardiovascular risk factors1,4,7,11,14,25,26. Although
it has been speculated that urinary albumin excretion levels relevant for
cardiovascular disease might be lower, no studies so far focused on lower urinary
albumin excretion rate levels. Our results demonstrate that high-normal
albuminuria is associated with diabetes, hypertension and smoking. Therefore,
reconsideration of the lower limit defining a "pathological" albuminuria is
strongly suggested.
Our study has some limitations. In the overall cohort we have only measured
urinary albumin concentrations without correcting for potential variability in urine
volumes. Previous studies have shown that the early morning spot urine gives a
good estimate of the 24-hour urinary excretion of albumin20,27,28. Furthermore, an
early morning urine sample allows screening in large populations. We therefore
feel it to be a reliable index of urinary albumin excretion in a population-based
study. Moreover, the analysis of the validation set, in which more accurate meas-
urements were performed (2 times 24 hr urine collections), confirmed the findings
from the total study cohort.
The response rate, although lower than might be achieved in research
conducted in a clinical setting, is reasonable for a postal survey. However, the
male to female ratio and the mean age were different for the responders versus
non-responders (45.6% males in responders versus 54.6% in non-responders;
mean age for responders was 51.9 years and 46.4 years for non-responders). The
effect this may have on the reported outcome is unclear.
Self-reported histories have limitations because misclassification and therefore
bias may occur. However, we do not believe that this has materially affected the
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results because the factors that were associated with microalbuminuria in the to-
tal study cohort showed similar trends as the sample of the total population in
which more detailed measurements were performed and strict non-diabetic, non-
hypertensive subjects were included. The estimated confidence intervals in this
subgroup were considerably larger because of a reduced sample size and the
utilisation of a “design-based analysis”29,30. Most of the statistical packages as-
sume that the data have been selected by simple random sampling and consider
the data as being independent and identically distributed. This may lead to
grossly underestimated confidence intervals and in some situations biased point
estimates. Our subgroup was not a random sample but a stratified sample of the
total population selecting all the subjects with a “high-normal” urine albumin ex-
cretion and a control group characterised with a “low-normal” urine albumin ex-
cretion.
A cross-sectional design limits the ability to causally relate albuminuria and car-
diovascular risk factors and cardiovascular morbidity. Further longitudinal research
is necessary to determine whether albuminuria contributes independently to car-
diovascular morbidity and mortality also in non-diabetic, non-hypertensive sub-
jects. Ongoing follow-up studies of the PREVEND natural course cohort will an-
swer these questions.
We conclude from this cross-sectional study that microalbuminuria is far from
being rare and an important indicator for cardiovascular risk factors and cardiovas-
cular morbidity also in non-diabetic, non-hypertensive subjects. Further prospec-
tive studies are needed to assess the relationship between the occurrence of micro-
albuminuria and the subsequent risk of cardiovascular disease. Eventually, the
measurements of urine albumin excretion may prove to be useful in early risk pro-
filing and prevention of cardiovascular disease and may lead to new therapeutic
strategies in the prevention of cardiovascular disease.
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Abstract
Background—The electrocardiogram (ECG) can be used to determine the
presence of ischemic heart disease in a population at large. In addition, there is
evidence that microalbuminuria increases cardiovascular risk in nondiabetic
populations. Little is known about the precise relation between urinary albumin
excretion (UAE) and cardiovascular disease. If UAE can be considered as a con-
tinuous variable this could have important implications for individual cardiovas-
cular risk assessment. We evaluated the association between the level of UAE,
including levels within the normal range, and ischemic electrocardiographic
(ECG) abnormalities in a general nondiabetic population.
Methods and results— In a population-based study 7,579 subjects (mean age
48 years, 51 % male) were eligible for analysis. UAE was measured as the mean
of two 24-hour urine collections. Using computerized Minnesota coding,
ischemic ECG abnormalities were divided into: infarct patterns, major ischemia,
and minor ischemia. Furthermore, T axes deviations, as potentially more sensi-
tive markers of cardiac disease, were categorized as normal, borderline, and ab-
normal. The presence of all ECG abnormalities increased with increasing levels
of UAE, which was already seen at levels of UAE below 30 mg/24h. After ad-
justment for other cardiovascular risk factors UAE remained significantly associ-
ated with major ischemia (Odds Ratio, [95% CI] 1.13, [1.00-1.27]) and abnormal
T-axis deviation (1.29, [1.10-1.51]).
Conclusions— In a large nondiabetic population a graded continuous relation
was present between the level of UAE and ECG abnormalities, without an appar-
ent threshold. In addition, UAE was associated with several ECG abnormalities,
independent from conventional cardiovascular risk factors. These data suggest
that the level of UAE can be used for establishing cardiovascular risk in the
population at large.
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Introduction
Microalbuminuria The electrocardiogram (ECG) can be used to determine the
presence of ischemic heart disease in a population at large. Microalbuminuria is
an independent predictor for cardiovascular disease in diabetes mellitus1. In addi-
tion, there is evidence that microalbuminuria increases cardiovascular risk in
nondiabetic populations2. However, in almost all studies microalbuminuria was
used as a dichotomous variable and little is known about the precise relation be-
tween urinary albumin excretion (UAE) and cardiovascular disease. If UAE can
be considered as a continuous variable this could have important implications for
individual cardiovascular risk assessment. We evaluated the association between
the level of UAE, including levels within the normal range, and ischemic electro-
cardiographic (ECG) abnormalities in a general nondiabetic population. To
establish the value of UAE as an independent risk factor, we also examined the
relation between UAE and these ECG abnormalities, taking conventional cardio-
vascular risk factors into account.
Methods
Study design and patient population
The population analyzed in this study was part of the cohort from the PREVEND
(Prevention of REnal and Vascular ENdstage Disease) study. The PREVEND
study is designed to investigate the natural course of microalbuminuria and its
relation with renal and cardiovascular disease in the general population. The
study cohort is formed by male and female inhabitants, aged 28 to 75 years, of
the city of Groningen, the Netherlands. These subjects were asked to send in a
morning urine sample. A sample from the population, consisting of all subjects
with an albumin concentration in the morning urine sample of > 10 mg/L, to-
gether with a randomly selected sample of the remaining population (morning
urine albumin excretion < 10 mg/L) underwent 2 examinations at an outpatient
clinic. Subjects using insulin or being pregnant were excluded.
Measurements
Measurements at the visits included anthropometry, blood pressure measure-
ments for ten minutes with an automatic Dinamap XL Model 9300 series device
(Johnson-Johnson Medical Inc, Tampa, Florida), collection of two 24-hour urine
samples, ECG recording, and fasting blood samples. Furthermore, all participants
completed a questionnaire on demographics and cardiovascular and renal history.
A total of 8,592 subjects completed 2 visits to the outpatient clinic. For the pre-
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sent study 18 subjects were excluded because of missing albuminuria data, 433
because of presence of erythrocyturia or leukocyturia, 91 because of macroalbu-
minuria and 63 because of missing ECG data. A total of 241 subjects met the
criteria for non-insulin dependent diabetes mellitus and in 167 subjects presence
or absence of non-insulin dependent diabetes mellitus could not be established
because of missing data; these subjects were also excluded from analysis.
Finally, 7,579 subjects were eligible for analysis. All participants gave written
informed consent. The PREVEND study was approved by the local medical
ethics committee and conducted in accordance with the guidelines of the
declaration of Helsinki.
Urinary volume and albumin were measured in each collection. Urinary albu-
min concentrations were determined by nephelometry with a threshold of 2.3
mg/L and intra- and inter-assay coefficients of variation of less than 4.3% and
4.4%, respectively (Dade Behring Diagnostic, Marburg, Germany). Leukocyte
and erythrocyte counts were determined by urine sticks (Nephur + leuco, Boe-
hringer Mannheim, Mannheim, Germany). Plasma glucose and serum cholesterol
were determined by Kodak Ektachem dry chemistry (Eastman Kodak, Rochester,
NY, USA). The UAE was measured as the mean of two 24-hour urine collec-
tions. Albumin measurements were considered unreliable in the case of erythro-
cyturia or leukocyturia, according to dipstick analysis (erythrocytes > 50/µl or
leukocytes > 75/µl, or leukocytes = 75/µl and erythrocytes > 5/µl)
Electrocardiogram
Standard 12-lead electrocardiograms were recorded with Cardio Perfect equip-
ment (Cardio Control, Rijswijk, the Netherlands), stored digitally, and classified
using the computer program Modular ECG Analysis System (MEANS), which is
also capable of performing a classification according to the Minnesota Code3.
Signal analysis and classification of MEANS have been extensively evaluated in
both clinical and general population samples4,5. Infarct patterns, suggestive for
myocardial infarction, were defined by Minnesota codes 1.1 and 1.2. Major
ischemic changes were defined by codes 4.1, 4.2, 5.1 or 5.2, after exclusion of
codes 1.1 and 1.2. Finally, minor ischemic changes were defined by codes 1.3,
4.3 or 5.3, after exclusion of infarct patterns and major ischemia. T axes were
computed from vectorcardiographic X, Y and Z leads which can be reconstructed
from the standard ECG leads. The mean spatial axis is obtained by vectorially
adding the instantaneous heart vectors during the T wave. The mean frontal axis
is then taken to be the angle between the X-axis and the projection of the mean
spatial axis on the frontal plane. T axes were classified into 3 groups: “normal”
(150 to 750), “borderline” (-150 to 150 and 750 to 1050), and “abnormal” (-1800 to
-150 and 1050 to 1800)6.
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Definitions
Mean blood pressure was defined as the mean of the last 2 measurements of both
visits. Subjects were considered to be hypertensive when systolic blood pressure
≥ 160 mmHg and/or diastolic blood pressure ≥ 95 mmHg, or when using anti-
hypertensive treatment. Non-insulin dependent diabetes mellitus was defined as
fasting plasma glucose levels ≥ 7.8 mmol/l or non-fasting glucose ≥ 11.1 mmol/l,
or the use of antidiabetic drugs. Hypercholesterolemia was defined as a total se-
rum cholesterol ≥ 6.5 mmol/l or the use of lipid lowering medication. Body mass
index was calculated as the ratio between weight (kilograms) and height (square
meters). Obesity was defined as a body mass index exceeding 27 kg/m2. When
first-grade relatives had established a cardiovascular event at < 55 years of age,
subjects were considered having a positive family history for cardiovascular dis-
ease.
Statistical analysis
Continuous data are reported as mean with standard deviation. In case of a
skewed distribution, the median was used. Patient characteristics were compared
over various ranges of urinary albumin excretion and tested for a linear trend by
means of 1-way analysis of variance or by chi-square statistics. Univariate and
multiple logistic regression analysis was used to explore the effect of UAE and a
group of known cardiovascular risk factors on the risk of ECG abnormalities. To
evaluate the association between UAE and ECG abnormalities four alternative
models were examined: linear, exponential, polynomial, and logarithmic. To
compare the fit of the models, the statistical significance of the coefficients and
the overall model, log-likelihood chi-square tests were assessed. The association
between UAE and the ECG parameters appeared to be logarithmic. Coefficients
of the logistic regression model were used to estimate prevalences of ECG ab-
normalities for each value of UAE. Interactions between UAE and the above-
mentioned covariates were explored in logistic regression models that included
UAE, the risk factor at issue, and the interaction term of these 2 factors. A two-
sided P-value of < 0.05 was considered statistically significant. Analyses were
performed using the statistical package SPSS 9.0 (SPSS Inc., Chicago, Illinois).
Results
Baseline characteristics are listed in Table 1. Increasing levels of UAE were ac-
companied by an increase in almost all major cardiovascular risk factors. Both
Figure 1 and Table 2 show that the presence of ischemic ECG abnormalities in-
creased with the level of UAE, which is demonstrated at very low levels of UAE.
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Table 1. Population characteristics stratified by various ranges of urinary al-
bumin excretion
Urinary albumin excretion (mg 24hour-1)









Age, yrs 47 ± 12 51 ± 13 55 ± 13 58 ± 11* 48 ± 12
Male gender, % 47 60 65 71 * 51
Diastolic blood pressure, mmHg 72 ± 9 77 ± 10 79 ± 11 81 ± 11* 74 ± 10
Systolic blood pressure, mmHg 124 ± 17 135 ± 20 141 ± 23 148 ± 25* 128 ± 20
Systemic hypertension, % 11 26 36 51 * 16
Cholesterol, mmol/l 5.6 ± 1.1 5.7 ± 1.1 5.8 ± 1.1 6.0 ± 1.1* 5.6 ± 1.1
Hypercholesterolemia, % 22 27 33 47 * 25
Body mass index, kg/m2 25.4 ± 3.9 26.6 ± 4.2 27.6 ± 4.8 28.3 ± 4.4* 25.9 ± 4.1
Obesity, % 30 43 51 57 * 34
Smoker, % 44 46 47 44 45
Cardiovascular family history, % 21 25 24 23 22
*P for trend < 0.001
Values are given as mean (standard deviation)
Figure 1. Unadjusted predicted prevalences of ECG abnormalities by the level
of urinary albumin excretion
Urinary Albumin Excretion (mg 24hour-1)
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Table 2. Prevalences of electrocardiographic abnormalities stratified by various
ranges of urinary albumin excretion
Urinary albumin excretion (mg 24hour-1)









Infarct patterns 3.6 3.9 7.1 7.1* 4.1
Major ischemia 6.7 8.8 12.4 16.5* 7.7
Minor ischemia 14.1 16.8 21.6 24.7* 15.5
Borderline T-axis deviations 3.2 5.0 6.6 8.3* 3.9
Abnormal T-axis deviations 2.3 5.4 8.4 15.5* 3.6
*P for trend < 0.001
Results of three different models examining the relation of UAE (logarithmically
transformed) and ECG abnormalities are presented in Table 3.
Table 3. Results from univariate and multivariate logistic regression analysis,
relating urinary albumin excretion with electrocardiographic abnormalities













Model 1 1.25 (1.17-1.35)* 1.40 (1.28-1.53)* 1.28 (1.14-1.46)* 1.46 (1.29-1.65)* 1.99 (1.77-2.24)*
Model 2 1.10 (1.02-1.18)‡ 1.28 (1.17-1.41)* 1.12 (0.99-1.28) 1.25 (1.10-1.43)* 1.60 (1.41-1.81)*
Model 3 1.02 (0.93-1.11) 1.13 (1.01-1.27)‡ 1.10 (0.93-1.29) 1.15 (0.98-1.35) 1.29 (1.10-1.51)†
* P <0.001 † P <0.01 ‡ P <0.05
Model 1 Unadjusted
Model 2 Adjusted for age and gender
Model 3 Adjusted for age, gender, diastolic and systolic blood pressure, cholesterol, body mass index,
current smoking, and cardiovascular family history
The unadjusted model shows that log UAE was significantly associated with all
categories of ECG parameters. When adjusted for age and gender log UAE re-
mained significantly associated with minor and major ischemic changes, and bor-
derline and abnormal T axis deviations. Further adjustment for conventional risk
indicators still disclosed a significant association between UAE, major ischemic
abnormalities, and abnormal T-axis deviations. We performed secondary
analyses evaluating several interaction terms. No interaction term was statis-
tically significant in the multivariate analysis.
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Discussion
By convention, microalbuminuria is defined as 30 to 300 mg UAE in 24-hour
period. However, these criteria have been derived from studies in diabetic popu-
lations7,8. We demonstrate that an increase of ECG abnormalities was seen in a
large nondiabetic population with UAE levels < 30 mg in a 24-hour period; these
abnormalities continued throughout the microalbuminuric range, without an ap-
parent threshold. We confirmed the relation between UAE and other established
cardiovascular risk indicators demonstrated in previous studies9,10. After adjust-
ment for these cardiovascular risk indicators, the association between UAE and
cardiac abnormalities attenuated, but remained significantly associated with ma-
jor ischemic changes and abnormal T-axis deviations. This suggests that UAE
has an additional value to conventional cardiovascular risk indicators in predict-
ing cardiovascular disease.
It has been postulated that UAE is a sensitive indicator of generalized vascular
damage11. An increased transcapillary albumin excretion rate, an increased
plasma level of von Willebrand factor and an attenuated endothelium dependent
response on vasodilator stimuli in subjects with microalbuminuria support this
hypothesis12-14. Thus, UAE might identify subjects at risk for vascular disease.
The value of microalbuminuria as an independent predictor for cardiovascular
disease has been demonstrated in diabetic as well as nondiabetic subjects1,2.
However, microalbuminuria is only currently used as a dichotomous variable. A
relation has previously been demonstrated between UAE, expressed as a con-
tinuous variable, and a history of myocardial infarction15. Our study supports this
finding by demonstrating a continuous relation between UAE and cardiovascular
risk in a general nondiabetic population. Moreover, this study shows that the uri-
nary albumin level associated with increased cardiovascular risk might already
be present at levels currently accepted to be normal, as reported before in smaller
studies16,17.
In conclusion, in a large nondiabetic population a graded continuous relation
was present between the level of UAE and ECG abnormalities, without an appar-
ent threshold. These data suggest that the level of UAE can be used for establish-
ing cardiovascular risk in the population at large.
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Abstract
Background— For the general population the clinical relevance of an in-
creased urinary albumin excretion rate is still debated. Therefore, we examined
the relationship between urinary albumin excretion and all-cause mortality and
mortality caused by cardiovascular (CV) disease and non-CV-disease in the gen-
eral population.
Methods and Results— In the period 1997-1998, all inhabitants of the city of
Groningen, The Netherlands, aged between 28 and 75 years (n = 85,421), were
sent a postal questionnaire collecting information regarding risk factors for CV
disease and CV morbidity, and a vial to collect an early morning urine sample for
measurement of urinary albumin concentration (UAC). The vital status of the co-
hort was subsequently obtained from the municipal register, and the cause of
death from the Central Bureau of Statistics. Of these 85,421, 40,856 subjects
(47.8%) responded, and 40,548 could be included in the analysis. During a me-
dian follow-up period of 961 days (maximum 1,139 days), 516 deaths with
known cause were recorded. We found a positive dose-response relation between
increasing UAC and all-cause mortality. A higher UAC increased the risk of both
CV and non-CV of death after adjustment for other well-recognised CV risk fac-
tors, the increase being significantly higher for CV mortality than for non-CV
mortality ( P = 0.014). A twofold increase in UAC was associated with a relative
risk of 1.29 for CV mortality (95%CI, 1.18-1.40) and 1.12 (1.04-1.21) for non-
CV mortality.
Conclusions— Urinary albumin excretion is a predictor of all-cause mortality
in the general population. The excess risk was more attributable to death from
CV causes, independent from the effects of other CV risk factors, and the rela-
tionship was already apparent at levels of albuminuria currently considered to be
normal.
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Introduction
Epidemiological and experimental data show that high levels of urinary albumin
excretion are associated with an increased incidence of all cause, and in particu-
lar cardiovascular (CV) mortality. This evidence comes from observations in
high-risk patients like diabetics, hypertensives, elderly, and in elderly subjects
with a history of established CV disease1-8. The link between urinary albumin ex-
cretion and atherosclerotic disease is suggested to be found in dysfunction of the
endothelium and its sequela. However, the relevance of urinary albumin excre-
tion as a risk indicator in the general population is controversial. The few pub-
lished studies are either small, have relied on retrospectively collected data, or
are coming from groups of subjects who were referred because of suspected dis-
ease5-7. The greater morbidity and poorer health status in these selected patient
populations hamper the generalisation of the results to the population at large. In
the present study we therefore address the question of a relationship between uri-
nary albumin excretion and all-cause mortality and both CV and non-CV mortal-
ity, in a large cohort selected from the general population.
Methods
Design and study population
The PREVEND (Prevention of REnal and Vascular ENd stage Disease) study is
designed to prospectively investigate the natural-course of increased levels of
urinary albumin excretion and its relation with renal and CV disease in a large
cohort drawn from the general population. Details of this protocol have been de-
scribed elsewhere9,10. In the period 1997-1998 all inhabitants of the city of Gron-
ingen (The Netherlands), between the age of 28 to 75 years, in total 85,421 sub-
jects, were sent a postal questionnaire and a vial to collect an early morning urine
sample in which urinary albumin concentration (UAC) was measured, and alto-
gether 40,856 subjects (47.8%) responded. The one-page questionnaire collected
information on the presence of established risk factors for CV disease and docu-
mented CV morbidity. Subjects were considered diabetic when they positively
answered the question whether they had a physician diagnosis of diabetes, re-
gardless of the type of anti-diabetic treatment. Those who reported taking anti-
hypertensive or lipid lowering medication were regarded as hypertensive and hy-
perlipidaemic, respectively. Subjects were classified as smokers if they reported
smoking or having smoked cigarettes during the previous 5 years. A history of
myocardial infarction or stroke was considered present if the subject reported
having been hospitalised for at least three days due to that condition. A family
history of CV disease was considered present if at least one first-degree relative
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had documented angina pectoris, myocardial infarction or stroke before the age
of 65 years.
All participants gave written informed consent. The PREVEND study was ap-
proved by the local medical ethics committee and conducted in accordance with
the guidelines of the declaration of Helsinki.
Urinary albumin measurements
Urinary albumin excretion was measured as the urinary albumin concentration
(UAC) in a morning urine sample. UAC was determined by a commercial immu-
noturbidimetry assay with sensitivity of 2.3 mg/L and inter- and intra-assay coef-
ficients of variation of 4.4% and 4.3%, respectively (BNII, Dade Behring Diag-
nostica). Microalbuminuria was defined as a UAC between 20 to 200 mg/L and
macroalbuminuria > 200 mg/L11.
Mortality data
From the time of recruitment, the vital status of the participants was checked
through the municipal register. The cause of death was obtained by linking the
number of the death certificate to the primary cause of death as coded by a physi-
cian from the Central Bureau of Statistics. Causes of death were coded according
to the tenth revision of the International Classification of Diseases (ICD-10).
Cause specific end points used in the analyses were CV disorders, and the re-
maining codes those from non-CV causes.
Survival time for participants was defined as the period from the date of the
urine collection of the participant to the date of death from any cause, or Septem-
ber 2000 until which date information regarding specific causes of death follow
up information was available. If a person had moved to an unknown destination,
the date on which the person was dropped from the municipal registry was used
as census date.
Statistical analysis
To study the effects of albumin excretion on mortality we fitted Cox proportional
hazards models to the data. Two competing death causes were distinguished: CV
and non-CV. Apart from UAC the following available explanatory variables for
CV and non-CV death were entered in the regression analysis: sex, age, presence
of diabetes mellitus, use of antihypertensive drugs, use of lipid-lowering drugs,
smoking, family history of CVD, previous myocardial infarction and stroke. We
used competing risk analysis, which allows to compare effects of explanatory
variables on either CV or non-CV death12. P-splines were employed to explore
the functional form of effects of continuous variables age and UAC. Results are
summarised by hazard (risk) ratios (RR) with confidence intervals based on ro-
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bust standard error estimates, by plotting adjusted hazard ratio as a function of
UAC, and by plotting cause-specific cumulative incidence functions for specific
covariate values. Five percent (two-sided) P-values were used as the nominal
level of statistical significance. We used the statistical package S-Plus 6 (2001,
Insightful Co, Seattle, USA) for the analysis.
Results
The total population sample comprised 40,856 subjects. During the follow-up
period, 518 cases were recorded. From these 518 deaths, 178 were classified as
CV, and 340 as non-CV, using the cause of death obtained from death certifi-
cates. The non-CV mortality group included 231 malignant neoplasms, 10 were
classified as diabetes, and 99 cases were classified as various. For 73 participants
the time on study was not available. Urine samples could technically not be ana-
lysed in 235 subjects. Two of these participants died from a non-CV cause. In
total, 40,548 participants from whom 516 were died were available for the analy-
sis. The median follow-up time was 961 days (maximum of 1,139 days).
Table 1 shows the baseline characteristics of the study cohort at the time of in-
clusion stratified into CV and non-CV mortality. Those who died were older,
more likely being male and more likely to have a history of diabetes, hyperten-
sion, hyperlipidemia, smoking or a (parental) history of CV disease than those
who survived. Moreover, those who died from CV causes had the highest preva-
lences of these risk factors.
Urinary albumin excretion and mortality
There was a clear dose response relation between UAC and all-cause mortality.
Crude incidence rates of all-cause mortality per 1000 person years were 3.5
(95%CI, 3.1-3.9) for patients with a UAC below 10 mg/L, 4.5 (95%CI, 3.6-5.5)
for subjects with UAC levels of 10 to 20 mg/L, 11.2 (95% CI, 9.1-13.7) for sub-
jects with UAC levels of 20 to 200 mg/L, and 29.1 (95%CI, 19.3-43.7) for those
with levels of 200 mg/L or higher (P for trend < 0.001).
Table 2 summarises the results of the Cox regression analysis adjusted for age
and sex. Both CV and non-CV deaths were found to be associated with presence
of diabetes mellitus, hyperlipidemia, smoking, myocardial infarction and UAC
level. CV-deaths were also associated with a history of stroke. The effect of age
on the log-hazard was found to be linear, the effect of UAC was linear after loga-
rithmic transformation of UAC. A higher UAC increased the risk of both types of
death, the increase being significantly higher for the CV deaths (P = 0.009). The
inclusion in the regression model of the other cardiovascular risk factors did not
substantially alter the relation between UAC and CV and non-CV death.
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Alive CV death Non-CV death Missing cases
(n)











Male gender,% 45.6 45.4 66.8 59.5
Diabetes, % 2.6 2.5 7.9 10.1 129
Hypertension, % 11.2 11.0 38.1 `22.3 1368
Hyperlipidaemia, % 4.7 4.7 11.4 6.1 1744
Family history of CVD, % 32.1 32.1 43.2 29.8 2213
History or actual smoking, % 42.2 42.1 47.7 54.1 252
Myocardial infarction, % 3.0 2.9 18.0 11.1 887
History of stroke, % 0.8 0.8 8.6 2.4 697










Microalbuminuria, % 7.2 7.0 22.5 16.0
Table 2. Cox regression: cause-specific hazard (risk) ratios
Adjusted for age and sex Mutually adjusted for multiple risk factors
Variable RR (95%-CI) P RR (95%-CI) P
Female sex 0.60 (0.49-0.74) < 0.001
Age (per 10 years) 2.58 (2.32- 2.84) < 0.001
Hyperlipidemia 0.88 0.62-1.24) 0.460 0.60 (0.42-0.85) 0.004
Diabetes 1.89 1.35-2.65) <0.001 1.62 (1.15-2.29) 0.006
Myocardial infarction 1.78 1.31-2.32) <0.001 1.84 (1.37-2.46) <0.001
Smoking
Cardiovascular 1.83 1.33-2.51) <0.001 1.65 (1.19-2.27) 0.002
Non-cardiovascular 2.60 2.07-3.27) <0.001 0.073# 2.49 (1.97-3.16) <0.001 (0.039)#
Stroke
Cardiovascular 5.49 3.07-9.81) <0.001 4.01 (2.20-7.30) <0.001
Urinary albumin excretion (doubling)
Cardiovascular 1.35 (1.24-1.46) <0.001 1.29 (1.18-1.40) <0.001
Non-cardiovascular 1.17 (1.09-1.25) <0.001 0.009# 1.12 (1.04-1.21) 0.002 (0.014)#
# Comparison of effect on CV mortality vs. non-CV mortality
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In this mutually adjusted model, a twofold increase in UAC, i.e. from 5 to 10
mg/L or 20 to 40 mg/L, was associated with a 1.29 higher risk for CV death and
1.12 for non-CV death (P = 0.014). Smokers tended to have an increased risk for
non-CV death (P = 0.039). The effects of the level of UAC on the cause-specific
hazards for CV and non-CV mortality, adjusted for all the risk factors as shown
in Table 2, are presented in Figure 1. The solid line curves corresponding to the
log-linear functional form lie within the dotted CI-curves. This supports reason-
ability of the chosen model, although the (P-spline based) CI-curves obviously
do not exclude the existence of a more complex functional relation. For CV
deaths the increase in risk associated with an increase in UAC is steeper than that
for non-CV deaths.
To show the effects of UAC within the currently used reference ranges, cause-
specific cumulative incidence functions using the Cox model were calculated for
two UAC levels well below the lower border of the definition of microalbuminu-
ria. The curves represent the cumulative incidence functions of CV and non-CV
mortality for a non-hypertensive, non-hyperlipidemic, non-diabetic, non-smoking
50 years old male without a history of myocardial infarction or stroke with UAC
levels set equal to the 25th percentile (3.8 mg/L), and to the 75th percentile (9.8
mg/L).
Non-cardiovascular death
Urinary Albumin Concentration (mg/L)
1 10 100 1000
Figure 1. Adjusted effect of UAE on hazard function. Solid lines show the esti-
mated relation when log-hazard is modelled as a linear function of log(UAC).
The dotted lines are 95% confidence limits for a more general functional rela-
tion as estimated by P-splines. The grey area represents the upper and lower
limit of the current definition of microalbuminuria (20-200 mg/L).
Cardiovascular death
Urinary Albumin Concentration (mg/L)























































The 2-year cumulative incidence of CV mortality for a UAC of 3.8 mg/L is
0.11% and for a UAC of 9.8 mg/L 0.15%, whereas for non-CV mortality these
figures are 0.21% and 0.24%, respectively (Figure 2).
Figure 2. Cause-specific cumulative incidence functions of CV and non-CV mor-
tality for non-hypertensive, non-hyperlipidemic, non-diabetic, non-smoking 50
years old males without a history of myocardial infarction or stroke with UAC
levels set equal to the 25th percentile (3.8 mg/L), and to the 75th percentile (9.8
mg/L).
Discussion
This is the first study to show that urinary albumin excretion is a strong predictor
of all-cause mortality in the general population at large. The excess risk was sig-
nificantly more attributable to death from CV causes than to death from non-CV
causes and independent from the effects of various well-recognised CV risk fac-
tors. Importantly, the relationship between UAE level and mortality was already
apparent at levels of albuminuria currently considered to be normal.
Microalbuminuria is associated with an increased risk for renal and CV
morbidity and all-cause mortality in diabetic patients, patients with hypertension,
and in elderly subjects1-8. We found a stronger relation between albuminuria and
mortality from CV causes when compared with non-CV mortality in an unse-
lected cohort derived from the population at large. In view of this finding, Albu-
minuria appears to be a marker of generalised vascular disease and indicates an
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incremental risk for CV mortality not only in CV compromised subjects. The
precise underlying mechanism is unknown. It is possible that the glomerular al-
bumin leak reflects a widespread atherosclerotic mediated capillary vasculopa-
thy13-15. Dysfunction of the coagulation and fibrinolysis systems has also been
suggested as a possible link between microalbuminuria and CV disease. In dia-
betic and non-diabetic subjects microalbuminuria has been associated with
changes in von Willebrand factor, fibrinogen, thrombomodulin, and PAI-116-18.
Urinary albumin excretion, however, is associated with several other risk factors
that may themselves be linked with mortality. These include e.g. diabetes melli-
tus, hyperglycemia, hypertension, renal dysfunction, dyslipidemia, hyperhomo-
cysteinemia, dietary protein, smoking, and markers of an acute phase response. A
critical question within this context is, whether the relation of urinary albumin
excretion and mortality is due to an association of urinary albumin excretion with
other predictors of mortality. If albuminuria and the other prognostic factors
share a common, causal pathway, adjustment for these factors may attenuate the
relation between albuminuria UAE and mortality. However, even after adjust-
ment for these factors, albuminuria remains relatively strong predictive after full
adjustment, suggesting an independent additive component in the relation be-
tween albuminuria and mortality from CV causes.
We also observed an association, although less strong, between albuminuria
and non-CV mortality. The incidence of non-CV mortality could mostly be at-
tributed to death due to malignant neoplasm’s. An elevated urinary albumin ex-
cretion in patients with malignancies has been reported before19. Interestingly,
although the precise underlying mechanism is unknown, it has been speculated
that in this type of patients the increased urinary albumin loss appears to be more
an isolated renal phenomenon than related with endothelial dysfunction because
a normal endothelial function was observed, as demonstrated by the transcapil-
lary escape rate of albumin which suggests an overall unaffected capillary per-
meability.
This study adds considerable data to the available information on urinary al-
bumin excretion as a vascular risk factor because we have used the full range of
UAC in studying the relationship with mortality and did not cluster UAC-levels
into several categories. Several objections could be raised to categorizing UAC,
including: (1) a step function is biologically implausible because estimating risk
of categories ignores the possibility that actual risk varies smoothly with the ex-
posure of the risk factor; (2) high risk individuals will be submerged in a pool of
lower-risk members, thereby diluting the effect size; (3) there may be significant
loss of power, especially when the effects are concentrated at the end of the UAC
scale, and, (4) cut off point bias may be introduced in the case cut-off points are
selected to maximize effect size.
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It has been suggested in selected patient populations, that even modestly
raised albuminuria values, within what hitherto has been considered the normal
range, are associated with a future risk for CV events3,5,20. Our finding of a dose-
response relationship between UAC and the risk of mortality extends such a sug-
gestion to the general population. Therefore, we suggest that the lower limit de-
fining a “pathological” albuminuria seems appropriate.
Our study has a number of limitations and to appreciate the findings some is-
sues need to be addressed. We have measured urinary albumin excretion concen-
tration only once and without correcting for potential variability in urine concentra-
tion. In addition, we were unable to perform detailed measurements of the CV
risk factors. Self-reported histories have limitations because a certain degree of
misclassification and therefore bias may occur. As we do not expect this mis-
classification to be related to the risk factors or to the morning urinary albumin
measurements themselves, misclassification would dilute the estimated effect,
which is to make the estimated RR closer to one. Therefore, our analysis may
have underestimated the true association between urinary albumin excretion and
mortality. The relatively short follow-up could have masked some of the long-
term health hazards of an increased urinary albumin excretion. The current large
population based study is not characterised by a high participation rate and hence
could be subject to selection bias. However, the finding that close to 40 percent
of all deaths in our study were classified as due to CV disease, which is in line
with previous prospective studies of subjects of the general population, favours
acceptable generalisibility21.
We conclude from this large prospective cohort study that albuminuria is an im-
portant marker for both CV and non-CV mortality. The use of UAC as a screening
tool is made more feasible by commercially available more sensitive assays,
which also in the lower ranges appear to be reliable. There may be an important
clinical role for albuminuria in CV disease screening, analogous to that of blood
pressure and lipid screening. Because albuminuria is a modifiable risk marker,
the current observation may lead to new therapeutic strategies in the prevention of
CV disease.
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In the early 1970s, mortality due to coronary heart disease (CHD) started to de-
cline in many industrialised countries because of reduced risk factors. Particu-
larly, there was less smoking and hypertension, and treatment strategies were im-
proved1. However, with the decline of CHD, the incidence of chronic heart fail-
ure (CHF) increased. Despite a number of therapeutically meaningful improve-
ments in the management of CHF, there is no clear evidence of any impact on the
overall morbidity and mortality of the disease in the community. In contrast, due
to ageing and improved survival of patients with CHD, CHF is an increasing
public-health problem, and the economic impact is enormous. Therefore, the cur-
rent pathophysiological and clinical considerations in the diagnosis and treatment
of CHF will need more improvement in terms of cardiovascular risk profiling,
preventive measures, earlier intervention, and patient-tailored disease manage-
ment.
Several clinical parameters have been reported to predict survival of patients
with CHF2. For routine clinical practice, measurement of the left-ventricular ejec-
tion fraction (LVEF), the clinical severity of the disease (NYHA functional
class), and the aetiology of the disease have been shown to have independent
prognostic value. Biochemical markers including serum sodium, urea, creatinine,
and markers for neuro-endocrine activation may have an additive value. To date,
the role of the kidney in CHF has mainly been considered within the context of
excessive salt and water retention due to reduced renal blood flow. However, re-
cent data indicate that the kidney may play a more decisive role in the progres-
sion and prognosis of the disease. The current chapter covers several aspects of
the relation between the kidney and the heart (and vasculature). We discuss clas-
sical and novel concepts of causal interrelations and the potential options of op-
timising individual therapies to prevent cardiovascular morbidity and mortality.
Classical cardiorenal relationships
A compensatory renal haemodynamic response to heart failure
Physiologically, the renal blood flow and glomerular filtration rate (GFR) are
regulated both intrinsically and extrinsically by the kidney itself. The intrinsic
phenomenon, whereby the renal blood flow and GFR are kept relatively constant,
is called autoregulation.
Autoregulation aims at keeping the renal blood flow and GFR relatively constant
over a wide range of physiological changes (80-180 mmHg) in systemic arterial
blood pressure. Two mechanisms are responsible for autoregulation: (1) the my-
ogenic mechanism that responds to changes in arterial pressure and (2) the tu-
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Figure 1 A,B. Role of intrarenal angiotensin II in the regulation of solute and water homeostasis in
heart-failure patients. Among other actions within the kidney, the intrarenal renin-angiotensin system
(RAS) is a physiologic regulator of the tone of glomerular efferent arterioles (A), thereby determin-
ing in part the fraction of glomerular plasma that will be filtered at the glomerulus (i.e. the "filtration
fraction"). In heart failure (B), increased efferent arteriolar tone mediated by angiotensin II results in
an increase in filtration fraction, which reduces transcapillary hydrostatic pressure and increases peri-
tubular capillary oncotic pressure, thereby increasing sodium and water resorption in the proximal
tubule. Adapted from Humes et al99.
bulo-glomerular feedback that responds to changes in the flow rate of tubular
fluid. Both mechanisms principally regulate the tone of the afferent arteriole. Im-
portantly, when the systemic blood pressure is outside the autoregulatory range,
the renal blood flow and GFR change in parallel with arterial blood pressure.
Progressive systolic dysfunction of the heart results in a diminishing cardiac
output, increasing systemic vascular resistance, smaller effective circulating vol-
ume, lower arterial blood pressure, and, ultimately, a reduction of arterial blood
pressure below the renal autoregulatory capacity. Renal blood flow can be re-
duced by at least 30% to 40% without apparently affecting the primary renal
function; that is, the GFR3. Remarkably, the reduced renal blood flow does not
lead to a vasodilative, but a vasoconstrictive renal compensatory response aiming
to increase its filtration pressure and thus maintaining the GFR. This compensa-
tory mechanism contributes importantly to the haemodynamic and clinical disor-
ders seen in patients with CHF. The kidney response, which is inappropriate
from the heart and circulation perspective, has been discussed in an excellent pa-
per by Packer, who describes the kidney response to preserve glomerular filtra-
tion from a nephrocentric point of view4. The moment arterial blood pressure
falls below the renal autoregulatory capacity, the extrinsic regulation becomes a
major player in the field by initiating an array of physiologic compensatory
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mechanisms in order to preserve circulatory homeostasis5. The extrinsic regula-
tion induces activation of the renin-angiotensin system (RAS). At least two
mechanisms are involved: the renal and the cardiopulmonary.
First, the kidney will excrete renin in the case of hypoperfusion and/or hy-
pofiltration. An increased renin secretion by the kidney initiates angiotensin-II
formation. Angiotensin II will induce a rise in systemic blood pressure and reten-
tion of sodium in an attempt to restore renal input. In contrast with the autoregu-
latory mechanisms, angiotensin II acts primarily on the efferent intrarenal arteri-
ole. It increases the glomerular hydraulic filtration pressure and the filtration
fraction (ratio of the GFR to the renal plasma flow) and preserves the GFR (Fig-
ure 1)6.
Glomerular pressure, efferent arteriolar tone, and filtration fraction are directly
correlated with the severity of CHF up to a point at which the filtration fraction
can no longer rise. At this point, the GFR falls commensurately with the declin-
ing cardiac output7.
Second, an important extrinsic regulation contributor is the cardiopulmonary
baroreflex axis. Cardiopulmonary baroreflex dysfunction is present in several
pathological conditions, including CHF8. In CHF patients, the inhibitory barore-
flexes are depressed, contributing to sympathetic excitation, which triggers mul-
tiple, vasoconstrictive, renal hormone systems, including the RAS.
The compensatory response in relation with the pathogenesis of heart failure
The renal responses in CHF on the reduction of the total renal blood flow are
characterised by sodium and water retention and, subsequently, rising cardiac
filling pressures. Similar renal responses can be observed in other situations of
decreased circulatory volume, like severe blood loss. The RAS plays a major role
in the sodium and water retention. Not only angiotensin II, but also aldosterone
plays an important physiologic role in sodium retention. In addition, the plasma
level of arginine vasopressin (AVP) is increased in CHF. This results in en-
hanced water reabsorption in the distal nephron, including cortical and medullary
collecting ducts. Decreased cardiac output unloads the baroreceptors, activates
the sympathetic nervous system, and stimulates AVP through a separate pathway
that overrides the osmotic pathway. Besides sympathetic nervous system activa-
tion, neurohumoral peptides such as angiotensin II, endothelins, natriuretic pep-
tides, and prostaglandins, could also participate in the nonosmotic AVP activa-
tion. Thus, a variety of neurohormones are involved and overexpressed in the
compensatory response of the kidney in CHF.
Until the last decade, interest was directed only towards the systemic haemo-
dynamic effects of these compounds. Nowadays, it has become apparent that
many of the so-called classic neurohormones are synthesised and act locally.
Overexpression of these neurohormones is capable of exerting toxic effects on
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the heart and kidney. Especially angiotensin II may play a central role in the
pathophysiology and progression of cardiovascular and renal diseases9. Via the
AT1 receptor, angiotensin II promotes phenotypic change and growth of cardiac,
vascular, and glomerular cells, and it induces expression of various growth fac-
tors (Figure 2)10. The persistent hy poxia and up-regulated angiotensin II may be
the causative factors of mesangiolysis associated with glomerular enlargement
and glomerular infiltration of leukocytes as shown by an autopsy study of 27
CHF patients11. Experimental evidence supports the hypothesis that important
factors in the pathogenesis of glomerulosclerosis are glomerular hypertension,
mesangial dysfunction such as mesangiolysis, and increased mesangial matrix12.
Nonclassical cardiorenal relationships
The kidney and clinical outcome – from outside to inside player
Renal function in CHF has been primarily discussed secondarily to the develop-
ment of CHF. However, we postu-
late that the syndrome of CHF is
preceded by clinical or subclinical
renal impairment; a factor that car-
ries important prognostic properties
itself.
It is well recognised that the kid-
ney plays a major role in the ad-
vanced stages of the clinical syn-
drome of CHF. The idea has only
just recently been brought into clini-
cal science that a compromised re-
nal function, that might be tolerated
by patients with a normal heart,
could independently precipitate the
development of overt CHF. Infor-
mation that supports this idea comes
from a study of patients after a first
acute myocardial infarction (AMI)
in which subclinical impaired base-
line renal function adds additional
independent predictive information to the development of heart failure13. More
supportive information comes from the prevention arm of the Studies of Left
Ventricular Dysfunction (SOLVD), encompassing patients with asymptomatic
CHF14. Moderate renal insufficiency, defined as a creatinine clearance of less
Figure 2. Pathways in the progression of renal
disease. Adapted from Klahr and Morrissey11
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than 60 ml/min, remained independently associated with an increased risk of the
composite endpoint death or hospitalisation for heart failure, all-cause mortality,
and heart-failure death. Furthermore, in a post-hoc analysis from the Heart Out-
comes Prevention Evaluation (HOPE) involving patients with either known car-
diovascular disease or diabetes mellitus and one other cardiovascular risk factor,
mild renal insufficiency (defined as a serum creatinine concentration greater than
1.4 mg/dl, but less than 2.3 mg/dl) was a substantial risk factor for cardiovascular
disease15. The independent prognostic value of renal function has been shown for
patients with severe CHF14,16. GFR, LVEF, and NYHA class were not only
prognostically important, but were also acting independently in part. Data regard-
ing them support the hypothesis that cardiac function, clinical status, and renal
function represent, in part, different prognostic entities of CHF. Four other stud-
ies in which serum creatinine was used as a measure for renal function have re-
ported the prognostic value of renal function for patients with CHF17-20. How-
ever, remarkably, the impact of this observation was not discussed in any of the
four papers. From a general population perspective, important information is de-
rived from a community-based sample of more than 6000 adults. It was shown
that mild renal insufficiency (defined as a serum creatinine values of 136 to 265
µmol/l in men and 120 to 265 µmol/l in women) during 15 years of follow-up
was associated with a 31% increase in risk of death for men, but not for
women21.
Impaired renal function: an independent contributor to increased risk of cardio-
vascular disease
The use and interpretation of impaired renal function as a risk factor needs more
discussion. A risk factor is an attribute (factor) that is associated with an in-
creased risk of an outcome. The term “risk factor ” is broad enough to encompass
both causal (determinants of the disease) and noncausal associations.
The studies in which the association was shown between impaired renal function
and increased cardiovascular risk used serum creatinine for an estimation of renal
function. Creatinine in itself is not directly harmful, but an elevated creatinine
level is, in general, directly associated with impaired renal function and predicts
an increased risk of total and cardiovascular mortality22. Creatinine marks very
many metabolic abnormalities that are related to impaired renal function. Such
factors may induce myocardial dysfunction and damage, and may increase the
risk of cardiovascular disease. These metabolic abnormalities include volume or
pressure overload, hyperparathyroidism, malnutrition, uraemic toxins, high cate-
cholamine levels, and the presence of an underlying disease, including proteinu-
ria, increased extracellular fluid, electrolyte disorders, and increased levels of
thrombogenic agents and homocysteine. A great prevalence of cardiovascular
disease and risk factors was shown, even for subjects with less severe degrees of
Renal risk markers and cardiovascular disease 109
renal impairment21. Thus, it should be noted that noncausal risk factor/disease
associations are very common in established renal disease because renal impair-
ment leads to a number of metabolic abnormalities that are associated with an
increased risk of cardiovascular disease and total mortality. Within this context,
the relative contribution of renal function as an indicator of increased risk should
be considered in the presence of the other risk factors and the time course of the
disease.
The kidney in the cardiorenal axis: from compensator to participator
Much pathophysiological information about compensatory renal changes in the
advanced stages of CHF is available. The general opinion is that the kidney’s
role in the early phase of CHF is marginal because mild CHF represents a
compensated phase of left-ventricular dysfunction characterised by a sodium
balance with increased endogenous atrial natriuretic peptide levels without
activation of the renin-angiotensin-aldersterone system (RAAS)23. However,
accumulating data suggest that renal alterations might have a great impact on the
prognosis of the disease, even in the early stages of CHF. Magri reports an
impairment of renal haemodynamic reserve in patients with asymptomatic heart
failure compared with that of a group of healthy subjects24. Treatment with
enalapril or losartan normalised the vasodilatory responses. Although the clinical
significance of renal functional reserve is unknown, it is blunted in various
models of renal damage, and it is postulated that renal functional reserve might
be an index of the intrarenal balance between angiotensin II and nitric oxide25.
Furthermore, a defective adaptation of sodium reabsorption in the proximal
nephron associated with sodium retention in response to increased salt intake has
been reported in the early or mild stages of heart failure26.
It is clear that heart failure is predominantly a disorder of older adults, and, to
a large extent, the epidemiology of heart failure reflects the convergence of age-
related changes in the cardiovascular system and the rising prevalence of age-
related cardiovascular diseases27. It could therefore be anticipated that the great
incidence of CHF in the elderly might be facilitated by age-related alterations in
renal haemodynamics and tubular function. The ability of the kidney to concen-
trate urine maximally after water deprivation decreases with age, as does the abil-
ity to excrete a water and salt load. The GFR and the effective renal plasma flow
decline in a linear fashion after the age of 30, even in the absence of renal dis-
ease, but it is compensated by glomerular hypertension and hyperfiltration by the
remaining nephrons28. The glomerular hypertension is assumed to promote the
development of glomerulosclerosis in the hyperfiltrating nephrons, potentially
leading to progressive loss of renal function in the long term, and the incidence
of sclerotic glomeruli increases with advancing age. Within this context, the time
course of renal function is of interest. Progressive loss of renal function has been
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reported not only in glomerular diseases like diabetic nephropathy, but also in
patient populations prone to develop CHF, such as those with elderly subjects
and subjects with hypertension. Such a loss has been reported for patients who
have had an AMI13,29,30. We showed that a first AMI was associated with pro-
gressive renal function loss in the 1st year after the infarction. This loss seems to
increase, especially in first days after the infarction, for patients with an already
impaired renal function. The loss was reflected as one observed in glomerular
diseases like diabetic nephropathy.
Thus, we can speculate that underperfusion, together with the intervening
basal pathology of the patient, generalised atherosclerosis, will lead to progres-
sive renal disease. In other words, subclinical kidney dysfunction, probably in-
duced by chronic structural and functional changes, makes the kidney more vul-
nerable to underperfusion and increased sympathetic activity. This may lead to
further activation of mechanisms facilitating renal retention of sodium and water,
which subsequently promotes further myocardial and renal dysfunction.
Epidemiology of impaired renal function
The importance of impaired renal function in cardiovascular disease, irrespective
of left-ventricular dysfunction, is undeniable. Consequently, from a disease-
management perspective, it is imperative to know the prevalence of impaired re-
nal function. In a large community sample (n = 6233), elevated serum creatinine
levels were found in 8.9% of the men (> 1.5 mg/dl) and 8.0% of women (> 1.4
mg/dl)31. Among 298 post-myocardial infarction patients, 30% had a renal func-
tion below 80 ml/min, which corresponds to the value defining the onset of renal
failure; and 7.5%, below 60 ml/min, which corresponds to an established renal
failure for whatever sex or age32. An unexpectedly large prevalence (10%) of
chronic renal insufficiency (serum creatinine > 2.3 mg/dl) has been reported in
the National Registry of Myocardial Infarction study, which included 117560 pa-
tients with an AMI33. In the SOLVD intervention study, which evaluated
asymptomatic patients with left-ventricular dysfunction, 10% of the patients had
a creatinine clearance of less than 60 ml/min. This was true for almost 30% of the
patients in the symptomatic treatment study14. In conclusion, a “subclinically”
impaired renal function appears to be far from rare in the general population. For
patients with established cardiovascular disease, a moderate renal insufficiency is
even more common, and it is an important indicator of increased cardiovascular
risk. It is clear that the measurement of renal function might be a useful tool in
risk profiling of the patient and may lead to improved therapeutic strategies in the
management of cardiovascular disease.
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Technical and physiological limitations of renal function measure-
ment
The serum creatinine level is widely used as an index of renal function in clinical
practice. However, the accuracy of the use of creatinine as a filtration marker is
limited by the fact that alterations in renal handling and the metabolism of
creatinine (tubular secretion) have a definite impact on the serum creatinine con-
centration34. Moreover, because of the reciprocal relationship between serum
creatinine values and the GFR, a large change in the GFR is required to increase
serum creatinine levels from the normal to the elevated range.
In addition, creatinine may not be an ideal marker for renal dysfunction since,
regardless of their cause, there is a heterogeneous involvement of the nephrons in
most renal diseases, especially in the early stages of the disease. As a conse-
quence, substantial alterations in nephron structure may occur without an appar-
ent decline in the GFR, since the remaining healthy nephrons can compensate for
the defective ones35. Unfortunately, there is no technique available to measure
the level of the individual human nephron. This hyperfiltration phenomenon
challenged the view that the GFR is a good indicator of renal lesion. Taking into
account that the progression of renal disease is a consequence of secondary
glomerular damage arising from increased glomerular capillary pressure, tech-
niques or markers that are suitable for the detection of hypofiltration and hyper-
filtration, preferably on an individual nephron level, are needed.
Alternative parameters for investigating renal involvement in pre-
dicting cardiovascular disease
Renal functional reserve
Within this framework, assessment of the renal functional reserve or increased
urinary albumin excretion might be promising parameters for assessing renal dis-
ease in the early stage. Renal functional reserve is an interesting tool for gaining
more pathophysiological understanding of processes in which an impaired renal
function might be involved. However, assessment of the renal functional reserve
is not suitable for large-scale clinical studies because it has to be performed clini-
cally, and it is invasive, expensive, and uncomfortable for the patient.
Urinary albumin excretion
At the present time, increased urinary albumin excretion, in terms of microalbu-
minuria and macroalbuminuria, is the only practical biochemical marker for the
diagnosis of several diseases affecting the glomerulus at an early stage36. By con-
vention, the albumin excretion rate for normoalbuminuria is less than 30 mg/24hr
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mg/24hr (or < 20 µg/min, or < 20 mg/l); microalbuminuria indicates an albumin
excretion rate of 30-300 mg/24 h (or 20-200 µg/min, or 20-200 mg/l); and for
macroalbuminuria, more than 300 mg/24 h (or > 200 µg/min, or > 200 mg/l)37.
Urinary albumin excretion predicts renal and cardiovascular disease
Of diabetic patients
Urinary albumin excretion originally received attention because it was identified
as an early marker of renal disease in diabetes38,39. The prevalence of microalbu-
minuria for insulin-dependent diabetes mellitus (IDDM) subjects is between 16%
and 32%; for non-insulin-dependent diabetes mellitus (NIDDM) subjects, be-
tween 30% and 40%40,41. The presence of microalbuminuria is a strong risk
marker of retinopathy in diabetes. Several prospective studies have shown that
microalbuminuria independently predicts renal as well as cardiovascular morbid-
ity and all-cause mortality in the setting of insulin-dependent and insulin-
independent diabetes41,42. Microalbuminuria in diabetic patients is associated
with higher blood pressures, hyperfiltration, lipid disorders, thrombocytopathy,
endothelial dysfunction and insulin resistance, and hyperinsulinemia42-45. In un-
complicated type-1 diabetes, insulin resistance predicts the increment in urinary
albumin excretion and may precede microalbuminuria46.
Of hypertensive patients
The prevalence of microalbuminuria among patients with essential hypertension
varies dramatically among various studies, ranging from 5% to 37%. It increases
with age and with the severity and duration of the hypertension47. In a study of
11,343 hypertensive subjects, microalbuminuria was present in 32% of the men
and 28% of the women48. In the Prevention of Renal and Vascular End-stage
Disease (PREVEND) study, involving a large sample of the general population
(n = 40,856), we found an age- and sex-adjusted prevalence of microalbuminuria
of 11.5% in nondiabetic, treated hypertensive patients (n = 4,022)49. The evi-
dence for renal risk associated with hypertension is less convincing than that as-
sociated with diabetes, but some studies suggest that hypertensive subjects with
microalbuminuria may experience a faster decline of renal function than hyper-
tensive subjects with normal urinary albumin excretion. In a retrospective analy-
sis of 141 hypertensive patients followed for 7 years, a decrease of creatinine
clearance of –12.1 ml/min for subjects with microalbuminuria versus –7.1
ml/min for subjects without microalbuminuria was observed50. In addition, sub-
jects suffering from essential hypertension with high creatinine clearance meas-
urements at baseline, indicating hyperfiltration, showed an increase in serum
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creatinine levels after 7 years compared with subjects without high creatinine
clearance measurements at baseline51. Microalbuminuria is also associated with
decreased renal reserve in hypertensive patients, earlier suggested for use as a
method of verifying the presence of hyperfiltration52. The debate whether micro-
albuminuria in hypertension is due to an increased intraglomerular pressure or to
glomerular damage continues.
Taking into consideration the evidence available at present, it can be postu-
lated that the pathogenic process that leads to microalbuminuria in hypertension
may vary with the severity of the hypertensive condition. In mild uncomplicated
hypertension, a haemodynamic concept seems to be more plausible, whereas in
moderate to severe hypertension, especially when it occurs with metabolic disor-
ders, a glomerular damage concept is likely to play a key role53-55. It has been
hypothesised that microalbuminuria in hypertensive subjects identifies a sub-
group with a cluster of risk factors, suggestive of the presence of insulin resis-
tance and a greater risk of end-organ damage56. Patients with hypertension who
develop microalbuminuria are more likely to have vascular complications, as
typically shown with insulin resistance57. Just recently, the longitudinal data that
has become available provides more or less similar results. In a study comprising
diabetic and nondiabetic subjects, microalbuminuria was independently associ-
ated with an approximately twofold increase of all-cause mortality. The relative
risk of all-cause mortality associated with microalbuminuria was approximately
four times greater among hypertensive subjects than among normotensive sub-
jects58. These results are in concordance with the findings in the hypertensive
population of the Monitoring Trends and Determinants in Cardiovascular Dis-
ease (MONICA) study, who were untreated at baseline. They showed a fourfold
increased risk of ischaemic disease during a 10-year follow-up. Finally, our own
preliminary data show that microalbuminuria is an independent indicator of the
increased risk of cardiovascular disease and death for hypertensive patients
(treated and untreated), whereas the population without microalbuminuria yields
only a moderate risk59. Thus, in general, it is clear that microalbuminuria in
combination with hypertension is more than an epiphenomenon and that cardio-
protective and renoprotective treatment modalities should pay more attention to
urinary albumin excretion.
Of nonhypertensive and nondiabetic patients
The clinical relevance of microalbuminuria as a common independent risk factor
in the general population and in the nondiabetic, nonhypertensive population is
still a matter of debate. Considering only studies of the west European popula-
tion, prevalences of microalbuminuria are reported in a range of 2.2% to 10.2%.
However, the number of subjects included ranges from 171 to 1684, which may
not reflect the general population. The only data available regarding the preva-
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lence of microalbuminuria specifically for nondiabetic and nonhypertensive sub-
jects come from the PREVEND study49. We found that microalbuminuria is
common in the general population; it has a prevalence of 7.2%. Importantly, the
majority of these microalbuminuric subjects (74.9%) had no reported diabetes or
hypertension. After excluding the diabetic and hypertensive subjects, microal-
buminuria is still prevalent in 6.5% of the subjects, and it is independently asso-
ciated with cardiovascular risk. Similarly to studies of hypertensive subjects,
many studies show that microalbuminuria is associated with an adverse cardio-
vascular risk profile in a cross-section of the general population, and it might in-
dicate which subjects are potentially at risk of cardiovascular end-organ damage.
Interestingly, as with hypertension, hyperinsulinemia occurring simultaneously
with microalbuminuria identifies a group of subjects with a greatly increased risk
of developing cardiovascular disease60. More prognostic properties of microal-
buminuria regarding increased risk of all-cause mortality have been found in
studies of elderly subjects and of 2085 consecutive subjects without ischaemic
heart disease, renal disease, urinary tract infection, or diabetes mellitus61-63. The
presence of microalbuminuria more than doubled the predictive effect of the
conventional atherosclerotic risk factors for developing ischaemic heart diseases
in one study61. It was concluded that microalbuminuria is not only an independ-
ent predictor of ischaemic heart diseases, but it also substantially increases the
risk associated with other established risk factors. These findings are confirmed
by the preliminary data of the PREVEND study. Microalbuminuria independ-
ently predicts an almost twofold risk of cardiovascular disease and a fourfold risk
of all-cause mortality59. Furthermore, among patients presenting with an AMI,
urinary albumin excretion of patients who developed heart failure and predicted
early mortality was increased64. Finally, we were the first who studied a large
nondiabetic population (n = 7,728), albeit in a cross-sectional study design to de-
termine the association between increased urinary albumin excretion and renal
functional abnormalities65. We found that great normal urinary albumin excre-
tion (15-30 mg/24 h) and microalbuminuria were more closely associated with an
elevated filtration rate, while macroalbuminuria was more closely associated with
a diminished filtration rate.
In summary, it is clearly suggested that the microalbuminuric state mirrors a
parallel development of renal and cardiovascular disease, which may lead to end-
organ damage in the long term: for the kidney, end-stage renal disease, for the
heart, chronic heart failure.
Pathophysiologic basis of increased urinary albumin excretion rate
As the first barrier to be crossed on the way to urinary space, the glomerular
basement membrane (GBM) plays a key role in urinary albumin excretion. The
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pathogenesis of increased glomerular leakage is determined by higher glomerular
pressures and perfusion rates and the altering of size- and charge-selective prop-
erties of the GBM. Excretion of albumin in the urine is determined by the amount
filtered across the GBM and the amount reabsorbed by the tubular cells. Urinary
albumin excretion in the early stages is probably mainly derived from increased
glomerular leakage instead from reduced tubular reabsorption66. Normoalbumin-
uric diabetic-type-1 patients showed changes in vascular haemodynamics rather
than changes in endothelial function or integrity of the vascular wall. This find-
ing favours the sequence of events that, in the early stages haemodynamic
changes, causes the increase in albumin passage through the capillary wall and in
the more advanced course of the disease, which alters the size- and charge-
selective properties of the GBM. Glomerular pressure cannot be determined in
humans, but the filtration fraction is presumed to reflect glomerular pressure. In
several patient populations, including CHF, the presence of an increased urinary
albumin excretion and filtration fraction has been shown67,68. It is suggested that
filtered albumin is a reflection of loss of renal function. Renal function loss stems
from a reduced number of nephron units and is followed by hyperfiltration. This
excessive filtration by each glomerulotubular unit would provoke the saturation
of the capacity of the proximal tubule cells to reabsorb the filtered albumin, and,
subsequently, the appearance of increased amounts of albumin in the urine. This
theory is, however, largely based on data from animal experiments, mostly per-
formed with the reduced renal mass model69.
A close correlation between the filtration fraction and urinary albumin excre-
tion has been proven in the microalbuminuric range, but a significant size defect
in the glomerular barrier appears only in the macroalbuminuric stage. A loss of
charge-selective properties at the glomerulus due to decrements in the anionic
components of the glomerular capillary wall may play a role in the development
from microalbuminuria to macroalbuminuria70. A decrease of the charge-
dependent restriction could be due to decrements in the anionic components that
compose the negatively charged electrostatic barrier of the GBM. It has been
shown that this charge-selective permeability of the GBM is related to the elec-
trostatic properties of covalently bound heparan sulfates. Alternatively, glycosy-
lation of circulating albumin may shift its net charge toward a more neutral
range.
Urinary albumin excretion: a specific renal marker or a more generalised vascu-
lar marker?
As already mentioned, microalbuminuria has been shown to be a predictor for the
appearance of overt diabetic nephropathy, and some pieces of evidence indicate
that it could also be a predictor of renal function decay in primary hypertension.
However, it has been speculated that microalbuminuria represents the renal ex-
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pression of a generalised disorder characterised by an increased endothelial per-
meability that may underlie the link between an increased urinary albumin excre-
tion and the increased risk of cardiovascular disease. It has been shown that ob-
served permeability changes could also be mediated by increased production of
vascular endothelial growth and permeability factors12,71. In this case, increased
urinary albumin excretion reflects the abnormal systemic transvascular macromo-
lecular leakage in atherogenesis, where permeability changes occur beginning at
the earliest stage. This is a consequence of damage to the vascular endothelium, a
structure intimately involved in vascular permeability as well as haemostasis, fi-
brinolysis, and vasomotion72.
Urinary albumin concentration has been associated with metalloproteinase-9,
the Von Willebrand factor, thrombomodulin, fibrinogen, thrombin-antithrombin-
III complexes, and homocysteinemia, which suggests that microalbuminuria
might be a marker of generalised endothelial dysfunction73-75. Microalbuminuria
clustered with the metabolic syndrome: hyperinsulinemia and insulin resistance,
increased triglyceride levels, and decreased high-density lipoprotein levels76-80.
This pattern of risk factors is typical of diabetes, but it has also been observed in
nondiabetic and prediabetic individuals76. The mechanisms underscoring the rela-
tionship between microalbuminuria and insulin resistance are unknown. The as-
sociation between insulin sensitivity and microalbuminuria did not differ be-
tween normotensive and hypertensive subjects, and it has been postulated that it
may be a feature of the prediabetic state81,82. Pathophysiologically, it was ex-
plained by an increased intraglomerular capillary pressure and an increased per-
meability of the glomerular capillary wall, probably induced by elevated glucose
levels. Interestingly, insulin resistance and concomitant hyperinsulinemia are al-
ready present early in the course of renal disease, even in patients with a GFR
within the normal range, irrespective of the type of renal disease. This observa-
tion may have potential implications with respect to the cardiovascular morbidity
and mortality of patients with renal disease46. It is obvious that we should con-
sider the roles of increased urinary albumin excretion, increased glomerular pres-
sure, and the development of glomerulosclerosis, as results of ageing, athero-
genesis, and underlying disease as expressed in Figure 3. Within this context, al-
though glomerular-pressure-induced hyperfiltration certainly has a role in the de-
velopment of increased levels of urinary albumin excretion, it is even reasonable
to hypothesise that increased levels of urinary albumin excretion may be more
related to other atherosclerotic risk factors and probably represent vascular dam-
age that is more generalised than renal vascular damage alone.
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In conclusion, renal insufficiency is a common and an important indicator of in-
creased cardiovascular risk. However, the use of creatinine as a marker is limited
by the fact that alterations in renal handling and the metabolism of creatinine
have a major impact on the serum creatinine concentration. In addition, substan-
tial alterations in nephron structure, especially in the early stages of renal dys-
function, may occur without an apparent decline of the GFR, since the remaining
healthy nephrons can compensate for the defective ones. Within this context, in-
creased urinary albumin excretion potentially shows early renal involvement.
However, pathophysiologically, increased levels of urinary albumin excretion
may also represent more generalised vascular damage. A substantial amount of
data shows that increased urinary albumin excretion mirrors a parallel develop-
ment of renal and cardiovascular disease, which may lead to end-organ damage
in the long term; for the kidney, end-stage renal disease and for the heart, CHF.
Novel strategies to decelerate cardiac disease
The overall conclusion derived from this overview is that adequate treatment of
the progression of cardiac disease requires a cardiorenal approach, since rela-
tively small changes in kidney function predict cardiovascular morbidity and
mortality. The strategy of including renoprotective interventions in the preven-
tion or progression of cardiac disease is a challenging one.
Renoprotective therapy is currently focussed on reducing blood pressure as
well as proteinuria. The benefits of reducing blood pressure to the renal function
of patients with diabetic renal diseases were first shown by Mogensen, who re-
ports that therapy with a thiazide diuretic and a beta blocker decreased urinary
albumin excretion and slowed the rate of decline of the GFR83. The renoprotec-
tive effect might be linked with reducing systemic blood pressure, which tends to
reduce glomerular pressure. However, several studies show that angiotensin-
converting enzyme (ACE) inhibitors are more effective in delaying the develop-
ment of nephropathy, for diabetics and nondiabetics alike, than other classes of
hypertensive agents, despite comparative antihypertensive action84,85. This has
been attributed to the selective vasodilation of the glomerular efferent arterioles
of ACE inhibitors, which may produce greater declines of glomerular pressure
for a given reduction in systemic arterial pressure. However, a direct effect of
these drugs on the GBM permselectivity could also be speculated. This idea is


















Figure 3. Effect of ageing on the renal glomerulus. Adapted from Anderson
and Brenner29
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In type-I diabetes, either in the microalbuminuric stage or the proteinuria-
stage, reduction of proteinuria is associated with a greater preservation of renal
function30. Intervention with an ACE inhibitor is recommended as soon as mi-
croalbuminuria has been diagnosed, irrespective of blood pressure. The notion
that microalbuminuria predicts cardiovascular complications suggests that reduc-
ing urinary albumin excretion may result in greater cardiovascular and renal pro-
tection. It should be noted that the degree of increased urinary albumin excretion
that requires an intervention is still a matter of debate. Studies of patients with
severe hypertension show that reducing the blood pressure results in decreased
urinary albumin excretion. Existing data give incontestable evidence that ACE
inhibition, well known for its cardioprotection, is currently also the best therapy
available for slowing down the loss of renal function in various diseases. We dis-
cussed a myriad of effects of angiotensin II in the kidney; it influences renal
haemodynamics and tubular transport, acts as a growth factor and a profibrogenic
cytokine, and even has inflammatory properties. Although in-vitro studies show
that many of these functions may be independent of haemodynamic alterations, it
is impossible to distinguish haemodynamically driven effects from nonhaemo-
dynamically driven ones. The beneficial effects could be attributed to a normali-
sation of hyperfiltration, reduction of albumin loss, and the interference in
glomerular and tubular growth processes. Within this context, the results of the
HOPE are very indicative89-91. The HOPE shows that inhibition of the RAAS by
the ACE inhibitor ramipril reduces the cardiovascular events in patients at high
cardiovascular risk. The benefit was evident for all predefined subgroups, includ-
ing those with microalbuminuria. Interestingly, a subset of patients with mild re-
nal insufficiency showed an increased risk, which was substantially reduced by
ramipril15.
The success of blocking the RAS by ACE inhibitors has led to efforts to block
other hormonal systems or receptors. Several other agents with renal haemody-
namic and parenchymal effects are involved in the setting of evaluating renopro-
tection, in combination with CHF or not.
Most experimental studies that compare the effects of ACE inhibition and
AT1 receptor antagonists have shown a striking similarity of actions. Both lower
the systemic and intraglomerular pressure and reduce proteinuria and morpho-
logical lesions as well92,93.
The vasoconstrictive and mitogenic properties of endothelin are abolished by
endothelin receptor agonists in experimental models94. In humans, blocking of
the ETA receptor in short-term studies improves haemodynamics and attenuates
the renal effects of endothelin. This might therefore be an important strategy for
attenuating renal hypoperfusion in CHF95,96. The experimental information that
endothelin has no direct effect on glomerular permeability is endorsed by data
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from studies with endothelin receptor antagonists in which proteinuria was not
normalised.
Neutral endopeptidase (NEP), the major enzymatic pathway for degradation of
natriuretic peptides, has a catalytic site similar to that of ACE. Inhibition of NEP
shows promise in experimental and clinical hypertension and heart failure, and it
is possible that NEP and ACE inhibitors may show synergistic effects97,98. Simi-
lar dual NEP/endothelin-converting enzyme (ECE) inhibitors are becoming
available. The hormone vasopressin has dual actions on the vasculature and the
kidney via specific membrane receptors. Specific, orally active, vasopressin-
receptor antagonists have been developed, and their therapeutic potential in hy-
pertension, heart failure, and oedematous states are being explored.
To summarise, taking into consideration the epidemiological characteristics of
CHF, optimisation of heart-failure therapy is still necessary. We postulate that
the kidney plays a pivotal role in myocardial failure. Therefore, interfering with
the cardiorenal axis is an important therapeutic objective. New therapeutic strate-
gies might be triggered by focussing on increasing our knowledge concerning the
adaptive and maladaptive mechanisms of the kidney involved in cardiac disease.
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The past 20 years has shown remarkable advances in the prevention and treat-
ment of cardiovascular disease, due to advances in coronary risk factor modifica-
tion and a better understanding of the atherosclerotic process. However, some
typical 'major' risk factors, like blood pressure, total cholesterol or left ventricular
hypertrophy, do not have a clear predictive role for cardiovascular mortality in
special populations like the elderly. Over the last decade, multiple other factors
have been identified as potential contributors for cardiovascular disease. Epide-
miological data have demonstrated a close relationship between cardiovascular
disease and renal disease. This leads to the issue whether assessment of renal risk
markers will improve the ability to predict: (1) who is at risk for cardiovascular
disease, (2) who is at risk over and above the predictive value of established risk
factors and finally (3) who will gain substantial improvement through elimina-
tion of these renal risk indicators. The current thesis studies several aspects of the
relation between the kidney and the heart (and vasculature). We discuss classical
and novel concepts of causal interactions between the kidney and the heart in
various stages of cardiovascular disease. Therapeutic strategies to intervene in
this cardiorenal axis by optimizing individual renal function are considered in
order to prevent cardiovascular morbidity and mortality.
The kidney in chronic heart failure (CHF) has mainly be concentrated on a re-
active hemodynamically driven response which is characterized by a reduction in
renal plasma flow and in case blood pressure drops below the renal autoregula-
tory capacity, a deterioration in glomerular filtration rate (GFR). This will lead
subsequently to water and sodium retention, hyponatremia and oedema. Within
this context, it could be anticipated that the level of renal function can indirectly
be used as an indicator of the overall compromised cardiovascular status of the
patient and therefore is potentially a more powerful indicator for prognosis than
other established risk factors. In chapter two we examined renal function as a
predictor of mortality in 1906 patients with advanced CHF who were enrolled in
a recent survival trial. We found that patients with renal dysfunction had a sig-
nificantly poorer prognosis compared with patients with relatively preserved re-
nal function, despite a similar NYHA functional class and LVEF. In addition, re-
nal function correlated significantly, and more strongly than LVEF, with plasma
neurohormones (in particular, N-terminal ANP). N-terminal ANP is a powerful
predictor of cardiovascular mortality. A direct relationship between the kidney
and natriuretic peptides has never been demonstrated, but the production of ANP
is the main counteracting mechanism available to the circulation to break through
the vicious circle of salt and water retention induced by the failing kidneys.
Interestingly, in the prevention arm of a large study, in patients with an im-
paired left ventricular ejection fraction (SOLVD), moderate renal insufficiency
remained independently associated with an increased risk for all-cause mortality,
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pump-failure death and the composite endpoint of death or hospitalisation for
pump-failure. A history of myocardial infarction (MI) is the leading cause of the
development of CHF. However, it has not been evaluated whether an impaired
renal function by itself could precipitate the development of overt heart failure
after acute MI. In chapter three we studied the course of renal function changes
after first MI, and the potential protective effect of ACE inhibition. In addition,
we studied the prognostic value of baseline renal function. The study population
consisted of patients who were enrolled in a post-MI trial (CATS: Captopril and
Thrombolysis Study). We found that a first anterior MI is associated with pro-
gressive renal function loss in the first year after the MI. This loss seems to be
particularly increased in patients with an already impaired renal function. Impor-
tantly, treatment with the ACE inhibitor captopril in this type of patients appears
to protect the kidney against a progressive long term function loss. Furthermore,
an impaired baseline renal function adds prognostic risk to develop CHF in pa-
tients after a first anterior MI. The beneficial renal effects could be explained by
an improved cardiac function that is mediated by ACE inhibition. However, an-
other attractive hypothesis, consistent with the data are the renal-protective prop-
erties of ACE inhibitors.
The question is why an impaired renal function adds prognostic risk to de-
velop CHF. A subclinically decreased renal function is unlikely to be the direct
cause. An impaired renal function is, however, associated with several other risk
factors that may themselves be causal or linked with causal processes. First, renal
function is known to correlate with a variety of cardiovascular risk factors like
e.g. insulin resistance, dyslipidemia, hyperuricemia, and hyperparathyrodism..
Similar risk factors could contribute to the pathogenesis of intrarenal disease.
So, it could be that renal function is an indicator of more generalized arterioscle-
rosis. Second, a number of these metabolic abnormalities are related to impaired
renal function and induce myocardial dysfunction and damage. Third, neurohor-
monal activation is not only readily apparent in patients with chronic heart failure
but also after a myocardial infarction. Especially angiotensin II, the central prod-
uct of the renin-angiotensin system, may play a central role in the pathophysiol-
ogy and progression of cardiovascular and renal diseases. So, a kidney with
chronic structural and functional changes may be more vulnerable for underper-
fusion induced by a decreased cardiac output and increased sympathetic activity
in the acute phase of MI. This may lead to further activation of the sympathetic
nervous system and the renin-angiotensin-system, subsequently promoting myo-
cardial dysfunction, either directly, or in relation with concomitant sodium reten-
tion. The beneficial effect of ACE inhibition on the development of CHF might
be mediated, at least in part, by its effect on renal function. It could also imply
Summary130
that therapy capable of improving or stabilizing renal function may improve
prognosis in patients after MI.
Unfortunately, the GFR may not be an ideal marker for renal dysfunction
since, regardless of its cause, there is a heterogeneous involvement of the
nephrons in most renal diseases, especially in the early stages of the disease.
Substantial alterations in nephron structure may occur without an apparent de-
cline in the GFR, since the remaining healthy nephrons can compensate for the
defective ones. Currently, there is no technique available to measure the level of
function of the individual human nephron. This hyperfiltration phenomenon
challenges the view that the GFR is a good indicator of renal lesion. At present,
an increased urinary albumin excretion, in terms of microalbuminuria (an albu-
min excretion rate of 30-300 mg/24 h, or 20-200 µg/min, or 20-200 mg/l) and
macroalbuminuria (an albumin excretion rate of more than 300 mg/24 h or, > 200
µg/min, or > 200 mg/l), is the only practical biochemical marker for the diagno-
sis of several renal diseases affecting the glomerulus at an early stage. Microal-
buminuria is an important early sign of incipient diabetic nephropathy in insulin-
dependent diabetes mellitus and, albeit less specific, in non–insulin-dependent
diabetes mellitus. Hyperfiltration has been observed in both IDDM and NIDDM
and is thought to occur before the loss of renal function. Little is known about the
relation between albuminuria and renal function in nondiabetic subjects.
In chapter four we studied the relation between urinary albumin excretion
(UAE) and creatinine clearance in 7728 nondiabetic subjects. We found that the
GFR in nondiabetic subjects might have a parabolic pattern that is associated
with the different levels of urinary albumin excretion (UAE). In other words, the
group with microalbuminuria has more subjects with an elevated filtration,
whereas in the macroalbuminuria group more subjects with a diminished filtra-
tion were found. The parabolic pattern in creatinine clearance seems similar to
the widely known parabolic or biphasic pattern in renal function as observed in
diabetes. Although the renal hemodynamic abnormalities in diabetes are likely to
be specific for the diabetic condition, it has been suggested that determinants of
progressive renal function loss are similar between patients with established
nondiabetic and those with diabetic renal disease. So, microalbuminuria has been
shown to be a predictor for the appearance of overt diabetic nephropathy, and
some pieces of evidence indicate that it could also be a predictor of renal func-
tion in non-diabetics. It has also been speculated that an increased urinary albu-
min excretion represents the renal expression of a generalised disorder character-
ised by an increased endothelial permeability that may underlie the link between
an increased urinary albumin excretion and the increased risk of cardiovascular
disease. Within this perspective the significance of microalbuminuria as a com-
mon independent risk factor in a non-diabetic, non-hypertensive population is
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still a matter under debate that needs to be solved in view of the potential signifi-
cance of microalbuminuria as a risk factor. In chapter five we determined the
prevalence of microalbuminuria using an early morning urine in a large sample
(40,856) in the general population and its relationship with cardiovascular risk
factors and morbidity. We found that microalbuminuria is common in the general
population with a prevalence of 7.2% and independently associated with cardio-
vascular risk factors and cardiovascular morbidity. The majority of these micro-
albuminuric subjects (75%) has no reported diabetes or hypertension. The results
show that even after excluding diabetic and hypertensive subjects microalbumin-
uria is still prevalent in 6.6% of the subjects. Cardiovascular risk factors were al-
ready elevated at levels of albuminuria currently considered to be normal (10-20
mg/L or 15-30 mg/24hr).
In chapter six we have evaluated the association between the level of UAE in
a population based study of 7579 subjects, including levels within the normal
range, and ischemic electrocardiographic (ECG) abnormalities in a general
nondiabetic population. We found a graded continuous relation was present be-
tween the level of UAE and ECG abnormalities, without an apparent threshold.
In addition, UAE was associated with several ECG abnormalities, independent
from conventional cardiovascular risk factors.
An increased risk of all cause, and in particular of cardiovascular mortal-
ity, has been demonstrated with urinary albumin excretion in type I and type II
diabetes, in hypertensives, in elderly and in subjects aged 55 years or more with a
history of established CV disease, by categorizing the albumin excretion arbitrar-
ily. In chapter seven we identified the relationship and specificity between UAE,
and CV versus non-CV mortality in the general population. We found an impor-
tant effect of UAE on all-cause mortality. The excess risk was significantly more
attributable to death from cardiovascular causes. The observed effects are inde-
pendent from the possible effects of various cardiovascular risk factors and the
relationship between urinary albumin excretion and mortality was already appar-
ent at levels of albuminuria currently considered to be normal. This study sup-
ports the view that urinary albumin excretion is not only a reflection of cardio-
vascular risk factors, but may also be a marker of generalized vascular disease,
not only in cardiovascular compromised subjects but also in the general popula-
tion.
Chapter eight presents a review of prior research in this area. This chapter
reviews a large number of studies that has investigated the cardio-renal axis in
various stages of cardiovascular disease. It also highlights several gaps within
our knowledge of this subject. This chapter presents an outline that structures the
research in this thesis, and identifies the contributions and themes of the individ-
Summary132
ual studies described in chapters two, three, four, five, six and seven. The differ-
ent study’s findings are discussed and placed into a larger context.
To summarise, adequate treatment of the progression of cardiac disease re-
quires a cardiorenal approach, since relatively small changes in kidney function
is associated with cardiovascular morbidity and mortality. Therefore, interfering
with the cardiorenal axis is an important therapeutic objective. New therapeutic
strategies might be triggered by focussing on increasing our knowledge concern-
ing the adaptive and maladaptive mechanisms of the kidney involved in cardiac
disease. The strategy of including renoprotective interventions in the prevention
or progression of cardiac disease is a challenging one.
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De laatste 20 jaar is er aanzienlijke vooruitgang geboekt in de preventie en be-
handeling van cardiovasculaire ziekten. Deze winst kan in belangrijke mate wor-
den toegeschreven aan een verbeterde stratificatie van risicofactoren en een toe-
genomen kennis omtrent de pathologie van atherosclerose. De prognostische be-
tekenis van een aantal cardiovasculaire risicofactoren zoals bloeddruk, plasma
cholesterol en linker ventrikel hypertrofie is echter niet bij iedereen hetzelfde. De
laatste jaren zijn er een aantal nieuwe biochemische en biometrische parameters
geïdentificeerd waarvan men vermoedt dat deze van grote prognostische beteke-
nis kunnen zijn voor het optreden van cardiovasculaire ziekten. Epidemiologi-
sche studies laten een nauwe relatie zien tussen cardiovasculaire aandoeningen
en ziekten van de nier. In hoeverre de aanwezigheid van risicofactoren op nier-
ziekten gerelateerd is aan een verhoogd risico op het krijgen van cardiovasculaire
ziekten is een intrigerende vraag. Indien dit zo is, dan is de volgende vraag hoe
groot het risico dan is dat een persoon met een dergelijke nefrogene risicofactor
na blootstelling hieraan een cardiovasculaire ziekte ontwikkelt. Tenslotte kunnen
wij ons afvragen welke gezondheidswinst er kan worden behaald wanneer deze
risicofactor wordt behandeld. Dit proefschrift bestudeert klassieke en nieuwe
concepten van de relatie tussen nier, hart en bloedvaten in verschillende stadia
van cardiovasculaire ziekten. Geconcludeerd wordt dat therapeutische interven-
ties in de cardio-renale as, gericht op een verbetering van de nierfunctie, een be-
langrijke bijdrage zouden kunnen leveren aan de behandeling en preventie van
cardiovasculaire ziekten en daarmee gepaard gaande sterfte.
De functie van de nier bij chronisch hartfalen is meestal beschreven vanuit een
hemodynamisch uitgangspunt waarbij een afname van de plasma doorstroming
van de nier centraal staat. In het geval dat de bloeddruk daalt beneden het niveau
van de autoregulatie van de nier, verslechtert de nierfunctie. Dit komt tot uit-
drukking in een afname van de glomerulaire filtratie. Deze afname leidt vervol-
gens tot het vasthouden van water en zout, een laag natrium gehalte in het bloed
en oedeemvorming. Een afwijkende nierfunctie kan een aanwijzing zijn voor een
cardiovasculaire aandoening van de patiënt. Een afwijkende nierfunctie hoeft dan
ook niet primair het gevolg te zijn van een onderliggende ziekte van de nier maar
kan ook secundair het gevolg zijn van dan wel een slechte pompfunctie van het
hart dan wel een onderliggend atherosclerotisch vaatlijden. Atherosclerotisch
vaatlijden kan zich namelijk in de nier presenteren als glomerulaire nefrosclerose
dat op zich zelf verlies in nierfunctie kan betekenen. Binnen deze context kan de
afwijkende nierfunctie gezien worden als een samengestelde indicator voor de
ernst van het onderliggende atherosclerotische vaatlijden dat door een veelheid
aan factoren kan worden veroorzaakt. Om die reden zou de nierfunctie een krach-
tige voorspeller zijn voor de prognose van de patiënt. In hoofdstuk 2 onderzoch-
ten we de prognostische betekenis van de nierfunctie op het risico van overlijden
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in 1,906 patiënten met chronisch hartfalen in het kader van een geneesmiddelen-
studie. Wij vonden dat patiënten met een verminderde nierfunctie een veel slech-
tere prognose hadden dan patiënten met een normale nierfunctie. Een opvallende
bevinding was verder dat de prognostische betekenis van de nierfunctie onafhan-
kelijk was van de hoogte van de ejectiefractie van het hart. Soortgelijke uitkom-
sten werden ook gevonden in de vergelijking met de functionele (NYHA) klasse
van de patiënt. Daarnaast waren plasma hormonen [in het bijzonder het N-
terminale atriaal natriuretische peptide (ANP)] sterker gecorreleerd aan nierfunc-
tie dan aan de linker ventrikel ejectiefractie. Het N-terminale ANP is een sterke
voorspeller van cardiovasculaire sterfte. Ofschoon een directe relatie tussen het
natriuretische peptide en de nier nooit is aangetoond, is het natriuretische peptide
bij nierfalen waarschijnlijk het enige nog beschikbare ontsnappingsmechanisme
om de vicieuze cirkel van zout- en waterretentie te doorbreken. We denken hier-
uit dan ook de voorzichtige conclusie te kunnen trekken dat het niet zo hoeft te
zijn dat een slechte pompfunctie van het hart de reden is voor een slechte nier-
functie. Derhalve blijft de mogelijkheid over dat nierfalen gerelateerd is met de
cardiale uitkomst van de patiënt, dan wel dat nier- en hartfalen onafhankelijk
van elkaar voorkomen.
Om deze vraag te beantwoorden is het hartinfarct, één van de belangrijkste
veroorzakers van hartfalen, interessant. In hoofdstuk 3 hebben we gekeken of de
nierfunctie ten tijde van het infarct van prognostische waarde is voor het optre-
den van hartfalen na een doorgemaakt hartinfarct. Tevens we gekeken naar het
beloop van de nierfunctie na het infarct en de mogelijk beschermende werking
van angiotensin-converting-enzyme (ACE) remmers. Hiervoor hebben we de ge-
gevens gebruikt van een onderzoek bij patiënten met een voor de eerste maal
doorgemaakt voorwand infarct; het CATS onderzoek (CATS: Captopril and
Thrombolysis Study). Wij vonden dat een slechte nierfunctie bij aanvang van het
onderzoek voorspellend was voor het optreden van hartfalen in het beloop van
het onderzoek. Bovendien bleek dat een progressief nierfunctieverlies optrad in
het eerste jaar na het infarct. Dit verlies van nierfunctie deed zich vooral voor bij
patiënten die al bij aanvang van het onderzoek een slechtere nierfunctie hadden.
Een belangrijke bevinding was verder dat de behandeling met de ACE remmer
captopril een beschermende werking op de nier- en hartfunctie had. Dit positieve
effect van ACE remming op de nier kan hemodynamisch verklaard worden om-
dat een verbeterde functie van het hart een verbeterde nierfunctie tot gevolg kan
hebben. Een andere verklaring van het effect zou kunnen worden toegeschreven
aan de beschermende eigenschappen van ACE remmers op de nier zelf, zoals
eerder is aangetoond in een aantal onderzoeken met ACE remmers bij verschil-
lende nierziekten.
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Een sluitende verklaring voor de bevinding dat na een doorgemaakt hartinfarct
een verminderde nierfunctie prognostisch is voor het ontwikkelen van hartfalen
op de lange termijn is op dit moment nog niet te geven. Een verminderde nier-
functie is echter frequent geassocieerd met andere cardiovasculaire risicofactoren
die ieder op zich in causaal verband kunnen worden gebracht met een toegeno-
men cardiovasculair risico voor de patiënt. Associaties zijn bijvoorbeeld be-
schreven tussen afgenomen nierfunctie enerzijds en insuline resistentie, afwijkin-
gen in het vetspectrum, hyperparathyroïdie, etc. anderzijds. Een aantal van deze
metabole afwijkingen kunnen echter evenzeer leiden tot nierschade. Pathofysio-
logisch is het aannemelijk dat een zelfde risicofactor tot vergelijkbare structurele
afwijkingen kan leiden bij twee afzonderlijke organen in het lichaam, in dit geval
het hart en de nier. Tenslotte, neurohormonale activatie treedt niet alleen op bij
patiënten in het beginstadium van hartfalen maar ook ten tijde van het hartinfarct
en erna. Vooral het angiotensine II, het centrale product van het renine-
angiotensine systeem, speelt een mogelijk centrale rol bij het ontstaan en de pro-
gressie van cardiovasculaire ziekten. Het is ook hier aannemelijk te veronderstel-
len dat bij onvoldoende bloeddoorstroming een chronisch zieke, functioneel aan-
gedane nier kwetsbaarder is dan een gezonde, goed functionerende nier. In de
acute fase van het hartinfarct kunnen een afgenomen hartminuutvolume en toe-
genomen sympatische activiteit aanleiding geven tot een verminderde bloeddoor-
stroming van de nier. Dit op zich leidt weer tot verdere activatie van het sympati-
sche zenuwstelsel en van het renine-angiotensine systeem. Deze door het hart ge-
induceerde neurohormonale activatie kan dus versterkt worden door een slechte
nierfunctie. Dit werkt verder functieverlies van het hart in de hand, hetzij direct,
hetzij indirect in samenhang met zout- en waterretentie. Derhalve kan gepostu-
leerd worden dat de beschermende werking van ACE remmers op het ontwikke-
len van hartfalen na het infarct niet alleen valt toe te schrijven aan een bescher-
mende werking van de ACE remmer op het hart, maar evenzeer op de nier. Het
is dus goed denkbaar dat medicamenteuze therapie, die wordt ingezet om de nier-
functie na een doorgemaakt infarct te stabiliseren dan wel te verbeteren, evenzeer
de cardiale prognose van de patiënt verbetert.
De glomerulaire filtratie snelheid is echter niet onder alle omstandigheden een
even nauwkeurige indicator van de nierfunctie. Vooral in beginstadia van nier-
ziekten is er een heterogene betrokkenheid van nefronen. In de nier kunnen aan-
zienlijke veranderingen plaatsvinden zonder dat dit direct leidt tot verlies van
nierfunctie doordat gezonde nefronen het functieverlies van aangedane nefronen
kunnen compenseren. Deze zogenaamde hyperfiltratie, waarbij gezonde nefronen
het filtratieverlies van zieke nefronen compenseren bemoeilijkt de toepasbaar-
heid van de nierfunctie als een betrouwbare risico-indicator voor de gezondheids-
ofwel activatietoestand van de nier. Op dit moment is er bij de mens nog geen
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techniek beschikbaar die het mogelijk maakt de functie van het individuele ne-
fron te meten. Een toegenomen eiwitverlies via de urine in termen van microal-
buminurie (een eiwitverlies van 30-300 mg per 24 uur of 20-200 µg per minuut
of 20-200 mg/l) en macroalbuminurie (een eiwitverlies van meer dan 300 mg per
24 uur of meer dan 200 µg per minuut of 200 mg/l) is op dit moment de enige
praktisch toepasbare indicator om afwijkingen aan de nier te kunnen vaststellen
op glomerulair niveau. Vooral bij patiënten die bekend zijn met diabetes mellitus
is de aanwezigheid van microalbuminurie een belangrijke voorspeller voor be-
ginnende diabetische nefropathie. Hyperfiltratie, zoals dat gezien wordt bij diabe-
tes type 1 en 2 patiënten, wordt beschouwd als een fase die vooraf gaat aan de
fase waarin daadwerkelijk verlies van nierfunctie aanwezig is. Er is echter weinig
bekend over het verband tussen eiwit in de urine en nierfunctie bij personen die
niet bekend zijn met diabetes mellitus.
In hoofdstuk 4 bestudeerden we de relatie tussen verlies van eiwit via de urine
en de creatinineklaring in 7,728 personen zonder diabetes mellitus. De relatie
tussen de creatinineklaring en de hoogte van het eiwit in de urine vertoonde het
beeld van een parabool. Met andere woorden, de groep van personen met eiwit-
verlies in het gebied van de microalbuminurie kenmerkte zich door een verhoog-
de filtratie, terwijl bij de groep met eiwitverlies in het gebied van macroalbumi-
nurie een verlaagde filtratie vaker werd aangetroffen. Deze parabolische relatie
komt overeen met het bifasische patroon zoals wij dat kennen bij patiënten met
diabetes mellitus. Dus de determinanten voor progressief verlies van de nierfunc-
tie, zoals wij die kennen van diabetes mellitus, komen overeen met die van per-
sonen zonder diabetes mellitus. Zoals microalbuminurie bij patiënten met diabe-
tes mellitus een voorspeller is voor optreden van diabetische nefropathie en een
aanwijzing is voor de aanwezigheid van hart- en vaatziekten, lijkt het dat de mi-
croalbuminurie vergelijkbare prognostische eigenschappen heeft bij personen
zonder diabetes mellitus. Er wordt gesuggereerd dat toegenomen eiwitverlies via
de urine een aanwijzing is voor een gegeneraliseerd vaatprobleem dat geken-
merkt is door een toegenomen permeabiliteit van het endotheel van de bloedva-
ten. Deze afwijking van het endotheel is misschien de link tussen eiwitverlies via
de urine en een toegenomen risico op het optreden van hart- en vaatziekten. Het
belang van microalbuminurie als een onafhankelijke risicofactor (of indicator) bij
personen zonder diabetes mellitus of hypertensie staat echter nog steeds ter dis-
cussie. De klinische relevantie moet nog worden aangetoond. In hoofstuk 5 on-
derzochten we de frequentie van voorkomen van microalbuminurie in relatie met
bekende cardiovasculaire risicofactoren en ziekten. Dit was onderzocht door
middel van een eenmalige, aselecte verzameling van de ochtendurine bij 40,856
personen uit de stad Groningen. Microalbuminurie bleek in deze grote steekproef
relatief vaak voor te komen met een prevalentie van 7.2% en bleek ook bij per-
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sonen zonder diabetes mellitus en hypertensie geassocieerd te zijn met cardio-
vasculaire risicofactoren en ziekten. Het overgrote deel van de personen met mi-
croalbuminurie (75%) bleek niet bekend te zijn met diabetes mellitus en/of hy-
pertensie. Een andere interessante bevinding was dat cardiovasculaire risicofacto-
ren reeds voorkomen bij eiwitconcentraties in de urine (10-20 mg/l of 15-30 mg
per 24 uur) die op dit moment als volstrekt normaal worden beschouwd.
In hoofdstuk 6 hebben we in 7,579 personen zonder diabetes mellitus geke-
ken naar de relatie tussen eiwitverlies via de urine en de aanwezigheid van
ischemische afwijkingen op het elektrocardiogram. Wij zagen een continu toe-
nemend verband, zonder dat er duidelijk sprake was van een bepaalde drempel-
waarde. Deze relatie tussen een verhoogd eiwitverlies via de urine en electrocar-
diografische afwijkingen bleef bestaan wanneer gecorrigeerd werd voor andere
bekende cardiovasculaire risicofactoren.
De combinatie van microalbuminurie en diabetes mellitus type 1 en 2, een
leeftijd ouder dan 55 jaar en een cardiovasculaire voorgeschiedenis laat een ver-
hoogd risico zien op vroegtijdig overlijden, in het bijzonder door een cardiovas-
culaire oorzaak. In hoofdstuk 7 onderzochten we de relatie tussen de hoogte van
de uitscheiding van eiwit via de urine en de kans op sterfte op basis van een car-
diovasculaire dan wel niet-cardiovasculaire oorzaak. Wij vonden een directe re-
latie tussen de hoogte van het eiwit in de urine en de kans op komen te overlij-
den. Deze relatie kon voornamelijk worden toegeschreven aan sterfte op basis
van een cardiovasculaire oorzaak en bleef bestaan wanneer de gevolgen van an-
dere cardiovasculaire risicofactoren in de analyse werden betrokken. Een toege-
nomen risico werd al aangetoond bij een hoeveelheid eiwitverlies via de urine die
op dit moment nog als volstrekt normaal wordt beschouwd. Dit onderzoek onder-
steunt de opvatting dat eiwit in de urine niet alleen een afspiegeling is van de
aanwezigheid van cardiovasculaire risicofactoren maar evenzeer van de aanwe-
zigheid van gegeneraliseerd vaatlijden. Deze bevinding is niet alleen van toepas-
sing op personen met de bekende cardiovasculaire risicofactoren maar evenzeer
op de algemene populatie, dus ook bij personen zonder deze risicofactoren.
Hoofdstuk 8 beschrijft een groot aantal studies over de cardio-renale as in uit-
eenlopende stadia van cardiovasculaire ziekten en waar onze kennis omtrent dit
onderwerp nog tekort schiet. Het hoofdstuk volgt de opbouw van dit proefschrift
en geeft aan op welke momenten onze onderzoeksresultaten een antwoord geven
op de nog openstaande vragen. De resultaten van studies zoals beschreven in
hoofdstuk twee, drie, vier vijf, zes, zeven en acht worden vervolgens in een bre-
dere context geplaatst met suggesties voor verder onderzoek.
Samenvattend, een adequate behandeling om progressie van ziekten van het
hart tegen te gaan dient rekening te houden met de nier. Dit omdat reeds kleine
veranderingen in de functie van de nier gepaard gaan met een toename in cardio-
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vasculaire risicofactoren, cardiovasculaire ziekten en cardiovasculaire sterfte.
Deze kleine veranderingen in functie kunnen bestaan uit een toegenomen lek van
het nierfilter zonder dat glomerulaire filtratie is afgenomen. Ook als er sprake is
van manifest nierfalen, waarbij een afname van de glomerulaire filtratie is opge-
treden, is er een toegenomen risico op cardiovasculaire ziekten en cardiovasculai-
re sterfte. Therapie die gericht is op zowel cardiale als nefrogene protectie zou
wel eens een belangrijke middel kunnen zijn om de prognose van de patiënt te
verbeteren. Het incorporeren van nierbeschermende therapie in de huidige be-
handelingsmethoden teneinde cardiovasculaire ziekten te voorkomen en de pro-




Wanneer de weg ophoudt, verander-
na verandering, kun je verder.
Deze inspirerende tekst van de zoeker L Tjing heeft mij richting gegeven om te
blijven kijken, om de weg vorm te geven en om te gaan met de moeilijkheden die
ik op mijn weg ben tegengekomen. Refererend aan de omslag van het proef-
schrift kan ik nu zeggen: “het meubilair is klaar, de compositie is gemaakt, we
kunnen aan tafel”. De eerste ideeën dateren reeds uit het eerste kwartaal van
1998. Dat er een cardio-renale tafel moest komen, daar was iedereen het over
eens. Maar de meningen waren verdeeld over hoe de stoelen vormgegeven moes-
ten worden en op welke wijze de plaatsen aan tafel door de stoelen bezet moesten
gaan worden. Met trots kan ik zeggen dat het ontwerp, de keuze van het materi-
aal en de verwerking grotendeels afkomstig zijn van de Cardio-Nefrologische
Groningse school. Het meubilair is een voorbeeld dat als we ons openstellen voor
de ander, andere ogen opengaan. Uiteraard hoort nu een woord van dank aan al
diegenen die hebben meegewerkt het meubilair vorm te geven.
Mijn grootste dank gaat uit naar mijn meest nabije dierbaren Ans, Wick Lize en
Derk. Het zijn zij die mij de inspiratie, woon- en werkplaats hebben gegeven. Zij
hebben mij in staat gesteld het meubilair te maken en een juiste plaats te geven.
Veel dank ben ik verschuldigd aan de meester meubelontwerper Prof. dr. D. de
Zeeuw. Beste Dick, je had eigenlijk meer de rol van procesarchitect. Je vervulde
de rol van ideeëngenerator, procesontwerper, adviseur, kennisleverancier en ver-
schaffer van zekerheid. Je leerde mij het concept van een heldere vraagstelling en
zorgde dat het meubilair binnen de geplande tijd werd afgeleverd. Als nefrolo-
gisch kennisleverancier ontlokte je heftige fundamentele reno-cardiale discussies
waarbij volledige overeenstemming direct gevolgd kon worden door een totale
babylonische spraakverwarring.
Mijn tweede ontwerper prof. dr. D.J. van Veldhuisen was een gedreven
leermeester in de snelle navigatie om tot een bepaald ontwerp te komen. Je
bracht mij de kracht bij van het eenvoudige concept, een heldere compositie en
bijzondere aandacht voor de weergave van het materiaal tijdens de afwerking.
Beste Dirk Jan, bij deze mijn dank voor de geboden ruimte en vertrouwen.
Mijn derde leermeester Prof. dr. P.E. de Jong was mijn coach en voorbeeld op
het gebied van doelgericht samenwerken. Jammer genoeg was ik voor hem vaak
niet de optimale gezel omdat ik nu eenmaal graag aan vijfentwintig stoelen tege-
lijk wil werken. Er staan nog steeds een aantal meubelstukken op zijn lijst met
mijn naam erachter. Beste Paul, ik ben er van overtuigd dat ik de lijst nog wel
weet weg te werken. Mijn speciale bewondering gaat uit naar je leermeesterschap
waar respect en integriteit voor de ander voorop staat.
Veel dank en respect heb ik voor Dr. W.M.T. Janssen die voor mij de deur
opende naar het eiwitverlies in de urine. Wilbert zal ongetwijfeld de boeken in-
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gaan als de microalbuminurie verslaafde van het eerste uur en heeft in Gronin-
gen een omgeving geschapen waarin de albuminurische verslaafde zich thuis
voelt.
Een diep gevoel van dankbaarheid en vertrouwen koester ik voor Prof. P.A.
de Graeff en mijn beide paranimfen Drs. T. Kingma en Prof. dr. W.H. van Gilst.
Beste Pieter, Tsjerk en Wiek, voor mij zijn jullie drie onbaatzuchtige mensen
waarbij ik weinig woorden nodig heb.
Dit brengt me tot de andere twee leden van de beoordelingscommissie, Prof.
dr. K.I. Lie en Prof. dr. D.E. Grobbee. Beide wil ik bedanken voor hun bereid-
heid mijn proefschrift te beoordelen. Ik wil verder Prof. Lie bedanken dat hij het
aan het eind van de jaren tachtig heeft aangedurfd, zijn mensen aan mij bloot te
stellen. Rick, veel dank ben ik je verschuldigd voor de richting die je gaf aan
mijn epidemiologische weg van onwetendheid.
Belangrijk voor mij is verder geweest Prof. dr. A.R.J. Girbes omdat hij de oor-
spronkelijke vraag heeft gesteld en mij vervolgens de ruimte heeft gegeven de
stoel te ontwerpen die aan het hoofd van de tafel geplaatst kan worden. Een stoel
die de omgeving bijzonder lijkt aan te spreken.
Belangrijk zijn verder mijn medepromovendi Sarah Joan Pinto-Sietsma en
Gilles Diercks die me vooraf zijn gegaan. Daarnaast Jacobien Verhage, Eric Stu-
veling en Folkert Asselbergs die mij vast en zeker zullen volgen. Het is hun bij-
drage dat ik omhoog ben blijven kijken om de grote dingen te blijven zien.
Speciale dank en waardering heb ik voor de “nier”verwarmende didacticus
Prof. dr. G. Navis die mij heeft getracht een nefro-fysiologische bril aan te me-
ten. Beste Gerjan, ik hoop dat onze wegen in de toekomst nog vaak zullen krui-
sen.
Zonder de hulp van Dr. V. Fidler was de stoel aan het andere hoofd van de ta-
fel nooit die stoel geweest die een stoel aan het hoofd van de tafel zou moeten
zijn. Beste Vaclav, ik zal je vakmanschap niet snel vergeten.
De mooie bekleding van het meubilair heb ik te danken aan Bauke Klomp,
terwijl ik ook hier Pieter de Graeff zeer erkentelijk ben voor zijn suggesties voor
verbeteringen van mijn verwoordingen van gedachten.
Het is de omgeving die motiveert. Om die reden bedank ik al degenen die in
meer of mindere mate hebben bijgedragen aan het welslagen van dit project
waarvoor ik hen zeer erkentelijk ben. Hiertoe behoren mijn vroegere collega’s
van de klinische farmacologie, het ACBG in Den Haag, de Prevend medewer-
kers in de breedste zin van het woord, de afdeling Nefrologie, het Thoraxcen-
trum en mijn “Dream Team”, het Trial Coördinatie Centrum.
De cirkel is rond, ik dank tenslotte mijn andere meest nabije dierbaren, mijn
eigen familie en de familie van Ans en mijn gedachten zijn bij degenen die er
niet meer zijn. Het zijn zij die mij de liefde hebben gegeven die mij in staat heeft




1. Brugemann J, van der MJ, Takens BH, Hillege HL, Lie KI. A systemic non-
lytic state and local thrombolytic failure of anistreplase (anisoylated plasmi-
nogen streptokinase activator complex, APSAC) in acute myocardial infarc-
tion. Br Heart J 1990;64:355-358.
2. Cromme-Dijkhuis AH, Henkens CM, Bijleveld CM, Hillege HL, Bom VJ,
van der MJ. Coagulation factor abnormalities as possible thrombotic risk
factors after Fontan operations. Lancet 1990;336:1087-1090.
3. van den Broek SA, van Bruggen A, de Graeff PA, Hillege HL, Van Gilst
WH, Wesseling H, Lie KI. The acute hemodynamic, hormonal, and phar-
macokinetic properties of oral spirapril in patients with moderate to severe
heart failure. J Cardiovasc Pharmacol 1991;18:614-621.
4. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege HL, Gosselink AM, Lie
KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after elec-
trical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Car-
diol 1991;68:335-341.
5. van den Broek SA, van Veldhuisen DJ, de Graeff PA, Landsman ML, Hil-
lege HL, Lie KI. Comparison between New York Heart Association classi-
fication and peak oxygen consumption in the assessment of functional status
and prognosis in patients with mild to moderate chronic congestive heart
failure secondary to either ischemic or idiopathic dilated cardiomyopathy.
Am J Cardiol 1992;70:359-363.
6. Gosselink AT, Crijns HJ, Van Gelder IC, Hillege HL, Wiesfeld AC, Lie KI.
Low-dose amiodarone for maintenance of sinus rhythm after cardioversion
of atrial fibrillation or flutter. JAMA 1992;267:3289-3293.
7. Gosselink AT, Crijns HJ, Hamer HP, Hillege HL, Lie KI. Changes in left
and right atrial size after cardioversion of atrial fibrillation: role of mitral
valve disease. J Am Coll Cardiol 1993;22:1666-1672.
8. Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI.
Torsades de pointes with Almokalant, a new class III antiarrhythmic drug.
Am Heart J 1993;126:1008-1011.
9. Tuininga YS, Crijns HJ, Wiesfeld AC, van Veldhuisen DJ, Hillege HL, Lie
KI. Electrocardiographic patterns relative to initiating mechanisms of exer-
cise-induced ventricular tachycardia. Am Heart J 1993;126:359-367.
10. Henkens CM, van der Meer J, Hillege HL, van der SW, Bom VJ, Halie MR.
The clinical expression of hereditary protein C and protein S deficiency: a
Bibliography 147
relation to clinical thrombotic risk factors and to levels of protein C and
protein S? Blood Coagul Fibrinolysis 1993;4:555-562.
11. van den Berg MP, Crijns HJ, Gosselink AT, van den Broek SA, Hillege HL,
van Veldhuisen DJ, Lie KI. Chronotropic response to exercise in patients
with atrial fibrillation: relation to functional state. Br Heart J 1993;70:150-
153.
12. van der Meer J, Hillege HL, Kootstra GJ, Ascoop CA, Mulder BJ, Pfisterer
M, Van Gilst WH, Lie KI. Prevention of one-year vein-graft occlusion after
aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose
aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Re-
search Group of the Interuniversity Cardiology Institute of The Netherlands.
Lancet 1993;342:257-264.
13. van den Broek SA, van Veldhuisen DJ, de Graeff PA, Crijns HJ, Van Gilst
WH, Hillege HL, Lie KI. Mode of death in patients with congestive heart
failure: comparison between possible candidates for heart transplantation
and patients with less advanced disease. J Heart Lung Transplant
1993;12:367-371.
14. de Muinck ED, den Heijer P, van Dijk RB, Crijns HJ, Hillege HL, Twisk
SP, Lie KI. Autoperfusion balloon versus stent for acute or threatened clo-
sure during percutaneous transluminal coronary angioplasty. Am J Cardiol
1994;74:1002-1005.
15. den Heijer P, van Dijk RB, Pentinga ML, Hillege HL, Lie KI. Laser throm-
bolysis in acute myocardial infarction: results of a clinical feasibility study.
J Interv Cardiol 1994;7:525-534.
16. van der Meer J, Hillege HL, Van Gilst WH, Brutel dlR, Dunselman PH,
Fidler V, Kootstra GJ, Mulder BJ, Pfisterer M, Lie KI. A comparison of in-
ternal mammary artery and saphenous vein grafts after coronary artery by-
pass surgery. No difference in 1-year occlusion rates and clinical outcome.
CABADAS Research Group of the Interuniversity Cardiology Institute of
The Netherlands. Circulation 1994;90:2367-2374.
17. van der Meer J, Brutel dlR, Van Gilst WH, Hillege HL, Pfisterer M, Koot-
stra GJ, Dunselman PH, Mulder BJ, Lie KI. Effects of low dose aspirin (50
mg/day), low dose aspirin plus dipyridamole, and oral anticoagulant agents
after internal mammary artery bypass grafting: patency and clinical outcome
at 1 year. CABADAS Research Group of the Interuniversity Cardiology In-
stitute of The Netherlands. Prevention of Coronary Artery Bypass Graft Oc-
Bibliography148
clusion by Aspirin, Dipyridamole and Acenocoumarol/Phenprocoumon
Study. J Am Coll Cardiol 1994;24:1181-1188.
18. van der Meer J, Hillege HL, Dunselman PH, Mulder BJ, Michels HR, Buser
PT, Van Gilst WH, Lie KI. Oral anticoagulation in the prevention of one-
year vein graft occlusion after aortocoronary bypass surgery: optimal thera-
peutic range and practical limitations. CABADAS Research Group of the
Interuniversity Cardiology Institute of The Netherlands. Thromb Haemost
1994;72:676-681.
19. den Heijer P, van Dijk RB, Hillege HL, Pentinga ML, Serruys PW, Lie KI.
Serial angioscopic and angiographic observations during the first hour after
successful coronary angioplasty: a preamble to a multicenter trial addressing
angioscopic markers for restenosis. Am Heart J 1994;128:656-663.
20. den Heijer P, Foley DP, Escaned J, Hillege HL, van Dijk RB, Serruys PW,
Lie KI. Angioscopic versus angiographic detection of intimal dissection and
intracoronary thrombus. J Am Coll Cardiol 1994;24:649-654.
21. Gosselink AT, Crijns HJ, van den Berg MP, van den Broek SA, Hillege HL,
Landsman ML, Lie KI. Functional capacity before and after cardioversion
of atrial fibrillation: a controlled study. Br Heart J 1994;72:161-166.
22. Szabo BM, van Veldhuisen DJ, Crijns HJ, Wiesfeld AC, Hillege HL, Lie
KI. Value of ambulatory electrocardiographic monitoring to identify in-
creased risk of sudden death in patients with left ventricular dysfunction and
heart failure. Eur Heart J 1994;15:928-933.
23. Brugemann J, van der MJ, Hillege HL, van Boven AJ, van Doormaal JJ, de
Graeff PA, Lie KI. Lipoprotein(a) levels in patients with myocardial infarc-
tion treated with anistreplase: no prediction of efficacy but inverse correla-
tion with plasminogen activation in non-patency. Int J Cardiol
1994;45:109-113.
24. de Jongste MJ, Hautvast RW, Hillege HL, Lie KI. Efficacy of spinal cord
stimulation as adjuvant therapy for intractable angina pectoris: a prospec-
tive, randomized clinical study. Working Group on Neurocardiology. J Am
Coll Cardiol 1994;23:1592-1597.
25. den Heijer P, Foley DP, Hillege HL, Lablanche JM, van Dijk RB, Franzen
D, Morice MC, Serra A, de Scheerder IK, Serruys PW, . The 'Ermenonville'
classification of observations at coronary angioscopy--evaluation of i. Eur
Heart J 1994;15:815-822.
Bibliography 149
26. Wout vdT, de Vries RJ, Portegies MC, Blanksma PK, Van Gilst WH, Hille-
ge HL, van Veldhuisen DJ, Lie KI. Effect of isradipine and nifedipine on
diastolic function in patients with left ventricular dysfunction due to coro-
nary artery disease: a randomized, double-blind, nuclear, stethoscope study.
J Cardiovasc Pharmacol 1994;23:952-958.
27. de Jongste MJ, Haaksma J, Hautvast RW, Hillege HL, Meyler PW, Staal
MJ, Sanderson JE, Lie KI. Effects of spinal cord stimulation on myocardial
ischaemia during daily life in patients with severe coronary artery disease.
A prospective ambulatory electrocardiographic study. Br Heart J
1994;71:413-418.
28. Gobel EJ, Hautvast RW, Van Gilst WH, Spanjaard JN, Hillege HL, De-
Jongste MJ, Molhoek GP, Lie KI. Randomised, double-blind trial of intra-
venous diltiazem versus glyceryl trinitrate for unstable angina pectoris.
Lancet 1995;346:1653-1657.
29. Gosselink AT, Blanksma PK, Crijns HJ, Van Gelder IC, de Kam PJ, Hillege
HL, Niemeijer MG, Lie KI, Meijler FL. Left ventricular beat-to-beat per-
formance in atrial fibrillation: contribution of Frank-Starling mechanism af-
ter short rather than long RR intervals. J Am Coll Cardiol 1995;26:1516-
1521.
30. Szabo BM, Crijns HJ, Wiesfeld AC, van Veldhuisen DJ, Hillege HL, Lie
KI. Predictors of mortality in patients with sustained ventricular tachycar-
dias or ventricular fibrillation and depressed left ventricular function: im-
portance of beta-blockade. Am Heart J 1995;130:281-286.
31. Wiesfeld AC, Crijns HJ, Hillege HL, Tuininga YS, Lie KL. The clinical
significance of coronary anatomy in post-infarct patients with late sustained
ventricular tachycardia or ventricular fibrillation. Eur Heart J 1995;16:818-
824.
32. Bergstra A, van Dijk RB, Hillege HL, Lie KI, Mook GA. Assumed oxygen
consumption based on calculation from dye dilution cardiac output: an im-
proved formula. Eur Heart J 1995;16:698-703.
33. van den Broek SA, de Graeff PA, Smit AJ, Girbes AR, Journee, Van Gilst
WH, Hillege HL, van Veldhuisen DJ, Wesseling H, Lie KI. Effects of
spirapril and captopril on regional blood flow in chronic congestive heart
failure: a comparison between a s. J Cardiovasc Pharmacol 1995;25:105-
112.
Bibliography150
34. Gosselink AT, Smit AJ, Crijns HJ, Hillege HL, Lie KI. Alteration of pe-
ripheral vasodilatory reserve capacity after cardioversion of atrial fibrilla-
tion. Eur Heart J 1996;17:926-934.
35. Wiesfeld AC, De Langen CD, Crijns HJ, Bel KJ, Hillege HL, Wesseling H,
Lie KI. Rate-dependent effects of the class III antiarrhythmic drug almo-
kalant on refractoriness in the pig. J Cardiovasc Pharmacol 1996;27:594-
600.
36. de Muinck ED, den Heijer P, van Dijk RB, Crijns HJ, Hillege HL, Lie KI.
Distal coronary hemoperfusion during percutaneous transluminal coronary
angioplasty. Cathet Cardiovasc Diagn 1996;37:233-240.
37. Wiesfeld AC, Crijns HJ, van den Broek SA, Landsman ML, Hillege HL,
Van Gilst WH, Lie KI. Angiographic left ventricular wall motion score to
predict arrhythmia recurrence in patients with sustained ventricular tachy-
cardia or fibrillation. Coron Artery Dis 1996;7:225-230.
38. van der Meer J, Hillege HL, Ascoop CA, Dunselman PH, Mulder BJ, van
Ommen GV, Pfisterer M, Van Gilst WH, Lie KI. Aprotinin in aortocoro-
nary bypass surgery: increased risk of vein-graft occlusion and myocardial
infarction? Supportive evidence from a retrospective study. Thromb Hae-
most 1996;75:1-3.
39. van den Broek SA, de Graeff PA, van Veldhuisen DJ, Van Gilst WH, Hille-
ge HL, Wesseling H, Lie KI. Clinical and neurohumoral differences be-
tween spirapril and captopril in mild to moderate chronic congestive heart
failure. J Card Fail 1997;3:165-171.
40. Pinto-Sietsma SJ, Hillege HL, Janssen WM. Inadequate management of
blood pressure in a hypertensive population. N Engl J Med 1999;340:1593-
1595.
41. Janssen WM, Hillege HL, Pinto-Sietsma SJ, Bak AA, De Zeeuw D, De
Jong PE. Low levels of urinary albumin excretion are associated with car-
diovascular risk factors in the general population. Clin Chem Lab Med
2000;38:1107-1110.
42. Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, De Jong
PE, Grobbee DE, Crijns HJ, Van Gilst WH. Microalbuminuria is independ-
ently associated with ischaemic electrocardiographic abnormalities in a
large non-diabetic population. The PREVEND (Prevention of REnal and
Vascular ENdstage Disease) study. Eur Heart J 2000;21:1922-1927.
Bibliography 151
43. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, De Zeeuw D, De
Jong PE. Smoking is related to albuminuria and abnormal renal function in
nondiabetic persons. Ann Intern Med 2000;133:585-591.
44. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De
Jong PE. Urinary albumin excretion is associated with renal functional
abnormalities in a nondiabetic population. J Am Soc Nephrol 2000;11:1882-
1888.
45. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, De Zeeuw D, Charles-
worth A, Hampton JR, van Veldhuisen DJ. Renal function, neurohormonal
activation, and survival in patients with chronic heart failure. Circulation
2000;102:203-210.
46. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ,
Van Gilst WH, De Zeeuw D, De Jong PE. Microalbuminuria is common,
also in a nondiabetic, nonhypertensive population, and an independent indi-
cator of cardiovascular risk factors and cardiovascular morbidity. J Intern
Med 2001;249:519-526.
47. Diercks GF, Hillege HL, van Boven AJ, Kors JA, Janssen WM, Grobbee
DE, Crijns HJ, Van Gilst WH. Relation between albumin in the urine and
electrocardiographic markers of myocardial ischemia in patients without
diabetes mellitus. Am J Cardiol 2001;88:771-774.
48. Diercks GF, Stroes ES, Van Boven AJ, Van Roon AM, Hillege HL, De
Jong PE, Smit AJ, Gans RO, Crijns HJ, Rabelink TJ, Van Gilst WH.
Difference in the relation between urinary albumin excretion and carotid in-
tima-media thickness in nondiabetic and type 2 diabetic subjects.
Diabetes Care 2002;25:936-937.
49. Diercks GF, van Boven AJ, Hillege JL, de Jong PE, Rouleau JL, van Gilst
WH. The importance of microalbuminuria as a cardiovascular risk indica-
tor: a review. Can J Cardiol 2002;18:525-535
50. Diercks GF, Stroes ES, Boven AJ, Roon AM, Hillege HL, Jong PE, Smit
AJ, Gans RO, Crijns HJ, Rabelink TJ, Gilst WH. Urinary albumin excretion
is related to cardiovascular risk indicators, not to flow-mediated vasodila-
tion, in apparently healthy subjects. Atherosclerosis 2002;163:121-126.

Stellingen
behorende bij het proefschrift “Renal risk markers and cardiovascular disease”,
door Hans L. Hillege.
1. Nierfunctie bij hartfalen is een betere voorspeller van de prognose van de
patiënt dan enig andere bekende factor en is onafhankelijk van de pomp-
functie van het hart. (Dit proefschrift)
2. Primaire en secundaire preventie van hart- en vaatziekten moet gericht zijn
op zowel cardiale als renale protectie. (Dit proefschrift)
3. Teneinde maximale cardiorenale protectie te kunnen uitoefenen dient thera-
pie met ACE remmers zo snel mogelijk na het hartinfarct ingesteld te wor-
den. (Dit proefschrift)
4. De noodzaak van onderzoek naar microalbuminurie blijkt uit het feit dat het
relatief vaak voorkomt en er een directe relatie bestaat tussen de hoeveel-
heid eiwit in de urine en de kans op vroegtijdig overlijden. (Dit proef-
schrift)
5. Microalbuminurie gaat bij zowel bij personen met als zonder diabetes mel-
litus gepaard met een verhoogde glomerulaire filtratie, oftewel een nier die
belast wordt. (Dit proefschrift)
6. Heb hart voor je nieren. (Dit proefschrift)
7. De waarde van het gebruik van erythropoietin (Epo) in hart- en vaatziekten
ligt in de niet-erythropoetische effecten ervan.
8. Het koppelen van een beloning aan voorschrijfgedrag is misbruik van het
vertrouwen van de patiënt.
9. Op basis van het gezegde “voorkomen is beter dan genezen”, dient het vak
lichamelijke opvoeding niet onder het ministerie van Onderwijs maar onder
het ministerie van Volksgezondheid, Welzijn en Sport te vallen.
10. Farmacotherapie op basis van “Evidence based medicine” zou moeten kun-
nen aanvangen met het voorschrijven van placebo.
11. Zo er al nut is in het buitenlands congresbezoek van medici, dan is deze
omgekeerd evenredig aan de duur van het congres/verblijf.
12. Het oplossen van een probleem wordt vaak eerder gerealiseerd door het
aanhoren van het probleem dan door het aandragen van oplossingen.
13. Gezien de onmogelijkheid van derde geldstroom fondsen om op lange ter-
mijn financiële verplichtingen aan te gaan is de ondersteuning van lange
termijn onderzoek bij uitstek een taak van de overheid. De uitvoering komt
echter niet verder dan verkiezingsprogramma's.
14. De zin van het leven is doorgeven. (Auteur onbekend)
